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CH Activation and CH2 Double Activation of Indolines: Towards the Synthesis 
of Aspidospermidine and Aspidofractinine 
By Sally Whiting. 
 
This thesis is concerned with the total synthesis of the two Aspidosperma alkaloid 
natural products, aspidospermidine and aspidofractinine. The two targets have a 
common pentacyclic molecular framework unique to this class of indole alkaloids. 
 
  Aspidospermidine has  previously proven an attractive target, with over 20 total 
syntheses completed. The hexacyclic framework of aspidofractinine has proven more 
challenging, with only 5 total syntheses to date. These synthetic approaches are 
discussed in Chapter 1 together with the pharmacological activity exhibited within 
the Aspidosperma alkaloid series. 
 
  Chapter 3 details the challenges of installing the first 4 rings of the targets (the 
ABDE ring system). Ring expansion of a C3 cyclopropyl indolone with an imine, 
ultimately provided a quick and efficient route to the tetracyclic structure. With the 
model system realised, Chapter 3 details the synthetic efforts towards an elaborated 
imine component and its subsequent use in the ring expansion methodology to give 
our key precursor. 
 
  Chapter 4 discusses model systems to prove our key radical translocation step can 
be achieved. Systems are described that show intramolecular translocation of an aryl 
radical to C2 of an indoline is a feasible means of elaborating this centre.   
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Chapter 1–Introduction to aspidospermidine and aspidofractinine. 
 
Background 
 The  Aspidosperma alkaloids are the largest group of monoterpenoid indole 
alkaloids, comprising over 250 members, with unprecedented structural complexity 
shown throughout the family. The alkaloid family occurs naturally in only a 
restricted number of plant genera, with the vast majority being isolated from one 
subgroup (Plumerioideae) of the Apocynaceae family which is widely distributed in 
the tropical rainforest. The interesting biological activity and structural complexity 
shown within this group have provided the inspiration for synthetic effort for over 40 
years and they remain a focus of extensive research activity in the present day. 
  The diverse molecular architecture shown throughout the family can be 
classified into several distinct subgroups which include: quebrachamine 1, 
aspidospermidine 2, vincadifformine 3, aspidofractinine 4 and the more elaborate 
vindolinine  5, meloscine 6, and kopsine 7 (Figure 1).
1 The vast majority of the 
Aspidosperma alkaloids contain a pentacyclic core exemplified by the 
aspidospermidine sub-group containing the 6.5.6.6.5 fused ring system.    
 
Figure 1: Aspidosperma alkaloid sub-groups. 
 
A number of species of the Aspidosperma genera are used in folk medicine to treat 
general fever, whilst others are used specifically against malaria. More recently, 
interest in the family has been considerable due to the pharmacological activity 
exhibited by a few of its members. In particular anti-cancer activity is displayed 
amongst the dimeric indole alkaloids, such as vincristine and vinblastine, which have 
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enjoyed early clinical success. Research into this sub-group produced vinorelbine
® 
(navelbine) 8, a semi-synthetic derivative of vinblastine currently being used as a 
chemotherapy drug to treat breast and lung cancers (Figure 2).
2 This ‘dimeric’ indole 
alkaloid is comprised of two ‘monomeric’ components that are analogues of 
quebrachamine and aspidospermidine and highlights the interest in both monomer 
natural products as individual targets. 
 
 
 
 
 
 
Figure 2: Anti-cancer agent, vinorelbine, 8. 
 
  The isolation of quebrachamine 1 was accomplished as early as 1882
3 but its 
structural features were not elucidated until Witkop and co-workers investigations in 
1960.
4 It was the pioneering work of Biemann et al. in the 1960’s that led to the full 
structural determination of quebrachamine along with many other alkaloids.
5 The 
bark of Aspidosperma Quebracho blanco, a South American tree located in the 
northern regions of Argentina, was investigated by Biemann et al.
5b Gas 
chromatography and mass spectrometry were used to investigate the crude alkaloid 
mixture obtained from the bark of the tree, leading to the detection of over 20 
compounds, 16 of which were isolated in sufficient quantity for structural 
determination. Amongst these compounds were the known alkaloids yohimbine 9, 
aspidospermine  10 and quebrachamine 1 along with the newly discovered 
aspidospermidine 2 (Figure 3). The mass spectral fragmentation behavior and UV 
data of the aspidospermine class of alkaloids allowed the structural elucidation of 
aspidospermidine to be achieved. 
Figure 3: Alkaloids of A. Quebracho blanco. 
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The targets 
Our primary synthetic targets are aspidospermidine 2 and aspidofractinine 4. Both 
are structurally complex monoterpenoid Aspidosperma indole alkaloids and the 
parent members of their individual subclass (Figure 4). 
 
 
 
 
 
 
 
 
 
Figure 4: Ring & numbering system
6 of aspidospermidine 2 and aspidofractinine 4. 
 
Whilst aspidospermidine 2 and aspidofractinine 4 are to date devoid of significant 
biological activity, their distinctive framework is found throughout the family of 
Aspidosperma alkaloids and in many bis-indole alkaloids which are 
pharmacologically significant. The fascinating molecular architecture of these 
natural products has inspired significant scientific effort. Both natural products, 
along with the others in their family, are isolated from the genera Aspidosperma 
from the Apocynaceae family. Aspidospermidine 2 is principally found in 
Aspidosperma Quebracho balanco (Argentina)
5b and Rhazya stricta (Asia)
7 with 
aspidofractinine  4 isolated from Aspidosperma refractum (Brazil)
8 and 
Aspidosperma pyrifolium (Brazil)
9.  
 Aspidospermidine  2 is the simplest alkaloid to contain the characteristic 
pentacyclic structure. It is devoid of sensitive functional groups and has 
consequently been used as the primary target to test the numerous synthetic 
strategies aimed at this family, resulting in numerous total syntheses. 
Aspidospermidine 2 is the parent of its subclass, the largest class of Aspidosperma 
alkaloids, with over 140 members; and typifies the core structure of this family with 
the pentacyclic ABCDE [6.5.6.6.5] ring system (Figure 4). Aspidofractinine 4, also 
the parent of its subclass (>30 members), retains this ring system but also has an 
additional F ring, ABCDEF [6.5.6.6.5.6]. The pentacyclic skeleton of 
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aspidospermidine  2, the four contiguous stereogenic centres on ring C and the 
creation of a tetrasubstituted carbon at the BCE ring junction are significant 
challenges that need to be realized in order to achieve a total synthesis. 
Aspidofractinine 4 has the additional challenge of installing the sixth ring.     
 
Biosynthesis 
  All indole alkaloids are derived from tryptophan 11 and the iridoid 
secologanin 13. Tryptophan decarboxylase converts tryptophan 11 to tryptamine 12, 
which then undergoes condensation with secologanin 13 to produce strictosidine 14, 
the general intermediate of indole alkaloid synthesis (Scheme 1).
10 The Apocynaceae 
family of plants produces a vast number of indole alkaloids with dramatically 
differing structures, all of which are obtained by rearrangement of the intermediate 
strictosidine  14 during secondary metabolism. As early as 1962 Biemann and 
coworkers postulated the presence of intermediates akin to 15 in the biosynthesis of 
these natural product systems.
5c However, the mechanistic pathways of some of 
these secondary metabolism processes still remain unclear today.  
Scheme 1: Proposed biosynthetic pathway for synthesis of Aspidosperma-type 
alkaloids. 
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It is believed that strictosidine 14 is deglycosylated to a reactive hemi-acetal, which 
opens to a dialdehyde that is subsequently captured by the secondary amine. Allylic 
isomerisation then gives the iminium intermediate 15 which undergoes conversion 
by unknown mechanism to stemmadenine 16. Dehydration and rearrangement to the 
acrylic ester 17 allows intramolecular cycloaddition to occur establishing the 
Aspidosperma skeleton, 18 (Scheme 1). 
  It is believed that the aspidofractinine-type alkaloids are biosynthesized from 
intermediates akin to 19. Tautomerism and saponification to 20, decarboxylation and 
enol formation (to 21), facilitate cyclisation to the hexacyclic skeleton giving 4 after 
reduction of the intermediate ketone (Scheme 2).
11 
 
Scheme 2: Late stage proposed biosynthetic pathway for synthesis of 
aspidofractinine-type alkaloids. 
 
Over the past half century numerous approaches to the complex ring systems of the 
Aspidosperma  alkaloids have been reported in the literature. Many follow bio-
mimetic pathways whilst others use these diverse ring systems as a template on 
which to develop new synthetic methodologies.  
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Previous syntheses 
  Over 20 total syntheses of aspidospermidine 2 have been reported
2,12,13,17-
32,34,35,40,41 since Stork and Dolfini’s pioneering work on this family in 1963.
12 Only 5 
have been reported for aspidofractinine 4.
36-41 The majority of the synthesis towards 
aspidospermidine 2 follow one of the following 3 synthetic strategies (Scheme 3): 
A – Stork’s Fischer indole cyclisation of aminoketone 22a with phenyl hydrazine.
12 
B – Harley-Mason’s rearrangement of 23.
13 
C – The elaboration of ring E onto the ABCD precursor 24a. 
Scheme 3: Synthetic strategies towards aspidospermidine 2. 
 
This literature review will discuss each of these strategies in turn, before reporting 
the more individual syntheses of aspidospermidine 2 and synthetic routes to 
aspidofractinine  4. Early syntheses of aspidospermine 10 will be covered where 
relevant. 
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Strategy A - Stork and Dolfini’s ground-breaking Fischer-Indole approach. 
  The first successful foray into this class of alkaloids targeted aspidospermine, 
10. In 1963 Stork and Dolfini performed a Fischer-Indole cyclisation between the 
key tricyclic ketone 22 and o-methoxyphenyl hydrazine to install the pentacyclic 
ring system of the natural product.
12 
  The key CDE tricyclic intermediate 22 was prepared according to Scheme 4. 
Alkylation of the pyrrolidine enamine of butyraldehyde, first with methyl acrylate 
then with methyl vinyl ketone, induced cyclisation to cyclohexenone 27. The ketone 
group was then protected by ketalisation before conversion of the ester moiety into 
the corresponding amide 28. LiAlH4 reduction of the amide next released the 
primary amine which on hydrolysis of the ketal underwent an internal Michael 
addition to the enone system installing the bicyclic system, 29. 
  Ring E was introduced by acylation of 29 with chloroacetyl chloride to give 
chloroacetamide 30. Cyclisation was then induced by treatment with potassium t-
butoxide. The key tricyclic aminoketone 22 was then accessed by ketalisation, 
lithium aluminium hydride reduction of the amide and subsequent deprotection of 
the ketone functionality.   
 
 
Scheme 4: Synthetic route to key intermediate 22.
12 
Reagents and conditions: (a) Pyrrolidine, methyl acrylate; (b) AcOH, H2O, RT, 67% (2 steps); (c) 
pyrrolidine, methyl vinyl ketone; (d) AcOH, H2O, , 48% (2 steps); (e) (CH2OH)2, H
+; (f) NH3, H2O; 
(g) LiAlH4; (h) H2O, H
+; (i) HO
-; (j) chloroacetyl chloride; (k) t-BuOK, benzene; (l) (CH2OH)2, H
+; 
(m) LiAlH4; (n) H2O, H
+. 
 
 With  aminoketone  22  in hand, the key Fischer-Indole cyclisation was 
performed. Treatment of the o-methoxyphenyl hydrazone of 22 with hot acetic acid 
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resulted in the formation of indolenine 32. Stereoselective reduction of the imine 
then set the C2 stereocentre. Finally, acetylation completed the total synthesis giving 
aspidospermine 10 (Scheme 5). 
 
 
 
 
 
Scheme 5: Fischer-Indole cyclisation and closing stages to aspidospermine 10.
12  
Reagents and conditions: (a) o-methoxy-phenylhydrazine, benzene,  then AcOH, ; (b) LiAlH4; (c) 
acetic anhydride. 
 
  This synthetic route represents a formal total synthesis of aspidospermidine 2 
and also allowed access to quebrachamine 1, another member of the Aspidosperma 
family. Cyclisation of the phenylhydrazone of 22 to give 33, followed by reductive 
cleavage with potassium borohydride gave quebrachamine 1, while reduction with 
LiAlH4 furnished aspidospermidine 2 (Scheme 6). 
 
 
 
 
 
 
 
 
 
Scheme 6: Closing stages to quebrachamine 1 and aspidospermidine 2.
12 
Reagents and conditions: (a) Phenylhydrazine, benzene,  then  AcOH, ; (b) KBH4, KOH, MeOH; 
(c) LiAlH4, THF, . 
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Ban’s approach towards tricyclic ketone 22.  
  Two years after Stork’s pioneering work, Ban and his co-workers completed 
their total synthesis of aspidospermine 10.
14 The route involved an alternative 
sequence for the preparation of aminoketone 22, at which point it converged with 
Stork’s original synthesis.
12  
  Condensation of 2 molar equivalents of acrylonitrile with methyl n-propyl 
ketone  34 gave 35 which afforded the bicyclic dicarbonyl 36 on treatment with 
sulfuric acid. Hydrogenation to 37 followed by steps to modify oxidation levels 
provided bicyclic amino ketone 29. The synthetic route then converged with Stork’s 
synthesis to insert ring E, then rings A and B to complete the total synthesis of 10 
(Scheme 7). 
 
 
 
 
 
 
 
 
 
 
 
Scheme 7: Synthetic route towards 10.
14 
Reagents and conditions: (a) 2 equiv. acrylonitrile; (b) 80% H2SO4, , 5 min, 80% (2 steps); (c) H2, 
Pd, HO
-, 79%; (d) LiAlH4, THF, 75 °C, 20 h, 81%; (e) Oppenauer oxidation, t-BuOK, cyclohexanone, 
74%. 
 
  The physical data obtained by Stork and Ban did not provide an exact match 
and it was found that Stork’s aminoketone 22a and Ban’s aminoketone 22b were 
stereoisomeric.
1 Stork’s elegant route to the natural product was not dependent on 
the stereochemistry of this tricyclic intermediate as it was deduced that the 
indolenine 32a, formed under the acidic conditions of the Fischer Indole cyclisation, 
could undergo isomerisation.
1 Reversible Mannich fission of the C12-C19 bond gave 
the open iminium ion 39 which can conceivably reclose to give either of the possible 
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isomers  32a  or  32b. Under equilibrating conditions the most thermodynamically 
stable arrangement dominates, irrespective of the stereochemistry in the initial 
aminoketone (22a or 22b), which in the Aspidosperma case is the natural one 32a 
(Scheme 8).  Ban et al. later reported the synthesis of the less stable kinetic product 
32b by performing the Fischer Indole cyclisation in formic acid.
15 
 
 
 
 
 
 
 
 
 
 
 
Scheme 8: Equilibration to the natural product arrangement. 
 
  Since Stork’s first contribution many groups have taken up the challenge of 
the total synthesis of aspidospermine 10, aspidospermidine 2 and related family 
members. Stork and Ban’s individual syntheses represent the first entry into this 
group of the indole alkaloids. Both prepared the tricyclic aminoketone 22 in racemic 
form before generating the pentacyclic core of the natural product using a Fischer 
indole synthesis. Many groups have followed this elegant strategy, preparing the key 
amidoketone intermediate 31 in various ways and completing the total synthesis 
using Stork’s closing sequence. 
 
Meyers’ asymmetric synthesis of tricyclic amidoketone 31. 
  In 1989 Meyers and Berney completed an asymmetric synthesis of the key 
amidoketone intermediate 31, and a total synthesis of the unnatural enantiomer, (+)-
aspidospermine 10.
16 The route used chiral bicyclic lactam 41 to set the absolute 
configuration at C5 of the natural product. With this centre set, the synthesis 
followed a similar strategy to Stork’s in next closing rings D and E. 
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  Meyers’ synthesis began by condensing the commercially available 
aminodiol 40 with a commercially available keto acid to give the chiral bicyclic 
lactam 41. This was then alkylated sequentially with ethyl iodide and allyl bromide 
to give 42 with the allyl group endo. Lactam 42  was next transformed into 
cyclohexenone 43 by treatment with Red-Al followed by acidic hydrolytic cleavage 
and the terminal olefin hydrated to alcohol 44 using 9-BBN with an oxidative work 
up. A short sequence of functional group manipulations afforded amide 45 which on 
heating in benzene with ethylene glycol and p-TSA induced closure of ring D to give 
46. Stork’s route was then used to incorporate ring E, giving chiral amidoketone 31a. 
The synthesis of (+)-aspidospermine 10 was then completed according to Stork’s 
synthesis (Scheme 9). 
 
Scheme 9: Meyers’ synthesis of (+)-aspidospermine 10.
16 
Reagents and conditions: (a) CH3COCH2CH2CH2CO2H, benzene, , 84%; (b) LDA, THF, EtI, 92%; 
(c) LDA, allyl bromide, 75%; (d) (1) Red-Al, toluene; (2) H2O, H
+, 77%; (e) 9-BBN, THF, 0 °C, then 
NaOH, H2O2; (f) Jones reagent, acetone, 70% (2 steps); (g) (1) oxalyl chloride, CH2Cl2; (2) NH3, 
73%; (h) ethylene glycol, p-TSA, benzene, , 85%; (i) (1) LiAlH4, THF, ; (2) H2O, H
+, , 87%; (j) 
chloroacetyl chloride, NEt3, benzene, 61%; (k) t-BuOK, benzene, 72%. 
  
Overall Meyers’ approach gave chiral amidoketone 31a in 11 steps and 7.4% overall 
yield from commercially available starting materials. 
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Aubé’s asymmetric synthesis of tricyclic amidoketone 31 and total synthesis of 
aspidospermidine (2). 
 Aubé  et al.
17 proposed the use of an intramolecular Schmidt reaction of azide 
47 to simultaneously install ring E and expand ring D in an enantiomerically pure 
synthesis of the Stork intermediate 31 (Scheme 10). The total synthesis would rely 
on the azide selectively reacting with the cyclopentanone in 47 in the key Schmidt 
reaction. 
 
Scheme 10. Retrosynthetic strategy employed by Aubé et al.
17 
 
  The preparation of enone 48 in an enantiomerically enriched form was 
achieved using a deracemizing imine alkylation protocol. Cyclopentanone 52 was 
condensed with (S)-α-methylbenzylamine and the resultant enamine condensed with 
vinyl ketone 51 (prepared in a 4 step process from diol 50). Acid hydrolysis followed 
by an intramolecular aldol reaction afforded the bicycle 48. γ-Oxidation to 53 was 
followed by ketalisation to 54, reductive debenzylation to 55 and a Mitsunobu 
reaction to azide 56, setting the stage for the crucial step. 
  The Schmidt reaction of 56 was not successful. However, following 
deprotection of the ketal to 47, which also induced isomerization of the side chain to 
the required α-position, it proceeded smoothly and selectively to give tricyclic 
lactam 31a as a single diastereoisomer (84% ee, ≥ 99% ee after recrystallisation). 
Paralleling Stork in the final stages, amidoketone 31a was converted in 3 steps to the 
corresponding ketoamine which underwent Fischer Indole cyclisation to complete 
the total synthesis of (+)-aspidospermidine 2 (Scheme 11). 
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Scheme 11: Aubé’s synthesis of (+)-aspidospermidine 2.
17 
Reagents and conditions: (a) NaH, BnBr, DMF; (b) PCC, CH2Cl2; (c) CH2=CH2MgBr, THF; (d) 
CrO3, H2SO4, acetone, 23% (4 steps); (e) (S)-α-methylbenzylamine, p-TsOH, benzene, reflux, 17 h; 
(f) 51, hydroquinone, fused ZnCl2, Et2O, reflux, 72 h; (g) 10% aq. AcOH, RT, 3 h; (h) NaOMe, 
MeOH, reflux, 24 h, 49% (4 steps); (i) p-TsOH, isopropenyl acetate, reflux, 5 h; (j) oxone, acetone, 3 
h, RT, 88% (2 steps); (k) bis(trimethylsilyl)neopentyl glycol, TMSOTf, CH2Cl2, 0 °C to RT, 10 h, 
69%; (l) H2, 10 % Pd/C, MeOH, RT, 12 h, 85%; (m) HN3, PPh3, DEAD, PhH, 0 °C to RT, 73%; (n) 
LiBF4, H2O, MeCN, 70 °C, 18 h, 89%; (o) TiCl4, CH2Cl2, 0 °C to RT, 2.5 h, 82%. 
 
In summary, Aubé’s approach incorporates a selective Schmidt cyclisation allowing 
the preparation of enantiomerically pure 31a in 14 steps from 50, with a 3.1% overall 
yield.  
 
Banwell’s synthesis of tricyclic amino ketone 22. 
  In 2002 Banwell and Smith reported a formal total synthesis of (±)-
aspidospermidine 2.
18 Their route exploits the multiple nucleophilic sites on pyrrole 
at N1, C2 and C3 to assemble the racemic CDE-ring substructure of aminoketone 22 
(Scheme 12). This late stage intermediate intersects Ban’s earlier synthesis of 
aspidospermidine 10.
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Scheme 12: Banwell’s formal synthesis of (±)-aspidospermidine 2.
18 
Reagents and conditions: (a) 160 °C, 2 h, 90%; (b) H3CNHOCH3.HCl, Et3N, pyridine N-oxide 
disulfide, Bu3P, CH2Cl2, 18 °C, 16 h, 87%; (c) (1) EtMgBr, Et2O, 18°C, 1 h, (2) 0.3 M aq. KHSO4 
(excess),  −40 °C, 0.1 h, (3) NaHCO3 (excess), −40 °C to 18 °C, 100%; (d) NaH (2 equiv.), 
(EtO)2POCH2CO2Me (2 equiv.), THF, 18 °C, 48 h, 77%; (e) AlCl3 (5 equiv.), Et2O, 18 °C, 5 h, 83%; 
(f) DIBAL-H (2 equiv.), CH2Cl2, −78 °C, 0.16 h, 75%; (g) MeSO2Cl, Et3N, CH2Cl2, 0−18 °C, 1 h, 
95%; (h) NaCN (5 equiv.), DMPU, 18 °C, 48 h, 91%; (i) KOH (26 equiv.), H2O, MeOH, , 16 h, then 
aq. HCl, 88%; (j) HCl (excess of a 5 M solution), 18 °C, 1 h, 72%; (k) H2, Pt2O (cat.), AcOH, 18 °C, 
18 h; (l) Dess-Martin periodinane (3 equiv.), CH2Cl2, 0−18 °C, 1 h , 28% over 2 steps. 
 
   The potassium salt of pyrrole 57 was heated with γ-butyrolactone 58 to give 
the product of N-alkylation. The resultant acid was then converted to a Weinreb 
amide which was treated with ethyl magnesium bromide to give ethyl ketone 59. A 
Wadsworth-Emmons olefination next gave 60, which underwent an intramolecular 
Michael-type addition to bicyclic ester 61. One carbon homologation to acid 62 was 
followed by a Friedel-Crafts cyclisation to give tricycle 63. Careful hydrogenation of 
63 gave alcohol 64 which in turn was oxidized to the tricyclic aminoketone 22a.  
  The late stage aminoketone 22a was achieved in 12 steps from pyrrole in 
5.8% overall yield. The racemic synthesis incorporates an intramolecular Michael-
type addition and a Friedel-Crafts type cyclisation to a pyrrole but is let down by a 
low yielding hydrogenation step 63→64.  
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Zard’s radical cyclisation approach to (±)-aspidospermidine. 
  In 2006 Zard et al. reported an approach to aspidospermidine 2 using a 
cascade reaction of amidyl radical 66 to construct the CDE tricycle 65 (Scheme 
13).
19 
Scheme 13: Retrosynthetic strategy employed by Zard et al.
19 
Their precursor for the amidyl radical cyclisation was synthesized according to 
Scheme 14. Thus, a Birch reduction of 67 with BrCH2CO2t-Bu quench yielded 
lactone 69 on treatment with aq. HCl, a precursor of 71.  Treating 71 under radical 
forming conditions initiated the desired 5-exo/6-endo sequential cyclisation to give 
tricycle 72 in 53% yield together with 23% of the mono-cyclisation product. 6-endo 
Cyclisation was promoted in the second ring closure by incorporation of a chlorine 
atom on the alkene acceptor. The tricycle 72 was then transformed to the 
aminoketone  22a by selective reduction of the lactam with 9-BBN and 
decarboxylation of the β-keto ester with LiCl in DMF (Scheme 14).  
  Zard’s synthesis achieves the synthesis of the late stage aminoketone 22a in 
19.8% overall yield in 10 steps. The tricycle (22a) was then converted to 
aspidospermidine 2 by the Fischer-indole cyclisation protocol. 
 
 
 
 
 
 
 
 
Scheme 14: Zard’s synthesis of (±)-aspidospermidine 2.
19 
Reagents and conditions: (a) AlCl3, AcCl, CH2Cl2, 98%; (b) H2, Pd(0), MeOH, 91%; (c) MeI, K2CO3, 
acetone, 85%; (d) Li, NH3, t-BuOH, THF, BrCH2CO2t-Bu; (e) HCl (aq.), THF, 90% (2 steps); (f) (1) 
isobutylchloroformate, Et3N, (2) hydroxylamine 70; (g) BzCl, Et3N, CH2Cl2, 67% (2 steps); (h) 
Bu3SnH, VAZO, α,α,α-trifluorotoluene, 53%; (i) 9-BBN, THF, , 93%; (j) LiCl, DMF, 140 °C, 88%. 
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Pearson’s [3+2] cycloaddition approach. 
  Also in 2006, Pearson et al. reported their formal total synthesis of three 
Aspidosperma alkaloids, including aspidospermidine 2, through the preparation of 
Stork’s intermediate 22.
20 Key steps in their sequence were a n-BuLi induced [3+2] 
cycloaddition of 76 to install rings C and E and an intramolecular Heck cyclisation 
of vinyl iodide 75 to install ring D (Scheme 15). 
Scheme 15: Retrosynthetic strategy employed by Pearson et al.
20 
 
  The key intermediate 76 was synthesized in a 14 step chain extension 
sequence from 2-bromoacrolein 77. Treatment of imine 78 with a dilute solution of 
n-BuLi gave cycloadduct 79 following successful [3+2] cycloaddition. N-alkylation 
of 79 with the allyl bromide 80 incorporates the vinyl iodide to give 81 which, under 
Heck conditions, gave tricyclic amine 82. A 2 step procedure was necessary to 
reduce the diene moieties and remove the BOM protecting group. Oxidation of the 
resultant alcohol with Dess-Martin then gave aminoketone 22a  to complete the 
formal total synthesis (Scheme 16).  
 
 
 
 
 
 
 
 
 
 
Scheme 16: Pearson’s formal synthesis of (±)-aspidospermidine A2.
20 
Reagents and conditions: (a) BuLi (2 equiv.), THF, −78 °C, then H2O; (b) 80, THF, K2CO3, 59% (2 
steps); (c) Pd(OAc)2, K2CO3, Bu4NCl, DMF, 43%; (d) H2, 10% Pd/C, MeOH, TFA, 98%; (e) Li, 
THF/NH3, NH4Cl, HCl, H2O/MeOH/THF; (f) Dess-Martin, HCl, H2O/Et2O, 54% (2 steps). 
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  Pearson achieved the synthesis of aminoketone 22a in 20 steps from 2-
bromoacrolein 77 in 4.6% overall yield. A lengthy synthesis gave access to the key 
intermediate 78 and the closing steps are let down by the low yielding Heck reaction 
and dissolving metal reduction/oxidation sequence. 
 
Coldham’s cyclisation/cycloadditon cascade approach to tricyclic amines. 
  The most recent total synthesis of aspidospermidine 2 was accomplished by 
Coldham  et al.
21 In a variation of Pearson’s [3+2] cycloaddition approach,
20 
Coldham envisioned a cyclisation/cycloaddition strategy to access tricyclic amine 85 
in one pot from acyclic precursors (Scheme 17). Coldham believed it should be 
possible to form the ylide from an aldehyde and amine together with in situ N-
alkylation and loss of Y by desilylation, destannylation or decarboxylation.  
 
 
 
 
 
Scheme 17: Coldham et al.’s planned synthesis of tricyclic amines (X = leaving 
group and Y = SiMe3, SnBu3 or CO2H).
21 
 
 Known  di-bromoketone  87 was readily prepared from ethyl 3-
bromopropionate 86 and subsequently transformed to protected enone 88. Sequential 
alkylation reactions then installed the nitrile functionality and side chain to give 90. 
Reduction of the nitrile with DIBAL-H provided the key aldehyde 91. Treatment of 
91 with glycine in the presence of 10 mol% camphorsulfonic acid initiated 
successful cyclisation/cycloaddition to tricyclic amine 92. Hydrolysis of the ketal 
with aq. acid along with isomerisation of the adjacent stereocentre provided the 
aminoketone 22a. The previously reported 3 step procedure of Stork et al. was then 
employed to complete the total synthesis of (±)-2 (Scheme 18). 
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Scheme 18: Coldham’s total synthesis of (±)-aspidospermidine 2.
21 
Reagents and conditions: (a) EtMgBr (2.2 equiv.), Ti(Oi-Pr)4 (0.1 equiv.), Et2O; (b) NBS, CCl4, 82% 
(2 steps); (c) HOCH2CH2OH, benzene, p-TsOH, , 18 h, then t-BuOK, THF/toluene, 0 °C, 2 h, 82%; 
(d) EtCH2CN, LDA, THF, −78 °C, then 88, 88%; (e) LDA, THF, −78 °C, 1 h, then 1-bromo-3-
chloropropane, 96%; (f) DIBAL-H, CH2Cl2,  −78 °C, then oxalic acid (0.5 M), 82%; (g) 
H2NCH2CO2H, toluene, camphorsulfonic acid (10 mol%), , 18 h, 79%; (h) 5% aq. HCl/THF, 80 °C, 
1 h, 89%. 
  
  Coldham’s synthesis exploits a cascade sequence to prepare the tricyclic 
amine  92 from 91, forming four new σ-bonds, three rings and three new 
stereocentres in the “one pot”. The route provides rapid access to Stork’s late stage 
intermediate in 8 steps from 86 in 32.8% overall yield. 
 
Strategy B – Harley-Mason’s rearrangement/cyclisation approach to the 
Aspidosperma skeleton. 
  In 1967 Harley-Mason et al. reported an elegant synthesis of (±)-
aspidospermidine 2 wherein the CDE rings were appended onto tryptamine using the 
acyclic precursor 96.
13 Alkylation of the pyrrolidine enamine of methyl 4-
formylhexanoate  93 with allyl bromide afforded aldehyde 94, which was 
subsequently converted to dimethyl acetal 95. Reductive ozonolysis of the terminal 
alkene afforded alcohol 96 which reacted smoothly with tryptamine to give hydroxy-
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lactam 23. Treatment of 23 with refluxing sulfuric acid induced cyclisation to C2 of 
the indole and rearrangement to the Aspidosperma skeleton, giving 97. LiAlH4 
reduction completed the total synthesis of (±)-aspidospermidine 2 in 20-25% yield 
from tryptamine (Scheme 19). 
 
 
Scheme 19: Harley-Mason’s total synthesis of (±)-aspidospermidine 2.
13 
Reagents and conditions: (a) Pyrrolidine, allyl bromide; (b) trimethyl orthoformate; (c) O3 then 
NaBH4; (d) tryptamine, AcOH, ; (e) 40% H2SO4 (or BF3.Et2O), 100 °C; (f) LiAlH4. 
 
Asymmetric approaches to aspidospermidine using the Harley-Mason 
methodology. 
  A number of asymmetric total syntheses of aspidospermidine have been 
reported using the cyclisation-rearrangement approach introduced by Harley-Mason 
and co-workers.
13 All involve the development of routes to cyclic analogues of 96 
with the absolute stereochemistry at the quaternary centre set. Fuji
22 and Schultz
23 
independently targeted (−)-aspidospermidine, the unnatural enantiomer of the natural 
product, while Okada
24 pursued (+)-aspidospermidine. 
  Fuji and coworkers prepared hydroxy lactam 23a as a 1:1 mixture of isomers 
in 9 steps from 98 in 47.7% overall yield.
22 The Harley-Mason cyclisation-
rearrangement strategy
13 followed by reduction then gave (−)-aspidospermidine 2 
(Scheme 20). This short efficient synthesis used the conjugate addition of the ester 
enolate of 99 to 98 to install the stereogenic centre. Reductive denitration of 100 then 
gave hemiacetal 101. Reduction to chiral lactone alcohol 102 and conversion to 
acetal 103 facilitated condensation with tryptamine to the desired intermediate 23a.  
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Scheme 20: Fuji’s total synthesis of (−)-aspidospermidine 2.
 22 
Reagents and conditions: (a) BuLi, DME/Et2O, −78 °C, 99%; (b) TiCl3, DME, pH 5; (c) NaBH4; (d) 
HCl, MeOH, 75% (3 steps); (e) CrO3, H2SO4, acetone; (f) DIBAL-H, Et2O; (g) TsOH, MeOH, , 
76% (3 steps); (h) tryptamine, AcOH, ; (i) NaOH, MeOH, 84%, (2 steps). 
 
  Schultz et al.
23 reported a synthesis of enantiomerically pure 107, a cyclic 
analogue of Harley-Mason’s intermediate 96. The key step in its preparation 
involved a diastereoselective dissolving metal reduction-alkylation sequence, which 
set the C5 quaternary carbon centre giving 106. A six step procedure afforded 
lactone  107 which underwent condensation with tryptamine to 108. DIBAL-H 
reduction to lactol 109, and acetic acid-induced cyclisation gave hydroxy lactam 23a 
as a 1:1 mixture of diastereoisomers, completing a formal total synthesis (Scheme 
21). 
 
Scheme 21: Schultz’s total synthesis of (−)-aspidospermidine 2.
23 
Reagents and conditions: (a) MeHN(CH2)2NMe2, n-BuLi, TMSCl, −20 °C, 24 h, then H3O
+, 87%; (b) 
(1) KMnO4, acetone, H2O, 94%; (2) (COCl)2, CH2Cl2, DMF, RT, 5 h, S-prolinol, CH2Cl2, -40 °C then 
Et3N; (3) NaH, THF, 0 °C, MeI, h, 88% (2 steps); (c) K, NH3, t-BuOH, THF, −78 °C, LiBr, 
piperylene, EtI, −78 °C, 97%; (d) tryptamine, (PhO)2P(O)N3, Et3N, THF, 84%; (e) DIBAL-H, 
CH2Cl2, −78 °C, 93%; (f) AcOH, , 20% NaOH/MeOH, 65 %. 
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The asymmetric synthesis was completed using the Harley-Mason rearrangement 
procedure to give (−)-aspidospermidine 2. Schultz’s synthetic route is the longest of 
this group with 18 linear steps to 2 in 13.6% yield. 
  More recently Okada et al. reported an asymmetric synthesis of (+)-
aspidospermidine via hydroxy lactam 23b.
24 This short synthesis introduced the key 
stereogenic centre by sequential alkylation of (S)-γ-trityloxymethyl-γ-butyrolactone 
110, firstly with ethyl iodide and then allyl bromide to give, after detritylation, 111. 
Complete removal of the hydroxy-bearing side chain provided 112 which, following 
reduction of the lactone and protection of the resultant lactol gave methyl acetal 113. 
Manipulation of the alkene side chain led to acid 114 which was condensed with 
tryptamine to give hydroxy-lactam 23b as a 1:1 mixture of diastereoisomers 
(Scheme 22).  
 
 
 
 
 
 
 
 
 
Scheme 22: Okada’s total synthesis of (+)-aspidospermidine 2.
24 
Reagents and conditions: (a) LDA, HMPA, EtI then, LDA, HMPA, allyl bromide, THF, −78 °C, 
93%; (b) 80% AcOH, 80 °C, 1 h, 98%; (c) 4 M aq. NaOH, dioxane, 100 °C, 1 h, CO2, aq. NaIO4, RT, 
3 h, 1 M HCl, 95%; (d) NaBH4, MeOH, RT, 1 h then, 4 M HCl-MeOH, 70 °C, 1 h, 92%; (e) DIBAL-
H, Et2O, −78 °C, 1 h then, CH(OMe)3, p-TsOH, MeOH, 80 °C, 40 min, 84%; (f) 9-BBN, THF, RT, 
16 h then, 30% H2O2, 3 M aq. NaOH, THF, RT, 1 h, 87%; (g) SO3-Py, DMSO, NEt3, CH2Cl2, RT, 0.5 
h; (h) NaClO2, t-BuOH, aq. NaH2PO4, Me2C=CHMe, RT, 1 h, 95% (2 steps); (i) tryptamine, AcOH, 
125 °C, 6 days, 87%; (j) 20% aq. NaOH, MeOH, RT, 1 h, 72%. 
 
Okada’s route gave hydroxy lactam 23b in 10 steps and 34.6% overall yield, 
allowing an asymmetric route of (+)-aspidospermidine to be completed. 
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Strategy C–Magnus’ end game E-ring closure. 
  The final group employ similar end game methodologies to that developed by 
Magnus  et al. to close ring E.
25   Magnus built the ABCD ring system through 
cyclisation of imine 117 with anhydride 118 to give 119 (Scheme 23). This 
tetracycle was then converted into pentacycle 121 through an intramolecular 
Pummerer reaction, closing ring E. Desulfurisation with Raney nickel and 
subsequent LiAlH4 reduction afforded (±)-aspidospermidine 2. This short synthesis 
(10 steps) achieved the natural product target in 3.4% overall yield from indole 3-
carboxaldehyde 115. The approach is let down by a low yielding step to install the 
requisite methyl at C2 of the indole centre in 116. The low yield associated with 
formation of tetracycle 119 (33%) from 117 and 118 is balanced by the formation of 
2 new rings and 3 key bonds in the one step. The Pummerer rearrangement strategy 
to close ring E, giving 121, is accomplished in 79% yield from 119 in 3 steps. 
 
Scheme 23: Magnus’ total synthesis of (±)-aspidospermidine 2.
25 
Reagents and conditions: (a) NaH, glyme, imidazole, 4-methoxybenzenesulfonyl chloride, , 2 h, 
70%; (b) t-BuNH2, CH2Cl2; (c) BuLi, THF, MeI, −78 °C to RT, 16 h, 43% (2 steps); (d) 2-
(phenylthio)ethylamine, 100%; (e) 118, chlorobenzene, 140 °C, 2.75 h, 33%; (f) MCPBA, CH2Cl2, 
NaHCO3, 0 °C, 97%; (g) Trifluoroacetic anhydride, CH2Cl2, 0 °C, 10 min;  (h) chlorobenzene, 130 
°C, 2.5 h, 81% (2 steps); (i) Raney nickel, EtOH, 20 °C, 1 h, 81%; (j) LiAlH4, THF, 20 °C, 48 h, 54%. 
 
  Numerous groups have reported synthesis of aspidospermidine using the E 
ring closing strategy of Magnus et al. These syntheses, six in total, employ 
N
H
O N
O
SO2
OMe
N
R
N
SPh
O
EtO2CO
N
N
R
O PhS
H
N
N
R
O
H
CF3CO2
SPh
N
N
R
O
H
PhS
N
H
N
H
a,b,c
115 117 116 118 119
120 121 2
de
f,g
h i,j23 
 
independent methods to establish the required ABCD ring system and are split into 
those which condense onto a ready formed indole nucleus and those which form the 
indole (AB) ring as a late stage development. 
 
E Ring closing strategy, routes to ABCD system via indole condensation. 
  Wenkert’s 1988 synthesis of (±)-aspidospermidine 2
26 accomplished the 
target according to Scheme 24. Carbinolamine lactone 125 was prepared by alkaline 
hydrolysis of cyclopropanecarboxylate 124, itself formed from enamide 123. The 
lactone was then condensed with indole in acetic acid to give amino acid 126. 
Cyclisation promoted by PPA installed the C ring giving 24b after LiAlH4 reduction. 
E ring closure was then accomplished by heating 24b in the presence of 1,2-
dibromoethane to install the remaining 2 carbons of the Aspidosperma skeleton. 
LiAlH4 reduction completes the sequence giving the natural product (±)-2 in 10 
linear steps from 122 and 4.0% overall yield. The closing of ring E was 
accomplished in only 32% yield to achieve the pentacycle (±)-2. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 24: Wenkert’s total synthesis of (±)-aspidospermidine 2.
26 
Reagents and conditions: (a) Methyl chlorocarbonate, NEt3, THF, 0 °C, 4 h, then HCl, 91%; (b) HBr, 
Et2O,  0 °C, 10 min, 1,3-propanedithiol, RT, 4 h, 48%; (c) W-2 Raney nickel, EtOH, , 12 h, 93%; (d) 
Ethyl diazoacetate, copper bronze, 135 °C, 0.5 h, 95%; (e) KOH, H2O, diethylene glycol, 110 °C, 12 
h, then HCl to pH 7, 88%; (f) indole, dioxane, HCl, 10% aq. AcOH, 80 °C, 18 h, 89%; (g)  PPA, 90 
°C, 45 min, 61%; (h) LiAlH4, dioxane, , 18 h, 97%; (i) K2CO3, 1,2-dibromoethane, 140 °C, 20 min, 
32%; (j) LiAlH4, Et2O, RT, 2 h, 70%. 
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 Rubiralta  et al.
27 set up the ABCD ring system through a tandem Michael 
addition-cyclisation of dithiane 129 with 3-methylene lactam 128 and ethyl iodide. 
Partial reduction of the resultant lactam 130 with DIBAL-H induced spontaneous 
cyclisation to 131 which, when treated with acetic acid, isomerizes to give the 
ABCD ring system 132. Finally, debenzylation, closure of ring E (via the tosylate) 
and reduction of the dithiane gave aspidospermidine 2 in 9 steps from 127 and 11% 
overall yield. E ring closure proved much more efficient via base mediated 
displacement of a tosylate, with this achieved in 77% from the corresponding alcohol 
(Scheme 25). 
 
 
Scheme 25: Rubiralta’s total synthesis of (±)-aspidospermidine 2.
27 
Reagents and conditions: (a) K2CO3, PhH, bromoethyl benzyl ether, , 24 h, 89%; (b) 6 M HCl, RT, 
12 h, 100%; (c) Ac2O, , 4 h, then aq. K2CO3, 0 °C, 4 h, 86%; (d) n-BuLi, THF, HMPA, EtI, −78 °C, 
2 h, 52%; (e) DIBAL-H, THF, 0 °C, 73%; (f) 50% aq. AcOH, , 2 h, 90%; (g) Me2S, CH2Cl2, 
BF3.Et2O, 35 °C, 2 h, 86%; (h) t-BuOK, TsCl, THF, 1 h, RT, 77%; (i) W-2 Raney nickel, dioxane, , 
30 min, 65%.  
 
E Ring closing strategy, routes to ABCD system via indole formation. 
 Heathcock
28 established the ABCD ring system from acyclic precursor 137 
using a pivotal intramolecular cascade to simultaneously form rings B, C and D 
(Scheme 26). A nine step sequence established precursor 137, which on treatment 
with TFA in dichloromethane initiates Boc deprotection, imine formation and two 
cyclisation reactions to give 138. Ring E was installed by conversion of the 
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chloroacetate 138 to the more reactive iodoacetate which, when treated with silver 
triflate, underwent cyclisation in 86%. Reduction of the lactam carbonyl completed 
the total synthesis of (±)-2. Heathcock accomplished the target in 13 linear steps in 
4.9% overall yield from 134.
28 
 
 
   Scheme 26: Heathcock’s total synthesis of (±)-aspidospermidine 2.
28 
Reagents and conditions: (a) o-azidobenzyl bromide, Cs2CO3, acetone, 94%; (b) acrylonitrile, 
Cs2CO3, t-BuOH; (c) KOH, 77% (2 steps); (d) CeCl3.7H2O, NaBH4, MeOH; (e) PCl5, pyridine, 63% 
(2 steps); (f) LiAlH4, 65%; (g) (ClCH2CO)2O, NEt3; (h) Boc2O, NEt3, 63% (2 steps); (i) O3, −78 °C, 
then Me2S; (j) 1:1 TFA: CH2Cl2, 37% (2 steps); (k) NaI, acetone; (l) CF3SO3Ag, 86%; (m) LiAlH4, 
82%. 
 
 Banwell
29 used a Pd[0]-catalysed Ullmann cross-coupling of iodide 140 
(prepared in 12 steps from commercially available 3-ethoxycyclohexenone 139) and 
o-iodonitrobenzene. The coupling was achieved in 75% affording the acetate 141, 
which was transformed into azide 142. Heating azide 142 in benzene for 3 days 
afforded aziridine 143 in good yield (72%) (Scheme 27).  
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Scheme 27: Banwell’s total synthesis of (±)-aspidospermidine 2.
29 
Reagents and conditions: (a) o-nitroiodobenzene (2 equiv.), Cu, Pd2(dba)3 (cat), DMSO, 70 °C, 5 h, 
75%; (b) aq. K2CO3, MeOH, 18 °C, 16 h; (c) MsCl, NEt3, Et2O, 0 to 18 °C, 2 h; (d) NaN3 (3 equiv.), 
DMF, 67 °C, 3 h, 87% (3 steps); (e) PhH, 75 °C, 3 d, 72%; (f) 1 M HCl in Et2O, CH2Cl2, −15 °C, 1.5 
h; (g) TiCl3.3THF (10 equiv.), H2O, 2.5 M aq. NH4OAc, acetone, 18 °C, 20 min, 46% (2 steps); (h) α-
chloroacetyl chloride, NEt3, CH2Cl2, 0 to 18 °C, 2 h, 69%; (i) NaI (10 equiv.), acetone, 56 °C, 2 h; (j) 
AgOTf (2 equiv.), THF, 18 °C, 30 min; (k) LiAlH4, THF, 66 °C, 2 h, 47% (3 steps). 
 
Regioselective cleavage to 144 and reduction to indole 24b allowed Heathcock’s E 
ring closing procedure to be mirrored to complete a total synthesis of (±)-
aspidospermidine 2. Banwell’s lengthy synthesis, 23 steps, achieves the target in 
1.8% overall yield. 
  The remaining syntheses in this group lead to asymmetric syntheses of (+)-
aspidospermidine. D’Angelo’s approach
30 employs a condensation between 2-
iodoaniline and dione 156 to establish the indole portion of the system and ABC 
rings onto which rings D and E are incorporated. Rawal’s synthesis
31 similarly builds 
up the ring system sequentially but establishes the indole moiety via the ACD ring 
system akin to the Banwell approach. 
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Scheme 28: Rawal’s total synthesis of (+)-aspidospermidine 2.
31 
Reagents and conditions: (a) 146, TsOH (cat.), CHCl3, , 1-2 d, 90%; (b) NaHMDS, TBSCl, −78 °C, 
THF, 100%; (c) 149a, 5 mol% 149b, CH2Cl2,  °C, 2 d, 91%; (d) Ph3PCH3Br, n-BuLi, THF, −78 
°C, 85%; (e) PhH, Schrock’s molybdenum catalyst (5 mol%), 60 °C, 1 h, 88%; (f) NPIF, DMSO, 
THF, 94%; (g) TiCl3, NH4OAc, THF, H2O, 89%; (h) TMSI (2 equiv.), CH2Cl2, MeOH, , 90%; (i) 
BrCH2CH2OH (10 equiv.), Na2CO3, EtOH, , 18 h, 100%; (j) MsCl, NEt3, CH2Cl2, 90%; (k) t-BuOK, 
THF, 87%; (l) NaBH4, EtOH; (m) H2, PtO2, EtOH, 73% (2 steps). 
 
 Rawal’s  synthesis
31 employed an enantioselective Diels-Alder reaction 
between 1-amino-3-siloxydiene 148  and ethylacrolein 149  to introduce the C5 
stereogenic centre. Converting the resultant aldehyde to triene 150 allowed ring D to 
be installed by ring-closing metathesis to give bicycle 151. (o-
Nitrophenyl)phenyliodonium fluoride (NPIF) was next used to introduce an o-
nitrophenyl group, giving 152. Reduction of the nitro group, indole formation and N-
alkylation then yielded 153. E ring closure was achieved in a similar fashion to 
Rubiralta, through mesylation and base-induced cyclisation. Finally, imine reduction 
(NaBH4) and hydrogenation of the remaining olefin completed the total synthesis of 
(+)-aspidospermidine 2. Rawal’s asymmetric synthesis was completed in relatively 
few steps (13) in 28% overall yield (Scheme 28). 
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  Earlier, d’Angelo had completed an asymmetric synthesis of (+)-2
30 using an 
asymmetric Michael addition a chiral enamine derived from 154 to introduce the C5 
stereogenic centre. The resulting cyclohexanone 155 was transformed into the 
cyclohexane-1,3-dione 156 in 6 steps and 35% yield, which was then condensed with 
2-iodoaniline to give precursor 157 (Scheme 29). Cyclisation and elaboration to 
amide 159 set up a TFA induced cyclisation to give tetracycle 160 as a single isomer. 
E ring closure mirrored that of Magnus et al.
25 Removal of the residual sulfur 
functionality and LiAlH4 reduction of the amide completed the asymmetric synthesis 
of the target in 22 steps from 154 in 2.7% overall yield. 
 
 
Scheme 29: D’Angelo’s total synthesis of (+)-aspidospermidine 2.
30 
Reagents and conditions: (a) (R)-(+)-phenylethylamine, toluene, p-TsOH, Dean-Stark, , 12 h; (b) 
methyl acrylate, hydroquinone, 65 °C, 3 d, then AcOH, THF, RT, 3 h, 83%; (c) 2-iodoaniline, p-
TsOH, toluene, Dean-Stark, , 5 h, 94%; (d) NaH, HMPA, CuI, 120 °C, 2 h, 84%; (e) LiEt3BH, THF, 
−40 °C, 1 h, then EtOH, 6 N NaOH, 0 °C, then 30% H2O2, RT, 15 h, 88%; (f) (1) NEt3, DMAP, 
CH2Cl2, THF, MsCl, 2 h, (2) DMF, NaN3, 80 °C, 2 h, (3) tetrabutylammonium hydrogensulfate, (p-
methoxyphenyl)sulfonyl chloride, CH2Cl2, 50 % aq. NaOH, 2 h, RT, 74%; (g) NaBH4, EtOH, , 30 
min, 92%; (h) PPh3, THF, 18 h, H2O, RT, 12 h, CH2Cl2, 0 °C, (phenylthio)acetyl chloride, NaOH, 30 
min, 62%; (i) TFA, CH2Cl2, 0 °C, 15 min, 94%; (j) sodium m-periodate, THF, MeOH, H2O, RT, 72 h, 
88%; (k) trifluoroacetic anhydride, CH2Cl2, 0 °C, 15 min, chlorobenzene, 135 °C, 2 h, 89%; (l) W-2 
Raney nickel, EtOH, DMF, 20 min, RT, 56%; (m) LiAlH4, THF, 0 °C, RT, 48 h, 68%.    
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Other syntheses. 
  Four further approaches are worthy of note here. Laronze and Levy reported 
a short total synthesis of aspidospermidine in 1974 (Scheme 30),
32 wherein the 2-
hydroxytryptamine equivalent 164 was prepared in a five step process from isatin 
161 according to the procedure reported by Harley-Mason.
33 This was then 
condensed with tricarbonyl diester 165 (prepared by exhaustive alkylation of 
butraldehyde) to give tetracycle 166 which, on treatment with PPA, underwent 
cyclisation, hydrolysis and decarboxylation to give 97b. LiAlH4 reduction of the 
lactam and imine gave the target pentacycle (±)-2 in 8 steps from isatin in 7.3% 
overall yield. 
 
Scheme 30: Laronze and Levy’s total synthesis of (±)-aspidospermidine 2.
32 
Reagents and conditions: (a) Ethyl cyanoacetate, EtOH, piperidine, , 4 h, 73%; (b) 3 N HCl, zinc 
dust, EtOAc, 90%; (c) 10% aq. NaOH, , 4 min, then HCl, 84%; (d) ethylene glycol monoethyl ether, 
, 2 h, 75%; (e) H2, PtO2, HCl, EtOH, H2O, RT, 60%; (f) 165, benzene, , 62%; (g) PPA, 125 °C, 10 
h, 68%; (h) LiAlH4, 70%.   
 
  In 2002 Marino et al.
34 reported a new strategy for the enantiospecific 
synthesis of Aspidosperma alkaloids resulting in a total synthesis of (+)-
aspidospermidine  2. Their synthesis employed a ketene lactonization reaction of 
chiral sulfoxide 169, which enatiospecifically set the critical C5 quaternary carbon 
centre. Lactone 168 in turn provided enone-amide 167, setting up a tandem 
conjugate addition-alkylation sequence on route to (+)-2 (Scheme 31). 
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Scheme 31: Retrosynthetic strategy employed by Marino et al.
34 
  
  Their synthesis began with the preparation of enantiomerically pure alkynyl 
sulfoxide  172 which was then added to the cuprate reagent derived from ortho-
lithiation of Boc-aniline, to give vinyl sulfoxide 169 after a further Boc protection. 
The crucial ketene lactonization step was then performed on 169 to afford 
dichlorolactone 173 which, after dechlorination and deprotection, gave lactone 168. 
Opening of the lactone with pyrrolidine next gave aldehyde 174 which underwent 
intramolecular aldol condensation and amide formation to give cyclohexenone 167. 
Exposure of amide 167 to NaH induced a stereoselective tandem conjugate 
addition/intramolecular alkylation sequence to establish the tetracyclic core of (+)-
aspidospermidine 2, giving enone 175 after oxidation. A sequential deprotection-
conjugate addition process then installed the indoline ring giving 176 with all five 
rings in place. A final reduction strategy completed the total synthesis in 15 steps 
and 7.9% overall yield (Scheme 32). 
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Scheme 32: Marino’s total synthesis of (+)-aspidospermidine 2.
34 
Reagents and conditions: (a) HOCH2CH2OH, benzene, cat. p-TsOH, , 90%; (b) THF, n-BuLi, −78 
°C, then MgBr2, 0 °C, then 171, −78 °C, 83%; (c) t-BuLi (2 equiv.), CuBr.Me2S, N-Boc-aniline, THF, 
−78 °C, 82%; (d) MeLi, Boc2O, THF, −78 °C, 81%; (e) Zn(Cu), Cl3CCOCl, THF, −45 °C, 78%; (f) n-
Bu3SnH, cat. Et3B, benzene, , 92%; (g) acetone, cat. p-TsOH, RT, 96%; (h) pyrrolidine, benzene, 
RT, 86%; (i) pyrrolidine, 2-propanol, 33% aq. AcOH; (j) i-BuOCOCl, NEt3, 3-chloropropylamine 
hydrochloride, THF, 0 °C, 64% (2 steps); (k) NaH, DMF, 0 °C, 86%; (l) KHMDS, TMSCl, THF, −78 
°C, then Pd(OAc)2/O2, DMSO, 60 °C, 80%; (m) 3 M HCl, 2-propanol, , 0.5 h, 90%; (n) 
H2NNH2.H2O/Na/HOCH2CH2OH, 160 °C, 1 h, then 210 °C, 3 h, 75%; (o) LiAlH4, THF, , 3 h, 90%. 
 
  In 1998 and 2000 Murphy and coworkers reported 2 total syntheses of (±)-
aspidospermidine.
2,35 Both approaches used radical methodology to install ring B. 
The first approach used a 12 step procedure to create precursor 183.
2 Electron 
transfer from TTF to diazonium salt 183 was followed by loss of dinitrogen to 
produce an aryl radical intermediate. This underwent cyclisation to install the cis-
[6,5] ring system (A and B). The resulting alkyl radical was trapped with TTF
+· to 
give a sulfonium salt which underwent uni-molecular solvolysis to yield the 
intermediate alcohol. Oxidation of the alcohol gave ketone 184  with the ABC 
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tricycle in place (Scheme 33). A Mukaiyama aldol reaction followed by spontaneous 
dehydration was then used to install the ethyl side chain giving 185. Luche reduction 
of ketone 185 followed by an internal Mitsunobu reaction of the alcohol closed ring 
E to afford 186 after reductive cleavage of the trifluoroacetamide group. This was 
followed by alkylation and a palladium-induced D ring closure to afford pentacycle 
190. Hydrogenation of the resultant alkenes followed by deprotection of the 
methylsulfonyl group completes the total synthesis of (±)-aspidospermidine 2 in 22 
steps (Scheme 33). 
 
  Scheme 33: Murphy’s total synthesis of (±)-aspidospermidine 2.
2 
Reagents and conditions: (a) NH3, Na, −78 °C, allyl bromide, −78 °C to RT, HCl, H2O, , 33%; (b) 
CeCl3, NaBH4, MeOH, 15 min, 71%; (c) PPh3, DEAD, THF, 0 °C to RT, 179, 1 h, 76%; (d) OsO4, 
NMO, acetone, H2O, t-BuOH, 20 h, 62%; (e) NaIO4, Et2O, H2O, MeOH, 4.5 h, 97%; (f) NaBH4, 
MeOH, 10 min, 91%; (g) MeSO2Cl, NEt3, CH2Cl2, 19 h, 70%; (h) NaN3, DMF, 96%; (i) 
HSCH2CH2SH, NEt3, i-PrOH, NaBH4, 48 h; (j) (CF3CO)2O, NEt3, DMAP, THF, 0 °C to RT, 4 d, 
87%; (k) NaBH4, Cu(acac)2, EtOH, 1 h, 70%; (l) NOBF4, CH2Cl2, 0 °C, 1 h; (m) TTF, acetone, H2O, 
2 d, 45% (2 steps); (n) PCC, CH2Cl2, 18 h, 83%; (o) TMSCl, NEt3, DMF, 80 °C, 48 h, then TiCl4, 
paraldehyde, CH2Cl2, −78 °C, 30 min, then RT, 48 h, 51%; (p) NaBH4, CeCl3.7H2O, MeOH, 0 °C, 
100%; (q) DEAD, PPh2Me, THF, 0 °C to RT, 99%; (r) NaBH4, EtOH, 60 °C, 82%; (s) 187, K2CO3, 
THF, 80%; (t) Pd(OAc)2, NEt3, PPh3, MeCN, , 37%; (u) 10% Pt/C, H2 40 psi, EtOH, 5 d, 58%; (v) 
Red-Al, toluene, 100 °C, 84%. 
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  Murphy’s second synthesis
35  employed a radical cascade cyclisation to 
simultaneously construct rings B and E in the target. An aldol condensation between 
the enolate of 191 and acetaldehyde, followed by mesylation, affords 192 which was 
further reduced to enone 193 with DIBAL-H. Luche reduction and a Mitsunobu 
reaction coupling produced sulfonamide 194. Sequential oxidative cleavage of the 
terminal alkene, aldehyde reduction to alcohol 195, elimination of the mesylate, 
mesylation and azide displacement gave azide 196. Treatment under radical forming 
conditions then induced a tandem radical cyclisation to install rings B and E, giving 
the known tetracycle 186 and intersecting their previous total synthesis (Scheme 34).  
 
 
Scheme 34: Murphy’s second total synthesis of (±)-aspidospermidine 2.
35 
Reagents and conditions: (a) LDA, CH3CHO, 72%; (b) NEt3, MsCl, DMAP, CH2Cl2, 83%; (c) 
DIBAL-H, CH2Cl2, 67%; (d) NaBH4, CeCl3.7H2O, MeOH, 67%; (e) 2-
iodophenylmethanesulfonamide, DIAD, Me3P, THF, pyridine, 51%; (f) OsO4, NMO, acetone, H2O, t-
BuOH, 78%; (g) NaIO4, Et2O, H2O, EtOH, 65%; (h) NaBH4, MeOH, 20 min, 95%; (i) DBU, toluene, 
, 91%; (j)  MsCl, NEt3, DMAP, CH2Cl2, 78%; (k) NaN3, DMF, 50 °C, 72%; (l) TTMSS, AIBN, 
benzene, , 40%. 
 
Previous syntheses of aspidofractinine. 
  In contrast to the numerous syntheses reported for aspidospermidine 2, the 
total synthesis of aspidofractinine 4 has been realized on just four occasions. Each is 
by a different group and employs a strategy successfully employed in a synthesis of 
aspidospermidine 2. 
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Ban’s early contribution. 
  Ban and co-workers were one of the first groups to develop an approach to 
the pentacyclic ABCDE ring system of the Aspidosperma family of alkaloids. 
Eleven years later they were the first to achieve a total synthesis of aspidofractinine 
4.
36 Ban’s synthesis began with 2-hydroxytryptamine hydrochloride 164a which was 
condensed with 3-oxobutanal ethylene ketal 197 to give tricyclic oxindole 198. A 
Michael-type intramolecular cyclisation next installed ring D giving 200. Treatment 
with NaH in refluxing DMSO for 60 hours followed to close ring C, giving 
pentacycle 201 after tosylation. Reduction of ketone 201 and subsequent dehydration 
furnished diene 202 which was then subjected to a Diels-Alder cycloaddition with 
nitroethylene, installing the final F ring to give 203. Further functional group 
manipulations accomplished the total synthesis of (±)-aspidofractinine 4 (Scheme 
35). 
 
Scheme 35: Ban’s first total synthesis of (±)-aspidofractinine 4.
36 
Reagents and conditions: (a) basic aq. EtOH, 63%; (b) β-chloropropionyl chloride; (c) H3O
+; (d) 
EtOH, CH2Cl2 NaOH, RT, 12 h, 89%; (e) Et3O
+BF4
- (6 equiv.), 1,2-dichloroethane, 65 °C, 20 h, 51%; 
(f) NaH, DMSO, , 60 h, 50%; (g) TsCl, CH2Cl2; (h) NaBH4, EtOH, THF, RT, 87%; (i) pyridine, 
PBr3, benzene, RT, 74% (j) nitroethylene, CH2Cl2, RT, 12 h, 80%; (k) H2 (5.3 atm), PtO2, 90%; (l) 
sodium nitrate, aq. AcOH, 55 °C, 5 h, 43%; (m) LiAlH4, 1,2-dimethoxyethane, , 3 h; (n) H2, Pt, 
EtOAc, 100% (2 steps).  
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  Some 10 years later, Ban and co-workers reported an adaptation of their first 
total synthesis from the common intermediate 201.
37 The two carbon Michael-
acceptor chloromethoxyvinyl sulfoxide was introduced onto ketone 201 using 
LiHMDS to give 205. Reduction and desulfurization produced enol ether 206, a 
precursor to allylic alcohol 207. A short reduction sequence then afforded unstable 
indolenine 208 which, when treated with dilute HCl at 110 °C, smoothly underwent 
cyclisation to produce the hexacyclic ring system 209. Finally, reductive removal of 
the ketone moiety gave the natural product (±)-4 (Scheme 36).   
 
Scheme 36: Ban’s second total synthesis of (±)-aspidofractinine 4.
37 
Reagents and conditions: (a) LiHMDS, THF, −78 °C; PhSOCH=C(Cl)OMe, 60%; (b) P4S10, THF, , 
78%; (c) Raney nickel, THF, , 67%; (d) LiAlH4, THF, −50 °C; (e) aq. H2SO4, THF, 86% (2 steps); 
(f) SOCl2, pyridine, CH2Cl2, −50 °C, 30 min then NaHCO3, 53%; (g) Pt, H2, EtOAc, 100%; (h) Na-
naphthalene, THF, −78 °C, 50%; (i) dilute HCl, 110 °C, 1.5 h, 90%; (j) Huang-Minlon reduction, 
74%. 
 
Levy and Cartier’s total synthesis. 
  In 1989 Levy and Cartier reported a total synthesis of aspidofractinine 4 
which combined their acid induced cyclisation/decarboxylation protocol
32,38 (used 
towards aspidospermidine 2 with Ban’s intramolecular cyclisation of a methyl 
ketone to an oxindolic lactam
36 to install the hexacyclic framework of the natural 
product. Key intermediate 213 was established through the condensation of aldehyde 
212 and amine 164 to install rings ABDE. Double cyclisation of 213 to 214 was 
achieved by treatment with p-TsOH in refluxing toluene and is thought to proceed 
via initial cyclisation of the methyl ketone onto the oxindole ring followed by 
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decarboxylative cyclisation of the ester side chain. Ketolactam 214 was sequentially 
reduced (via the thioketal 215) to complete the total synthesis of (±)-aspidofractinine 
4 in 7 steps and 1.4% overall yield (Scheme 37). 
 
Scheme 37: Levy’s total synthesis of (±)-aspidofractinine 4.
38 
Reagents and conditions: (a) methyl acrylate, benzene, Triton-B (cat.), K2CO3, , 20 h, 26%; (b) 
ozonolysis, 65%; (c) toluene, , Dean & Stark, 2 h, then AcOH, , 5 h, 40%; (d) p-TsOH, toluene, , 
50%; (e) ethanedithiol, AcOH, BF3, RT, 12 h, 70%; (f) Raney nickel, EtOH, 87%; (g) LiAlH4, 70%.  
 
Gramain’s formal total synthesis. 
 Gramain’s
39 15 step formal synthesis of (±)-aspidofractinine 4 followed the 
common strategic plan to install the F ring but builds up the pentacyclic framework 
(ABCDE) in a unique way. Enamide 218 was synthesized in 4 steps from benzyl 
protected aniline 216 and 1,3-cyclohexanedione 217 to give the tetracycle 218. The 
necessary carbons for ring D were then introduced via  N-alkylation of 218. 
Subsequent functional group manipulation allowed D ring closure through 
intramolecular cyclisation to give pentacycle 220 from 219. The total synthesis was 
completed by hydrogenolysis of the residual N-benzyl group, Swern oxidation to 
indolenine 208 and cyclisation to 209 (Scheme 38). Reduction of 209 to (±)-4 had 
been accomplished by Ban et al.
37 so therefore Gramain’s work completed a formal 
total synthesis. 
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Scheme 38: Gramain’s total synthesis of (±)-aspidofractinine 4.
39 
Reagents and conditions: (a) p-TSA, toluene, , Dean-Stark, 8 h, 97%; (b) benzene, irradiation, 1 h, 
95%; (c) KH, THF, iodoacetamide, 30 min, RT, 93%; (d) camphorsulfonic acid, CH2Cl2, molecular 
sieves, , 8 h, 100%; (e) KH, THF, I(CH2)3-O-allyl; (f) LiAlH4, THF, ; (g) CH3COCl, NEt3, CH2Cl2, 
72% (3 steps); (h) LiAlH4, THF, 20 °C, 5 min, 60%; (i) DABCO, RhCl3, EtOH, H2O; (j) H3O
+, EtOH, 
H2O; (k) TsCl, pyridine, 48 h, 0 °C; (l) NaH, benzene, , 20%; (m) H2, Pd/C, EtOH, CHCl3; (n) 
(COCl)2, DMSO, NEt3; (o) HCl, MeOH, , 85% (3 steps). 
 
Wenkert’s joint total synthesis of (±)-aspidospermidine and (±)-
aspidofractinine. 
  In 1991 Wenkert reported his second total synthesis of aspidospermidine 2,
40 
followed in 1994 by a unified approach to aspidospermidine 2 and aspidofractinine 
4.
41 Thus a total synthesis of aspidospermidine 2
40 was accomplished through the 
rapid construction of the natural skeleton from indoleacetic anhydride and piperidine 
221 giving, after cyclisation, 223. Following oxidation to 201, the ethyl side chain 
was installed by treatment with KH, LiI and EtI to give 224. N-Deprotection and 
exhaustive reduction of the carbonyl groups gave 225 which, on hydrogenation gave 
(±)-aspidospermidine 2 to complete a 7 step total synthesis in 6.5% overall yield 
(Scheme 39). 
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Scheme 39: Wenkert’s second total synthesis of (±)-aspidospermidine 2.
40 
Reagents and conditions: (a) indolacetic anhydride, THF, RT, 24 h, 71%; (b) BF3.Et2O, 85 °C, 10 
min, 42%; (c) lead tetraacetate, CH2Cl2, , 15 min, 85%; (d) n-BuLi, TsCl, THF, 92%; (e) KH, LiI, 
EtI, THF, 52%; (f) LiAlH4, THF, , 65%; (g) H2, Pt/C, THF, 40 psi, 82%. 
 
 The  key  intermediate  223 was also transformed into diene 226 in 3 steps. A 
Diels-Alder cycloaddition reaction between this and phenyl vinyl sulfone installed 
ring F, furnishing hexacycle 227. Raney nickel and LiAlH4 reductions gave 
aspidofractinine 4. Alternatively, treatment of 227 with ethylene glycol and t-BuOK 
induces fragmentation of the F ring to give pentacycle 228. Reduction with LiAlH4 
provided (±)-aspidospermidine 2 (Scheme 40). 
 
 
 
 
 
 
 
 
 
Scheme 40: Wenkert’s synthesis of aspidospermidine 2 and aspidofractinine 4.
41 
Reagents and conditions: (a) n-BuLi, MeOCOCl, THF, 87%; (b) NaBH4, CeCl3, MeOH, 79%; (c) 
Et2O.BF3, 88%; (d) phenyl vinyl sulfone, benzene, 4 d, 120 °C, 75%; (e) EtSLi, HMPA, THF, 93%; 
(f) Ni, isopropanol, 88%; (g) LiAlH4, THF, 76%; (h) t-BuOK, HOCH2CH2OH, 150 °C, 87%; (i) 
LiAlH4, THF, 74%. 
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Our approach 
  Our approach to aspidospermidine 2 and aspidofractinine 4 drew inspiration 
from an unlikely source. Previous work within our group had shown that treatment 
of indoline 229 under radical forming conditions (TTMSS, AIBN, , PhMe) created 
indole 230 (Scheme 41). This result showed that translocation of an aryl radical to 
C2 of an indoline was both fast and efficient. We believed that such alkyl radicals 
could provide a way of elaborating the C2 position of an indoline under very mild 
conditions.   
 
 
 
 
 Scheme  41 
  Extrapolation of this result to the targets led us to an unusual disconnection 
for the Aspidosperma alkaloids in which a halogenated arene attached to the indoline 
nitrogen is used to activate the proximal methylene unit (Scheme 42). We believe 
that an aryl radical generated from 231a would induce 1,5-H atom abstraction, 
resulting in translocation to C2 of the indoline. In turn, this would readily undergo a 
6-endo-trig cyclisation to the proximal alkene to establish the [6.5.6.6.5] ring system 
of aspidospermidine 2 after hydrogenolysis. Importantly, by employing the same 
reaction conditions with di-iodide 231b, it should be possible to achieve double 
activation of the methylene group and a tandem radical translocation-cyclisation 
sequence leading to aspidofractinine 4.  
 
Scheme 42: Retrosynthesis of our proposed approach to aspidospermidine 2 and 
aspidofractinine 4. 
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The key intermediate 231 could in turn be obtained by ring opening of cyclopropane 
232 with imine 233. At first sight our suggestion that the radical cyclisation strategy 
will follow a 6-endo-trig cyclisation mode rather than the more usual 5-exo-trig 
pathway seems counterintuitive. However, we believe that the molecule’s rigid 
framework makes it easier to adopt a reactive conformer placing the terminal carbon 
of the acceptor alkene close to the C2 radical centre. 
  Our approach follows a unique strategy establishing the ABDE ring system 
initially before closing ring C (or rings C and F) using radical intermediates. Many 
of the previously reported routes have the C ring completed early in the synthetic 
strategy i.e. Fischer indole
12, Harley-Mason rearrangement
13 and the E ring closing 
strategies.
25-31 Those that do have the ABDE ring system established use indole 
(Wenkert
40) and oxindole (Laronze
32, Ban
36, Levy
38) centres to achieve closure of 
ring C. Our strategy allows the ABDE system to be established in one reaction 
giving a common precursor 231 to both aspidospermidine 2 and aspidofractinine 4.  
 
Radical methodology 
  Selective and direct activation of C-H bonds to allow replacement with new 
C-C bonds represents an important and long term goal in organic chemistry. 
Selective functionalisation of sp
3 C-H bonds could, in principle, allow targets to be 
synthesized with minimal functionalisation and maximum atom economy. One such 
way of elaborating C-H bonds is via radical translocation. The term ‘radical 
translocation’ is applied to reactions involving intramolecular abstraction of a 
hydrogen atom by a radical centre resulting in the relocation of the radical site. The 
new radical can then be used to elaborate positions which are unreactive to selective 
modification. H-atom abstraction generally occurs at a position 5 centres removed 
from the initial radical to accommodate the stereoelectronic preference for a X---H---
C ‘bond’ angle close to 180° (Figure 5).
42 The translocation step is driven by the 
formation of a more stabilized radical species and the creation of a relatively strong 
bond (e.g. Ar-H) at the expense of that which is broken (e.g. alkyl-H).     
 
 
 
Figure 5: Radical translocation by 1,5-H atom abstraction. 
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  In 1988 Curran
43 and Parsons
44 independently reported examples of radical 
translocation being used for C-C bond formation. Curran and co-workers showed 
that vinyl halide 234, on treatment with tri-butyltin hydride, under standard radical 
forming conditions, readily forms a reactive vinyl radical. 1,5-H-atom abstraction 
from the proximal acetate provides an alkyl radical centre able to undergo cyclisation 
to the acceptor alkene giving 235. The acetal group acts as a radical stabilizing 
group, weakening the C-H bond sufficiently to allow the chain reaction to propagate. 
Curran cleverly extended this tactic, by employing a modified protecting group, 
benzyl iodide, to act as the initiating radical intermediate. For example, the alkyl 
derived from 236 readily promotes 1,5-H atom abstraction from a proximal ethereal 
carbon, inducing cyclisation to 237. This leaves a simple benzyl group which can be 
removed by hydrogenolysis to reveal an alcohol (Scheme 43). 
 
 
 
 
 
 
 
 
Scheme 43: Curran’s radical translocation methodology.
43 
 
  Contemporaneously, Parsons and Lathbury
44 reported a radical cyclisation 
route to the pyrrolizidine ring system involving formation of a vinyl radical from 
238. 1,5-H atom abstraction from the allylic methylene was followed by a 5-exo-trig 
cyclisation to the pendant double bond leading to 239 (Scheme 44). 
 
 
 
 
 
 
Scheme 44: Parsons’ abstraction-addition sequence.
44 
 42 
 
In 1995 Undheim employed o-benzylhalides to initiate translocation to C2 of an 
indoline using samarium(II) iodide (Scheme 45).
45 In this case the α-aminyl radical 
is then reduced to a presumed α-amino samarium(III) intermediate which is trapped 
by the addition of the ketone to give alcohol 241 in a radical-polar crossover 
reaction.  
 
 
 
 
 
Scheme 45: Undheim’s approach to α-substituted amines.
45 
 
The above results provide some precedence for our key step, and demonstrate the 
potential of radical translocation in the functionalisation of remote carbon centres, 
including the 2-position of an indoline centre.  
 
Aims and objectives 
  Our goal is to complete short and efficient total syntheses of 
aspidospermidine 2 and aspidofractinine 4. Key steps include cyclopropane opening 
with imine 233 to prepare key intermediate 231 and the aforementioned radical 
translocation/cyclisation sequence to achieve CH activation and CH2 double 
activation in pursuit of the targets. The radical methodology will also be investigated 
to further explore the chemistry of the 2-indoine radical. 
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Chapter 2 – Establishing the ABDE Ring Core 
 
Early Approaches    
  The first phase of our program was concerned with establishing the ABDE 
ring system common to aspidospermidine 2, aspidofractinine 4 and the intermediate 
(242) for our key radical translocation step. Our primary plan was to construct the 
tetracyclic system 242 from the C3 substituted indoline 246 via amines 245 and 244 
(Scheme 46). 
Scheme 46: Retrosynthetic analysis for construction of the ABDE ring framework. 
 
Following introduction of the quaternary centre at C3, our plan envisioned a 
condensation between 245 and an aldehyde side chain unit with the carbon chain 
required for construction of rings D and E. Reduction of the Weinreb amide in 244 
provides an aldehyde which we hoped would react spontaneously with the proximal 
amine to close ring E. The resulting iminium ion intermediate would in turn be 
trapped by the incorporated silyl enol ether closing ring D to give spirocycle 243. 
The diene unit could then be incorporated, facilitating the radical cyclisation to close 
the final ring (Scheme 46). 
 Indoline-3-carboxylic  acid  246, the proposed starting material for this 
sequence, was not commercially available and consequently our attention turned to 
methods for its synthesis. Examination of the literature provided only one 
documented preparation from Wolf et al. in 1972.
46 They synthesized the indoline 
via a Birch-style reduction of 3-indole carboxylic acid 247a using sodium in 
anhydrous ethanol (Scheme 47).  
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Scheme 47: Early approaches towards C3 substituted indolines. 
 
In our hands the reduction was successful in furnishing the target, but proved 
capricious, low yielding (20-40%), difficult to perform and unsuitable for scale-up. 
Isolation and purification also proved problematic prompting us to examine the 
dissolving metal reduction conditions to the corresponding alcohol, ester and 
aldehyde derivatives 247b-d. Sodium and magnesium were both examined as 
reducing agents, though without success. Attention next turned to the possibility of 
effecting hydrogenation of the indole. Reductions of this type are known to proceed 
under forcing conditions of high pressure and temperature where over-reduction is 
often a problem.
47 Transfer hydrogenations have also been reported with 
functionalized indoles,
48 wherein protonation at C3 initially gives a 3H-indolium 
cation which is then attacked by the hydride source. Reported methods include: 
triethylsilane and TFA, NaB(CN)H3 and AcOH, BH3.DMS and TFA and Pd/C and 
formic acid.
48 These conditions were each applied to alcohol 246b, ester 246c and 
aldehyde 246d without success. Only Pd/C with formic acid succeeded in reducing 
the indole, but this caused decarboxylation at C3 so was of no practical use. Direct 
lithiation-addition protocols were also attempted but to no avail (Scheme 47).  
  With direct methods of preparing the required 3-substituted indoline proving 
unproductive, our attention turned to two alternative approaches. In the first we 
sought to use an oxindole core to elaborate C3; while in the second we sought to 
build the indoline core from an acyclic precursor (Scheme 48).  
 
  
 
 
Scheme 48: Retrosynthetic approach towards C3 substituted indolines. 
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Initial attempts to elaborate oxindole 251 proved unsuccessful. Though the C2 
carbonyl increased acidity at C3 we encountered intractable selectivity problems 
between N, C3 alkylation and O-alkylation (e.g. Scheme 49).  
 
 
 
 
 
Scheme 49: Oxindole selectivity problems. 
Reagents and conditions: (a) NEt3, CH2Cl2, RT, 48 h, 34%.  
  
  Formation of the indoline unit from acyclic precursors was investigated in 
numerous experiments, including the potential Lewis acid mediated opening of 
epoxide 255.
49 Epoxide 255 was formed from N-methylaniline 254 in 73% yield by 
alkylation with epibromohydrin. Unfortunately only starting epoxide 255 was 
recovered when treated with a variety of Lewis acids, with forcing conditions 
yielding complex product mixtures (Scheme 50). 
 
 
 
 
 
Scheme 50: Epoxide opening. 
Reagents and conditions: (a) K2CO3, epibromohydrin, EtOH, , 5 h, 73%.  
 
Radical cyclisation methodologies were also investigated, following an approach 
reported by Boger and Coleman.
50 The radical precursor 259 was prepared from 2-
bromoaniline 257 by sequential benzylation with 3,4-dimethoxybenzyl bromide 261 
(to 258) and alkylation with propargyl bromide (Scheme 6). Treatment of 259 under 
radical forming conditions, tributyltin hydride and VAZO in refluxing toluene, 
initiated C-Br homolysis and 5-exo-dig cyclisation of the resultant aryl radical. Rapid 
isomerisation of the resultant exo-cyclic alkene followed to give indole 260 as the 
major product in 90% yield.   
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Scheme 51: Radical cyclisation.  
Reagents and conditions: (a) NaH, DMF, 3 h, RT, then BnBr 261, 90 °C, 16 h, 67%; (b) NaH, DMF, 
RT, 4 h, then propargyl bromide, 60 °C, 72 h, 55%; (c) n-Bu3SnH, VAZO, PhMe, , 48 h, 90%. 
 
In the hope of preventing isomerisation of the exo-cyclic alkene the N-protecting 
group was modified to an amide moiety. Treatment of amide 262 with propargyl 
bromide gave the radical precursor 263 in 86% yield. When treated under the 
aforementioned radical forming conditions, 263 unexpectedly yielded tricycle 264 
indicating that the 6-exo/endo-trig cyclisation to the arene moiety was faster than the 
corresponding 5-exo-dig cyclisation to the alkyne (Scheme 52)! 
 
Scheme 52: Radical cyclisation. 
Reagents and conditions: (a) NEt3, CH2Cl2, RT, 16 h, 81%; (b) NaH, DMF, RT, 4 h, then propargyl 
bromide, RT, 16 h, 86%; (c) n-Bu3SnH, VAZO, PhMe, , 48 h, 32%. 
 
Curran and Jones
51,52 have both reported interesting findings in the radical 
cyclisation reactions of substituted anilides. In systems such as 263 the aryl radical, 
resulting from C-Br homolysis, has the choice of reacting with the functional group 
in the carbon substituent of the amide (in this case the electron-rich aryl) or in the 
other N-substituent (alkyne), leading potentially to a complex product mixture. The 
product ratios obtained were determined by the conformational preference of the 
starting material, with Curran and Jones both finding an overwhelming preference 
for one product in most cases. The anilide systems investigated had two significant 
factors contributing to their preferred conformation: (1) restricted rotation about the 
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C-N bond of the amide, and (2) restricted rotation about the aryl C-N bond 
(atropisomerism). The short lifetime of the unstable aryl radical means there is no 
time for rotation around either of these restricted bonds before cyclisation occurs; 
therefore the regioselectivity of the reaction is predetermined by the lowest energy 
conformation of the starting material.     
N-aryl amides have a preference to exist in an E geometry, placing aryl and O 
anti to one another. Thus, with regard to the amide rotatmers, conformers 263-C and 
263-D are lower in energy than 263-A and 263-B (Figure 6). On the radical 
cyclisation timescale the amide C-N geometry is essentially fixed. On consideration 
of the amide rotamers alone, the aryl radical can still potentially add to the alkyne or 
arene through rotation of the aryl C-N bond. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Conformations of amide 236. 
 
It is known that ortho-substituted anilides are chiral by virtue of the N-aryl 
twist and have significant rotational barriers.
53 The extent of the twist is determined 
by the competition between the need for planarity to allow resonance stabilization of 
the nitrogen lone pair into the aromatic ring and the severe steric interactions 
between the ortho-halide and the amide substituent which favours a perpendicular 
orientation. The resulting chirality induced by this twisted conformation is seen in 
the 
1H NMR spectrum of 263, which shows the diastereotopic nature of the NCH2 
hydrogens showing as two separate signals (5.09 (1H, b d, J=17.4 Hz, HC≡CCHH), 
4.12 (1H, dd, J= 17.4, 2.4 Hz, HC≡CCHH)).  
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Energetic maxima are expected at planar conformations where steric 
interactions are maximized and therefore regioselectivities shown during the radical 
cyclisation are due to the conformer with the least enathalpic and entropic costs. 
Curran suggested, on the basis of previous work,
51,53 that there was an overwhelming 
preference for the aryl radical to react with the functional group in the amide side 
chain, which suggests that in our system 263-D is the lowest energy conformer, 
leading to the regioselectivity seen.   
  With the C3-substituted indoline still evading us, our attention turned to an 
NCS-promoted oxidative alkylation procedure developed by Booker-Milburn et al.
54 
They had shown that the commercially available methyl indole-3-carboxylate 265 is 
readily transformed into oxindole 266, with a Claisen rearrangement generating a 
quaternary centre at C3 (Scheme 53). 
 
  
 
 
 
 
 
 
 
 
Scheme 53: Booker-Milburn’s addition-Claisen rearrangement sequence.
54 
 
We believed that reduction of the oxindole centre and subsequent manipulation of 
the C3 groups would provide access to our target indoline 245 (Scheme 54). 
 
Scheme 54: Retrosynthetic approach towards C3 elaborated indoline 245. 
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  In our hands the NCS promoted Claisen sequence proceeded smoothly to 
give oxindole 266  in 61% (Scheme 55). Reduction of the product with LiAlH4 
produced alcohol 271  in 43% yield together with significant amounts of 
decarboxylated by-products. Attempts to protect the resultant indoline as its 3,4-
dimethoxybenzyl ether proved low yielding (18%), prompting an examination of an 
array of related strategies. 
 
 
 
 
 
Scheme 55: Booker-Milburn addition-Claisen rearrangement. 
Reagents and conditions: (a) Dimethyl piperazine, NCS, CH2Cl2, 0 °C, 2 h, then, allyl alcohol, TFA, 
CH2Cl2, RT, 2 h, then, PhMe, silica gel, RT, 48 h, 61%; (b) LiAlH4, THF, , 24 h, 43%; (c) NaH, 
DMF, 3,4-dimethoxybenzyl bromide 261, RT, 16 h, 18%. 
 
  It was hoped that N-benzylation of indoline 266  would be an efficient 
process. Alas, protection with 3,4-dimethoxybenzoyl chloride proceeded in a 
disappointing 10% yield. Global reduction of the oxindole, ester and amide 
functionality of 273 with LiAlH4 did produce the desired protected indoline 272 
albeit in 11% yield. The major product of the reaction was indoline 271 which was 
formed in 63% yield (Scheme 56).  
 
 
 
 
 
 
Scheme 56: Reduction problems. 
Reagents and conditions: (a) 3,4-dimethoxybenzoyl chloride, NEt3, CH2Cl2, RT, 16 h, 10%; (b) 
LiAlH4, THF, , 16 h. 
 
The ease of C3-decarboxylation proved a constant burden in our investigation. For 
example, our attempt to effect the protection of oxindole 266 with benzyl bromide 
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274 gave rise to a complex product mixture from which two components were 
isolated. These were identified as the desired N-protected oxindole 275 (24%) and 
oxindole 276 (21%). The latter results from decarboxylation at C3 and benzylation 
of the resulting enolate (Scheme 57). 
 
Scheme 57: Attempted benzylation of 266 with 274. 
Reagents and conditions: (a) NaH, DMF, RT, 16 h. 
  
  A re-evaluation of the problems encountered with the oxindole system led us 
to consider whether we could use the C3-decarboxylation issues to our advantage. 
The ease with which decarboxylation occurs provides a good indication of the 
stability of the resulting enolate. Intercepting this with a suitable Michael acceptor 
provides a potential pathway to the required ABDE ring system (Scheme 58). 
 
 
 
 
 
Scheme 58: Retrosynthetic route from oxindole 279. 
 
Thus, oxindole 266 was subjected to the decarboxylating conditions of NaBr in 
refluxing DMF. The major product obtained was the N-methylated oxindole 281 
highlighting the nucleophilicity of the oxindole nitrogen. Ozonolysis of the resultant 
alkene gave aldehyde 282, which was subsequently reduced to alcohol 283 using 
NaBH4. A Mitsunobu reaction was then examined in the hope of conjoining alcohol 
283 and enamine 284. However, treatment with DIAD and PPh3 in THF produced 
cyclopropane  285 as the only significant product of the reaction, along with 
recovered starting materials. This was undoubtedly formed via an intramolecular 
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Mitsunobu reaction between the activated alcohol and the enolate of 283 (Scheme 
59). 
 
Scheme 59: Synthetic route towards cyclopropane 285. 
Reagents and conditions: (a) NaBr, DMF, , 2 h, 51%; (b) O3, CH2Cl2, -78 °C, PPh3, 1 h, 55%; (c) 
NaBH4, MeOH, RT, 1 h, 58%; (d) DIAD, PPh3, THF, RT, 16 h, 55%, (e) HBr, AcOH, RT, 6 h, 70%. 
 
The Mitsunobu Reaction 
Since its discovery in 1967
55 the Mitsunobu reaction has found wide spread 
use in many fields due to its versatility and high reliability. The reaction couples an 
alcohol with an acid/pronucleophile in the presence of diethyl azodicarboxylate 
(DEAD) and triphenylphosphine. The reaction proceeds with inversion of the 
alcohol stereocentre and can utilize a range of range of nucelophilic partners 
including acids, phenols, diols and imides. The reaction mechanism has been widely 
studied. The generally accepted mechanism with DEAD and PPh3 is shown in Figure 
7. Reaction of DEAD and triphenylphosphine produce a betaine intermediate A 
which reacts with the alcohol component to yield anion B and phosphonium C. 
Proton abstraction by anion B on the nucleophilic partner yields Nu- which attacks 
phosphonium C, displacing triphenylphosphine oxide, to give the coupled product 
that has inverted stereochemistry relative to the alcohol starting material. 
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Figure 7: Mechanism of the Mitsunobu reaction. 
 
  One of the major drawbacks to the Mitsunobu reaction is the requirement for 
stoichiometric quantities of DEAD and PPH3 that each produces a by-product. Thus 
even in high yielding reactions the desired product can often be difficult to isolate 
from the reaction mixture. Much research has been directed towards developing 
alternatives to DEAD and PPH3 that facilitate isolation of the coupled product.
56 An 
additional constraint of the reaction is the requirement of a nucleophilic coupling 
partner with a pKa of below 13, preferably below 11. If the pKa of the coupling 
partner is over 11, side reactions can lead to undesired products. Alternative reagents 
that moderate the limitations of pKa and extend the scope of the reaction are also 
being sought.
56  
A range of conditions were examined in the hope of promoting the desired 
intermolecular Mitsunobu reaction but to no avail. In each case the intramolecular 
cyclisation to 285 outpaced the desired coupling reaction to 278. We also explored 
the opening of cyclopropane 285 with various nucleophiles. Our only success came 
using the forcing conditions of HBr in acetic acid, which gave the bromide 286 in 
modest yield. To our frustration, attempts to displace the bromide with various 
nucleophiles resulted in ring closure to cyclopropane 285.  
 
Cyclopropane ring expansion-a route towards the ABDE ring system 
  At this juncture our attention turned to a recent publication by Carreira and 
coworkers, who had successfully induced the expansion of activated cyclopropanes 
with imines to saturated 5 membered ring nitrogen heterocycles.
57 The reaction used 
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MgI2 as a bifunctional catalyst, combining the Lewis acidity of the metal centre 
(Mg
II) with nucleophilicity in the counterion (I
-) (Scheme 60). 
 
 
 
 
 
Scheme 60: Carreira’s ring expansion strategy.
57 
 
Carreira et al. found that cyclopropane 287 could be smoothly transformed into the 
ring expanded tricycles 289 (as a mixture of diastereoisomers) on heating with an 
imine in the presence of 5 mol% MgI2. Stereoselectivity was dependent on the 
substituted imine partner 288 and on the N-protecting group of the oxindole 287. The 
major isomer isolated in the majority of cases, had the correct stereochemistry for the 
Aspidosperma alkaloids. Carreira proposed three possible mechanistic pathways for 
the reaction which differ in the sequence of events leading to C-N and C-C bond 
formation.
57 In pathway A, the imine acts directly as the nucleophile to open the 
cyclopropyl ring in 287. The resulting iminium ion 290 then undergoes ring closure 
giving 289. In pathway B, ring opening is induced by iodide to provide enolate 291. 
N-alkylation of the imine follows to give 290 and then 289. In pathway C, enolate 
291 is first captured by the imine to give 292, to set up an alkylative cyclisation to 
289 (Figure 8).  
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Carreira’s potential mechanistic pathways leading to ring expansion.
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The observation that the halide counterion played a critical role in the reaction (no 
reaction was observed with Mg(OTf)2) led Carreira to conclude that iodide 291 was 
indeed a likely intermediate.  
  This chemistry seemed ideally suited for construction of the ABDE ring 
system of aspidospermidine as the requisite cyclopropane 287 was easily prepared 
on a multi-gram scale (Scheme 61). Thus, N-benzylation of isatin 293 was followed 
by a Wolff-Kishner style reduction of the C3 ketone to 295. The Na-enolate of 295 
then underwent a clean alkylative cyclisation with 1,2-dibromoethane to afford 
cyclopropane 287.  
 
  
 
 
 
Scheme 61: Synthetic route towards cyclopropane 287. 
Reagents and conditions: (a) NaH, BnBr, DMF, RT, 1 h, 91%; (b) NH2NH2.H2O, , 16 h, 99%; (c) 
NaH, DMF, BrCH2CH2Br, RT, 16 h, 67%. 
 
Construction of the ABDE ring system of aspidospermidine next required us to 
prepare a cyclic imine. In the first instance we decided to examine a model system as 
the unsubstituted cyclic imine 297 is a literature compound available through 
oxidation of piperidine 296.
58 Thus, N-chlorination of piperidine with calcium 
hypochlorite led to the in situ formation of N-chloropiperidine, which underwent 
smooth dehydrochlorination with alcoholic potassium hydroxide to yield imine 297 
as the polycyclic trimer 298 (Scheme 62). 
 
 
 
 
 
Scheme 62: Synthesis of imine 297. 
Reagents and conditions: (a) (1) Ca(OCl)2, MTBE, AcOH, H2O, -10°C. (2) KOH, MeOH, MTBE, 
RT, 16 h, 17%. 
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With imine 297 and cyclopropane 287 in hand, our attention focused on the key ring 
expansion protocol. Pleasingly, heating a THF solution of cyclopropane 287, imine 
297 and MgI2 to 125 °C under microwave irradiation gave the desired tetracycle 299  
in 70% yield (Scheme 63). The sealed tube conditions described by Carriera
57 were 
not successful in our hands. Initially the reaction proved highly capricious which we 
attributed to the need for rigorously anhydrous conditions. However, further 
experimentation showed that imine purity was of far greater importance, as with 
freshly recrystallised imine trimer 298 the reaction worked consistently well even 
with ‘aged’ catalyst.  
  
 
 
 
 
 
Scheme 63: Ring expansion towards the ABDE ring system. 
Reagents and conditions: (a) MgI2, THF, 125 °C, 5 h, microwave, 70%. 
 
The reaction was examined in a range of solvents, at various temperatures, catalyst 
loading and substrate stoichiometries. The use of dioxane as a reaction solvent 
allowed us to increase the reaction temperature to 140 °C, though this afforded no 
apparent benefit. Best yields were attained when a THF solution of 287 (1 equiv.), 
297 (1 equiv.) and MgI2 (1 equiv.) were heated in a microwave at 125 °C for 5 h.   
  With the model tetracyclic ABDE system realized and the ring expansion 
reaction understood we looked at reduction of the oxindole centre. For the key 
radical cyclisation step to occur in the natural product system the C2 position of the 
indoline ring needs to be unmasked to allow for radical translocation by 1,5-H atom 
abstraction. The model ABDE system 299 gave us the opportunity to test the 
reduction of this centre. Pleasingly treatment of a THF solution of oxindole 299 with 
LiAlH4 at 70 °C for 2 h afforded indoline 300 in 79% yield (Scheme 64).  
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Scheme 64: Oxindole reduction. 
Reagents and conditions: (a) LiAlH4 (1.0 M in THF), THF, 70 °C, 2 h, 79%. 
 
Conclusions 
  Early investigations into the preparation of the indoline core were beset with 
significant problems. Switching to an oxindole base starting material facilitated 
elaboration of the C3 centre and installation of a cyclopropane moiety. Ring 
expansion of cyclopropane 287 with imine 297 provided a quick and efficient route 
to the ABDE ring system of the Aspidosperma alkaloids. Subsequent reduction of 
the oxindole unmasked C2 in indoline 300, completing work on this model for the 
natural product ring system.    
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Chapter 3 – Towards Aspidospermidine and Aspidofractinine 
 
Required divinyl imine    
  With a route to the ABDE ring system realized, attention turned to our 
natural product targets. For the proposed radical translocation chemistry to proceed, 
viz. 231a→2 and 231b→4, we needed to introduce two vinyl substituents at C3 of 
the cyclic imine (i.e. 233) (Scheme 62). With no literature method reported, we set 
about the task of developing an approach to this seemingly trivial target.   
 
Scheme 65: Retrosynthesis of our proposed approach to aspidospermidine 2 and 
aspidofractinine 4. 
 
Early routes towards divinyl imine 233 
  Our first approach drew inspiration from the work of Grieco and coworkers 
who prepared α-substituted cyclic imines from lactams by a method akin to that 
shown in Scheme 66.
59 Our plan was to introduce the vinyl groups using a double 
alkylation of TEOC-protected δ-valerolactam 304 to 303. Oxidation and thermally 
induced elimination should then reveal divinyl lactam 302. Reduction of the amide 
and fluoride-induced elimination then gives imine 233 (Scheme 66). 
 
Scheme 66: Retrosynthesis of our first approach to divinyl imine 233. 
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  The approach proved troublesome from the outset with TEOC protection of 
305 proceeding poorly in 23% yield. Our attempts to introduce the requisite sulfide 
containing side chains, viz.  304 to 306 or 307, proved equally fruitless with no 
products derived from α-alkylation of the enolate being observed (Scheme 67). 
 
  
 
 
 
 
Scheme 67: Alkylation of TEOC-protected δ-valerolactam 304. 
Reagents and conditions: (a) LiHMDS, THF, -78 °C, 30 min then 2-(trimethylsilyl)ethyl 4-
nitrophenylcarbonate, -78 °C to RT, 16 h, 23%; (b) LDA, THF, -78 °C, PhSCH2CH2Cl; (c) LDA, 
THF, -78 °C to RT, phenyl vinyl sulfone. 
 
  With the introduction of the sulfur-containing side-chains proving 
problematic, a less direct method of introducing two vinyl groups at C3 was 
examined. Our idea centered on the use of allyl bromide as the electrophilic partner 
in the enolate alkylation reactions. This would facilitate the introduction of two allyl 
groups at C3 which could be transformed into the required vinyl groups by an array 
of protocols. Here too, the approach was thwarted at an early stage, as we were 
unable to control the allylation reaction. In a typical reaction the major isolated 
product was that derived from mono-allylation at nitrogen, 308 (46%). In addition, 
both the bis-allylated and  tris-allylated products, 309 (27%) and 310 (7%) 
respectively, were formed in low yield (Scheme 68). Reaction optimization proved 
ineffective with low yields of the required product 310 obtained on each occasion. 
 
 
 
 
Scheme 68: Alkylation of δ-valerolactam 305. 
Reagents and conditions: (a) n-BuLi, TMSCl, THF, -78 °C to 0 °C, 3 h, then LDA, allyl bromide, 
THF, -78 °C to RT, 16 h. 
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  Our attention next focused on a reported synthesis of lactam 312 by Michael 
and coworkers,
60 as we hoped that the two esters could be manipulated to form the 
requisite 3,3-divinyl substituents (Scheme 69). 
 
 
Scheme 69: Retrosynthesis of our second approach to divinyl imine 233. 
 
 Nitrile  314 was prepared according to Michael’s procedure
60 from triethyl 
methanetricarboxylate 315 and acrylonitrile. Harsh hydrogenation conditions (Raney 
Ni, high pressures) were reported for the reduction of nitrile 314 to amine 313, so 
alternative conditions were sought to achieve this conversion (Scheme 70). 
Pleasingly, chemoselective reduction of the nitrile was achieved by reduction of a 
THF solution of 314 with LiAlH4 at RT for 24 h, followed by heating at reflux for 1 
h. However, the product given was lactam 320, lacking one of the ester functions at 
C3. This suggests that the hydride initially adds to one of the ester moieties. The 
resultant alkoxide 316 next collapses to enolate 317 with ejection of ethyl formate. 
Reduction of the nitrile follows, with cyclisation, to give 320 on workup.  
  With hydride additions proving problematic, hydrogenation conditions were 
explored using less forcing conditions than those performed by Michael. 
Hydrogenation of nitrile 314 was achieved using Adams’ catalyst (PtO2) and 
hydrogen at RT and atmospheric pressure resulting in three products. These were the 
desired lactam 312 (17%), the rearranged malonate 322 (36%) and unidentified 
dimeric material. The major products 312 and 322 arise from nucleophilic attack of 
the intermediate amine 313 on one of the ester functionalities. The thus formed 
tetrahedral intermediate 321 may then collapse with ejection of ethanol to provide 
lactam 312. Alternatively, ejection of the malonate leads to ring scission and the 
formation of 322 (Scheme 70).  
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Scheme 70: Tri-ester pathway towards lactam 312. 
Reagents and conditions: (a) acrylonitrile, Bu4NHSO4, K2CO3, PhMe, RT, 72 h, 46%; (b) LiAlH4 (1.0 
M in THF), THF, RT, 24 h, , 1 h, 80%; (c) PtO2, H2, EtOH, RT, 16 h. 
 
A return to sulfur: route towards divinyl imine 233 
  A solution to our problem was finally realized using the strategy outlined in 
Scheme 71. The plan sought to take dimethyl malonate 326 and introduce two 
sulfide-containing side-chains as precursors to the 3,3-divinyl moiety 325. 
Decarboxylation of 325 followed by trapping of the resultant anion with acrylonitrile 
introduces the required three carbon unit and a masked amine. Reduction of nitrile 
324 should then induce cyclisation to lactam 311 which in turn can be transformed to 
the imine 233.   
 
 
 
 
 
 
Scheme 71: Retrosynthesis of our third approach to divinyl imine 233. 
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  Alkylation of dimethyl malonate 326 with 2-chloroethyl phenyl sulfide gave 
the mono-addition product 327 (36%) and traces of decarboxylated material. Double 
addition could not be achieved with this electrophile, but was readily accomplished 
using phenyl vinyl sulfone, providing the known
61 bis-sulfone 328 (95%) and trace 
mono-addition product (3%) (Scheme 72). 
 
 
Scheme 72: Sulfides and sulfones. 
Reagents and conditions: (a) NaH, DMF,  RT, 30 min, then PhSCH2CH2Cl, 60 °C, 16 h, 36%; (b) 
Phenyl vinyl sulfone, [RuH2(PPh3)4], MeCN, RT, 4 d, 95%; (c) acrylonitrile, NaI, DMF, , 16 h; (d) 
DMF, , 24 h or DMF, microwave, 2 h. 
 
 With  the  bis-alkylated material in hand the decarboxylation-addition protocol 
was attempted. A solution of 328, acrylonitrile and NaI was heated at 130 °C for 16 
h to give an inseparable mixture of desired product 329 (major) and decarboxylated 
material 330 (minor). Attempted thermal elimination of the sulfones met with failure 
when heating at reflux in DMF or at 200 °C under microwave irradiation. We 
concluded that the sulfone moiety was too stable (with no degradation seen) to 
undergo elimination and that a switch to the corresponding sulfoxide would be 
beneficial. 
  Phenyl vinyl sulfoxide was thus used, along with catalytic NaH (0.2 equiv.), 
to introduce two sulfoxide side chains to form malonate 332 (77%) and the mono-
addition product 333 (9%) (Scheme 73). Use of a full equivalent of NaH diminished 
the yield significantly through formation of polymerized products. 
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Scheme 73: Exchange to sulfoxides. 
Reagents and conditions: (a) NaH (0.2 e.q.), DMF, phenyl vinyl sulfoxide, RT, 48 h. 
 
 With  bis-sulfoxide  332 in hand, we next examined the decarboxylation-
addition sequence. Heating bis-sulfoxide 332, acrylonitrile and NaI in DMF to 130 
°C for 16 h produced a complex product mixture comprised of the desired material 
336, decarboxylation product 337 and lesser amounts of the sulfoxide elimination 
products 331, 334, 335 and 338 (Scheme 74).  
 
 
 
 
 
 
 
 
 
Scheme 74: Sulfoxide elimination issues. 
Reagents and conditions: (a) NaI, acrylonitrile, DMF, 130 °C, 16 h. 
 
The extent to which each of these products were produced was strongly influenced 
by reaction temperature and time. Higher reaction temperatures (>140 °C) and 
prolonged reaction times (> 12 h) produced more of the elimination products 331 
(10%) and 335 (10%). However, in general these reactions were less efficient and 
gave products of lower purity. Limiting the temperature to 130 °C and the reaction 
time to 10 h, produced cleaner reactions, with higher overall yields for the usual 
isolated products 336 (65%) and 335 (20%). These could each be transformed into 
331 in high yield by thermolysis (Scheme 76), the two-step process being superior to 
all the ‘one-pot’ procedures investigated. 
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  Reduction of the nitrile functionality in 336 was explored in the hope that the 
resulting amine would undergo spontaneous cyclisation to the vicinal ester to 
produce the lactam core. Hydrogenation was investigated as a means to reduce the 
nitrile moiety of 336 but with no success. A range of catalysts, loadings and 
temperatures were examined using hydrogen at atmospheric pressure, but no sign of 
reaction was observed. Reduction with LiAlH4 at -78 °C unexpectedly gave 
aldehyde 340 in 56% yield (Scheme 75). We suspect that the neighboring sulfoxide 
groups stabilize the tetrahedral intermediate 339 preventing its collapse in situ and 
further reduction to the alcohol.  
 
 
 
 
Scheme 75 
Reagents and conditions: (a) LiAlH4 (1.0 M in THF), THF, -78 °C, 2 h, 56%. 
 
  With the sulfoxide functionality proving troublesome for the required nitrile 
reduction, we decided to re-order the reaction sequence and conduct the sulfoxide 
elimination at an earlier stage. Thermally induced elimination was achieved by 
heating  bis-sulfoxide  336 or mono-sulfoxide  335 under microwave irradiation at 
140-150 °C in DMF (Scheme 76). Classical thermolysis conditions proved an 
effective alternative, but extended reaction times considerably and produced less 
pure product. 
 
 
 
 
Scheme 76: Thermal elimination of sulfoxides 335 and 336. 
Reagents and conditions: (a) DMF, microwave, 110 W, 150 °C, 2 h, 75%; (b) DMF, microwave, 100 
W, 140 °C, 30 min, 64%. 
 
With the divinyl functionality now established in three steps from dimethyl 
malonate 326, attention turned to formation of the imine. LiAlH4 reduction of the 
nitrile and ester moieties in 331 could now be achieved. Using LiAlH4 at -78 °C for 
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2 h achieved reduction of the ester functionality only. By allowing the reaction to 
warm to 0 °C for 4 h, we hoped to achieve reduction of both the ester and nitrile 
groups. Unexpectedly, the product given was aminodiol 342¸ along with RSM 
(Scheme 77). Consequently, we found it necessary to employ a stepwise sequence to 
achieve our goal of reducing both the ester and nitrile functions. Thus, protection of 
alcohol 341 as its TBDMS ether produced smoothly silyl ether 343. Reduction of the 
nitrile with LiAlH4  at 0 °C then gave amine 344 in an optimized 72% yield. 
Deprotection to alcohol 345 followed by oxidation (IBX) to the aldehyde 346 should 
produce the desired imine directly through condensation of the amine and resultant 
aldehyde. Unfortunately, although we believe that deprotection of silyl ether 344 
with TBAF gave amino-alcohol 345, its high water solubility prevented its isolation 
or purification. Attempted oxidation (IBX) of the crude alcohol 345 proved 
unsuccessful. 
 
Scheme 77: Functional group manipulation towards imine 233. 
Reagents and conditions: (a) LiAlH4 (1.0 M in THF), THF, -78 °C, 2 h, 0 °C, 4 h, 5%; (b) LiAlH4 
(1.0 M in THF), THF, -78 °C, 6 h, 84%; (c) imidazole, TBDMSCl, DMF, RT, 20 h, 65%; (d) LiAlH4 
(1.0 M in THF), THF, 0 °C, 5 h, 72%; (e) TBAF (1.0 M in THF), THF, RT, 24 h. 
 
  Though the reaction sequence had failed to deliver imine 233, we believed 
that a change in the protecting group strategy would allow its preparation. Thus, 
reduction of ester 331 was accomplished with LiAlH4 at -78 °C then the resultant 
alcohol 341 was oxidized to aldehyde 347 with Dess-Martin periodinane. Protection 
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of the aldehyde as acetal 348 then facilitated reduction of the nitrile with LiAlH4 at 
60 °C to give amine 349. Finally deprotection of the acetal was achieved with 10% 
HCl, inducing spontaneous cyclisation to the desired divinyl imine 233 (Scheme 78). 
Interestingly, divinyl imine 233 was a stable entity and unlike its unsubstituted 
analogue 297, showed no tendency to form a cyclic trimer akin to 298. 
 
Scheme 78: Functional group manipulation towards imine 233. 
Reagents and conditions: (a) LiAlH4 (1.0 M in THF), THF, -78 °C, 6 h, 84%; (b) Dess-Martin 
periodinane, CHCl3, RT, 3 h, 95%; (c) ethylene glycol, p-TSA (5 mol%), PhMe, Dean-Stark, , 6 h, 
98%; (d) LiAlH4 (1.0 M in THF), THF, 60 °C, 4 h, 84%; (e) 10% HCl, RT, 2 h, then 10% NaOH to 
pH 9, RT, 2 h, 68%. 
 
Ring expansion: towards the targets 
  With a reliable synthesis to the divinyl imine 233 realized, attention turned to 
the cyclopropane ring expansion reaction that had proved successful in our model 
study. Cyclopropane 287, divinyl imine 233 and an equivalent of MgI2, were heated 
at 125 °C under microwave irradiation in a small scale reaction to give tetracycle 
350 in an unoptimised 4% yield along with recovered cyclopropane 287 (64%) 
(Scheme 79). 
 
 
 
 
 
Scheme 79: Ring expansion of cyclopropane 287 with imine 233. 
Reagents and conditions: (a) MgI2, THF, 125 °C, microwave, 3 h, 4% and 64% RSM. 
  
O
CN
MeO O H
CN
O
CN CN
O
O
O
O NH2
N
331 341 347
ab
348
c
349
d
e
233
N O
Ph
N
N
N O
Ph
H
+
287 233 350
a66 
 
Attention now turned to the synthesis of the more advanced analogue 354 
containing an ortho-halide in the N-benzyl group, as this would allow us to effect the 
key radical translocation sequence. Thus, isatin 293 was protected with 2-
bromobenzyl bromide to give 351. A Wolff-Kishner reduction to 352 was followed 
by cyclopropane formation to give 353. Pleasingly, ring expansion of cyclopropane 
353 with divinyl imine 233 provided tetracycle 354 in an unoptimised 44% yield 
together with recovered starting material (34%) (Scheme 80). Thus, in a short, highly 
convergent sequence, we had successfully prepared the ABDE ring system of 
aspidospermidine with the requisite functionality required to initiate C-ring closure 
through radical translocation and cyclisation to the acceptor alkene.  
 
  
Scheme 80: Synthetic route towards tetracycle 354. 
Reagents and conditions: (a) 2-bromobenzyl bromide, K2CO3, KI, MeCN, RT, 16 h, 98%; (b) 
NH2NH2.H2O, , 24 h, 88%; (c) NaH, DMF, BrCH2CH2Br, RT, 72 h, 62%; (d) MgI2, 233, THF, 125 
°C, microwave, 3 h, 44% and 34% RSM. 
 
Completion of the total synthesis required reduction of the C2 carbonyl of the 
oxindole in 354. Reduction was first examined with LiAlH4 at -78 °C, the low 
temperature being a precautionary measure to avoid reduction of the aryl bromide. 
Alas, no reaction was seen at these low temperatures. Warming to 0 °C facilitated 
consumption of the starting material to a more polar product which was shown to be 
aminal  355 with the aryl-halide bond still intact. Subjecting 355 to prolonged 
treatment with LiAH4 at 0 °C failed to induce further reduction, even after 24 h. 
Allowing the system to warm to RT for 4 h showed complete consumption of 
intermediate 355 to a less polar product. Unfortunately, the product formed was 
indole 357 rather than the desired indoline 356 (Scheme 81).  
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Scheme 81: Reduction of oxindole 354. 
Reagents and conditions: (a) LiAlH4 (1.0 M in THF), THF, 0 °C, 5 h, 45%; (b) LiAlH4 (1.0 M in 
THF), THF, RT, 4.5 h, 45%. 
 
Formation of 357 is assumed to occur via a Lewis acid mediated fragmentation of 
the E ring (via 358) to form indole 359. Reduction of the resulting iminium cation 
359 and aryl halide then furnishes indole 357 (Scheme 82). That the reduction did 
not progress in accordance with our model system (299→300) is presumed to be due 
to steric hindrance around the C2 centre. Relief of steric congestion, combined with 
the need to employ more forcing conditions, presumably contrive to make this 
unwanted side reaction more favourable. 
 
Scheme 82: Fragmentation of ring E. 
 
Unfortunately, time escaped us before alternative reduction conditions and the 
radical translocation methodologies could be investigated. 
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Conclusions and future work 
  In conclusion, robust syntheses of divinyl imine 233 and cyclopropane 353 
have been developed. Their union to form the ABDE ring system of 
aspidospermidine has also been realized using a recently developed ring expansion 
protocol by Carriera et al. Reduction of the oxindole failed to give the desired 
precursor 356 as seen in the model system (299→300).  
  It should be plausible to achieve the desired reduction of the C2-carbonyl and 
further investigations are ongoing to establish appropriate reducing conditions 
(Scheme 83). The ideal situation would leave the carbon-to-halogen bonds intact 
during the reduction. Results of model studies on the radical translocation 
methodology are presented in Chapter 4.  
 
Scheme 83. C2 reduction. 
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Chapter 4 – Radical Translocation-Cyclisation Methodology 
 
Towards a model system    
  The second key step in our proposed total syntheses involved a radical 
translocation and cyclisation cascade. Thus, our plan was to construct the C ring of 
aspidospermidine 2 from iodide 231a. Initial homolysis of the C–I bond by treatment 
of iodide 231a with Bu3SnH under standard radical forming conditions, would be 
followed by translocation of the aryl radical intermediate to C2 of the indoline. A 6-
endo-trig cyclisation to the proximal alkene then establishes the requisite 6.5.6.6.5 
ring system. Similarly aspidofractinine 4 could be achieved from di-iodide 231b, via 
sequential CH activation at C2 of the indoline to establish its 6.5.6.6.6.5 ring system 
(Scheme 84). 
 
 
 
 
 
 
Scheme 84: Radical translocation-cyclisation of key intermediate 231 towards the 
targets. 
 
The key step relies on a 6-endo-trig cyclisation of the C2 indoline radical 
intermediate to the proximal alkene. At first sight this cyclisation mode may seem 
counterintuitive with the 5-exo-trig cyclisation pathway being more usual. On closer 
inspection it can be seen that the molecule’s rigid molecular framework, owing to the 
ABDE ring structure, makes it easier to adopt a reactive conformer placing the 
terminal carbon of the acceptor alkene close to the reactive C2 radical centre (Figure 
9). 
 
 
 
 
Figure 9: Reactive conformer derived from 231. 
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As this key step was to be employed at a very late stage in our synthetic sequence, 
we decided to investigate some model systems to examine whether this methodology 
was practicable and efficient. We required a system that would allow us to test the 
efficiency of intramolecular translocation from the aryl radical to C2 of the indoline 
by 1,5-H atom abstraction. Having achieved this CH activation, we also needed to 
show that the cyclisation of the indoline radical to a pendant alkene was a facile 
process (Scheme 85). Importantly, we also wanted to show that by using a 2,6-diiodo 
benzyl group as a radical primer, CH2 double activation could be achieved and was 
capable of installing both the C and F rings of aspidofractinine 4 in the one step. 
Indoline 362 provided the means to examine this chemistry and to investigate the 
reactivity of the C2 indoline radical intermediate. Lacking the rigid molecular 
framework of 231, we anticipated a preference for cyclisation via the ubiquitous 5-
exo-trig cyclisation mode with 362a yielding 363a and 362b yielding propellane 
364.  
 
Scheme 85: Proposed model system. 
 
Towards a model system: early approaches    
  Our retrosynthetic analysis for 362 is outlined in Scheme 86. We hoped that 
it could be prepared from oxindole 367 via reduction of the C2 carbonyl moiety. The 
C3 side chains could be introduced to 368  via sequential alkylation, with N-
benzylation of isatin 293 providing the means to introduce this key element. 
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Scheme 86: Retrosynthetic analysis for the model system. 
 
In using isatin 293 as our starting point, we hoped to counter the intractable problem 
of N- vs. C-benzylation that had thwarted our early attempts to elaborate oxindole 
directly.  Introduction of the radical primer 370 to isatin 293 proceeded smoothly in 
98% yield and a subsequent Wolff-Kishner style reduction of the C3 ketone also 
proceeded in a pleasing 98% yield to give oxindole 372 (Scheme 87). C3 alkylation 
of oxindole 372 with 4-bromo-1-butene was then attempted via its sodium enolate. 
Various conditions were attempted without success, with starting material recovered 
on most occasions along with trace amounts of O-alkylation products.  
 
Scheme 87 
Reagents and conditions: (a) K2CO3, KI, DMF, 50 °C, 6 h, 98%; (b) NH2NH2.H2O, , 5 h, 98%, (c) 
NaH, DMF, 4-bromo-1-butene, RT. 
 
Exchanging the electron rich benzyl moiety 370 for 2-iodobenzyl bromide 374 was 
easily accomplished and allowed the derivatised oxindole 377 to be prepared in 3 
steps from isatin. Alkylation proceeded smoothly in this case to give bis-alkylation 
product 377 in 46% yield together with recovered starting material (Scheme 88).  
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Scheme 88 
Reagents and conditions: (a) NaH, DMF, RT, 1 h, 97%; (b) NH2NH2.H2O, , 16 h, 68%; (c) 3 equiv. 
NaH, DMF, 2.5 equiv. 4-bromo-1-butene, RT, 4 h, 46% (and 376, 30%). 
 
 
The analogous aryl bromide 378 was also prepared in similar fashion (Scheme 89). 
 
 
 
 
 
Scheme 89 
Reagents and conditions: (a) 2-bromobenzyl bromide, K2CO3, KI, MeCN, RT, 16 h, 98%; (b) 
NH2NH2.H2O, , 24 h, 88%; (c) 3 equiv. NaH, DMF, 3 equiv. 4-bromo-1-butene, RT, 4 h, 38%. 
 
To complete the synthesis of the model system we now needed to effect the 
reduction of oxindoles 377 and 378 to the respective indolines 362. Attempts to 
achieve this with LiAlH4 proved intractable as both the oxindole and the carbon-to-
halogen bonds in 377 and 378 were reduced to give indoline 379 (Scheme 90).  
 
Scheme 90 
Reagents and conditions: (a) LiAlH4 (1.0 M in THF), THF, , 2 h, 80%; (b) LiAlH4 (1.0 M in THF), 
THF, RT, 4 h, 40%. 
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To overcome this difficulty, we sought to effect the reduction of 378 at reduced 
temperature. Monitoring the reaction by HPLC showed that after 5 hours at 0 °C and 
4 hours at RT, significant amounts of starting material remained along with 
substantial quantities of the over-reduced products 379 and oxindole 380. Increasing 
the temperature of reduction led to complete consumption of the starting material but 
gave only 379 (60%) and 380 (15%) in appreciable quantity. Alternative reducing 
reagents were investigated including LiBH4, NaBH4 and Et2O.BF3, and DIBAL-H 
but each returned the staring material with good mass recovery.  
  Due to the problems encountered in both the alkylation and reduction steps, it 
was decided to change the synthetic plan and employ an alternative protecting group 
for the oxindole nitrogen. In this way we hoped to be able to exploit the 
aforementioned chemistry to prepare the requisite indoline, then introduce the radical 
primer group and investigate the radical methodology. 
 
Synthesis of a model system 
 Oxindole  351 was Boc-protected to 381 in 70% yield. Treatment of 381 with 
NaH and alkylation with 4-bromo-1-butene proceeded to give mono-alkylated 
oxindole  382 in 20% yield, bis-alkylated oxindole 383 in 44% yield, and trace 
amounts of O-alkylated material 384 (3%) (Scheme 91).  
 
Scheme 91: Boc-oxindole route towards the model system. 
Reagents and conditions: (a) Boc2O, Na2CO3, THF, RT, 16 h, 70%; (b) 2.5 equiv. NaH, DMF, 2.5 
equiv. 4-bromo-1-butene, RT, 4 h. 
 
The mono- and bis-alkylated indolines 382 and 383 were both needed for our model 
study so no attempt was made to optimize the reaction for either product. 
Deprotection of 383 with TFA in CH2Cl2 proceeded smoothly to give oxindole 385 
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in quantitative yield. Treatment with LiAlH4 then gave indoline 386 in excellent 
yield (Scheme 92).  
 
 
 
 
 
 
Scheme 92: Boc-oxindole route towards the model system. 
Reagents and conditions: (a) TFA, CH2Cl2, RT, 16 h, 100%; (b) LiAlH4 (1.0 M in THF), THF, 60 °C, 
16 h, 88%;  
 
The  mono-alkylated analogue 382 was first subjected to a second alkylation to 
replace the C3 hydrogen with a methyl group and hence prevent indole formation in 
the radical translocation step. Thus, the Na-enolate of 382 was treated with MeI to 
give 387, then subjected to the deprotection-reduction sequence to furnish indoline 
389 (Scheme 93). 
 
Scheme 93: Boc-oxindole route towards the model system. 
Reagents and conditions: (a) NaH, DMF, MeI, RT, 4 h, 41%; (b) TFA, CH2Cl2, RT, 16 h, 98%; (c) 
LiAlH4 (1.0 M in THF), THF, , 20 h, 98%. 
 
With the indoline analogues in hand, our next task was to prepare the radical primer 
groups (Scheme 94). Iodination of the electron-rich benzyl alcohols 390 and 393 was 
achieved in good yield by treatment with iodine and silver trifluoroacetate to give 
mono-iodide 391 (68%) and di-iodide 394 (99%) respectively. Subsequent treatment 
of the benzyl alcohols with thionyl chloride then gave the requisite benzyl chlorides 
392 (91%) and 395 (100%) in excellent yield. 
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Scheme 94: Preparation of radical primer groups. 
Reagents and conditions: (a) I2, CF3COOAg, CHCl3, RT, 1 h, 68%; (b) SOCl2, CH2Cl2, RT, 16 h, 
91%; (c) 2.5 equiv. I2, 2.5 equiv. CF3COOAg, CHCl3, RT, 16 h, 99%; (d) SOCl2, CH2Cl2, RT, 16 h, 
100%. 
 
The indolines 386 and 389 and radical benzyl primer groups 392 and 395 were now 
combined to give the three model systems 396, 397 and 398 (Scheme 95). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 95: Coupling indoline core and radical primer groups. 
Reagents and conditions: (a) K2CO3, acetone, , 16 h, 50%;  (b) K2CO3, KI, acetone, , 16 h, 79%; 
(c) K2CO3, KI, acetone, , 16 h, 46%. 
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CH activation and CH2 double activation of indolines 
  Our investigation of the radical translocation methodology began with model 
system 396. Under radical forming conditions, using TTMSS (2.2 equiv.) and 20 
mol% VAZO in refluxing toluene for 16 h, we were delighted to find that tricycle 
399 was given in 62% yield as a single diastereomer. The result proved that 
translocation of the aryl radical to C2 of the indoline was both fast and efficient and 
could be used to induce a subsequent radical cyclisation reaction (Scheme 96).  
 
 
 
 
 
Scheme 96: Radical translocation and cyclisation. 
Reagents and conditions: (a) 2.2 equiv. TTMSS, VAZO (20 mol%), PhMe, 120 °C, 16 h, 62%. 
 
Similarly, treatment of mono-iodide 397 under the radical forming conditions of n-
Bu3SnH (2.2 equiv.) and 20 mol% VAZO in refluxing toluene for 16 h smoothly 
gave tricycles 400 in 76% as an inseparable 6:1 mixture of diastereoisomers (Scheme 
97). The switch from TTMSS to n-Bu3SnH as the mediator of the radical reaction 
was for purely practical reasons. It allowed us to use our potassium carbonate/silica 
purification methodology (10% K2CO3, by weight of silica in stationary phase 
during column chromatography)
62 to remove tin residues from the product mixture, 
greatly assisting in the separation of 400 from the by-products of the radical reaction.  
 
 
 
 
 
 
Scheme 97: Radical translocation and cyclisation. 
Reagents and conditions:(a) 2.2 equiv. n-Bu3SnH, VAZO (20 mol%), PhMe, 120 °C, 16 h, 76%, 
d.r.6:1. 
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A more striking result was achieved when di-iodide 398 was treated under the 
radical forming conditions of n-Bu3SnH (4.4 equiv.) and 20 mol% VAZO in 
refluxing toluene for 16 h. In this case propellane 401 was isolated as a 1:1 mixture 
of diastereoisomers in an excellent 90% yield (following K2CO3/silica column 
chromatography). Sequential C-I bond homolysis led to successive translocation of 
the radical centers to achieve an efficient CH2 double activation of the C2 indoline 
centre (Scheme 98)!  
 
 
 
 
 
 
 
Scheme 98: Radical translocation and cyclisation towards a propellane system. 
Reagents and conditions: (a) 4.4 equiv. n-Bu3SnH, VAZO (20 mol%), PhMe, 120 °C, 16 h, 90%, d.r. 
1:1. 
 
  The three results highlight the potential of radical translocation as a means 
for derivatisation of centres generally thought of as unactivated. The radical 
methodology employs a CH bond to effect a ring closure and, more remarkably, CH2 
double activation to construct the propellane ring system from an indoline moiety. 
These successes show how the radical translocation-cyclisation methodology offers 
great prospects for achieving a unified approach to our natural product targets.    
 
Towards other propellanes 
  With the positive results obtained from the primary model systems we were 
encouraged to investigate the scope of the reaction further by looking at related 
approaches to propellane formation. We envisaged the possibility of cyclisation of a 
C2 indoline radical intermediate to benzyl substituents at C3 via a 5-exo/endo-trig 
cyclisation mode. Using a 2,6-diiodobenzyl group at N1 as a radical primer, the 
tandem cyclisation methodology would give access to propellanes of the type 402 
(Scheme 99).  
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Scheme 99: Towards other propellanes. 
 
The new system was prepared according to our previously established synthetic 
route. Thus, Boc-protection of oxindole 251 furnished 382, which was twice 
alkylated at C3 using NaH and benzyl bromide to give 404. N-Deprotection (to 405) 
followed by LiAlH4 reduction provided indoline 406. Its coupling with benzyl 
chlorides 392 and 395 supplied the required precursors 407 and 408 respectively in 
good yields (Scheme 100). 
 
Scheme 100: Synthesis of a second system. 
Reagents and conditions: (a) NaH (2.5 equiv.), DMF, benzyl bromide (2.5 equiv.), RT, 16 h, 60%; (b) 
TFA, CH2Cl2, RT, 4 h, 90%; (c) LiAlH4 (1.0 M in THF), THF, 60 °C, 16 h, 60%; (d) K2CO3, KI, 392, 
acetone, , 16 h, 76%; (e) K2CO3, KI, 395, acetone, , 16 h, 83%. 
 
Treatment of mono-iodide 407 under radical forming conditions (n-Bu3SnH, VAZO) 
failed to induce the anticipated cyclisation to 409 producing instead indole 410 in 
95% yield (Scheme 101). This implies that a successful radical translocation to C2 
was followed by loss of a stabilised benzyl radical and that this outpaced radical 
cyclisation to one of the proximal arenes.   
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Scheme 101: Radical translocation and elimination. 
Reagents and conditions: (a) n-Bu3SnH (2.2 equiv.), VAZO (20 mol%), PhMe, 120 °C, 16 h, 95%. 
 
Mindful of this result, we now expected treatment of di-iodide 408 under radical 
forming conditions to furnish tetracycle 411 rather than propellane 402 (Scheme 
102). The first radical translocation to C2 would be expected to form, after loss of a 
benzyl radical, indole 414. Homolysis of the second C-I bond would then give aryl 
radical 415, setting up a 5-exo-trig radical cyclisation to C2 of the indole giving 
tetracycle 411.
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Scheme 102 
Reagents and conditions: (a) n-Bu3SnH (4.4 equiv.), VAZO (20 mol%), PhMe, 120 °C, 16 h, 60%. 
 
Pleasingly, when the reaction was conducted using 4.4 equivalents of Bu3SnH and 
20 mol% VAZO in refluxing toluene, 411 was given in 60% yield. NOE experiments 
confirmed the stereochemical assignment of 411. Irradiation of the proton at C3 
(5.06 ppm), intensified the proton signals for the phenyl ring (7.42-7.34 ppm, 5H), 
OMe (3.70 ppm, 3H) and most importantly the CH2Ph group (3.16 and 3.07 ppm, 1H 
and 1H). On irradiation of the CHCH2Ph proton no significant enhancement was 
seen in the proton region below 6 ppm. 
  It is interesting to note that rearomatisation of benzyl radical 416 to indole 
417 does not occur. Instead H-atom abstraction completes the reaction sequence to 
give indoline 411. It is interesting to note the radical at C3 cannot align with the C-H 
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bond at C2 in this case, which would be required for aromatization through loss of 
H
·. It is also plausible that H-atom abstraction from one of the proximal aryl methyl 
ethers, 416→418, is facile and that this prevents aromatization to the indole. This 
would also explain the stereochemical outcome, in which a hydrogen atom is 
delivered to the more encumbered concave face of 418 (Scheme 103). 
 
 
 
 
 
 
Scheme 103 
 
Further studies on the C2-indoline radical 
  To further examine the chemistry of the C2-indoline radical, we decided to 
prepare the related homobenzyl derivatives 422 and 423. Boc-oxindole 382 was bis-
alkylated with 2-phenylethyl bromide to give 419 in 42% yield. N-Deprotection to 
420 and reduction to 421 furnished the indoline core structure which was 
subsequently coupled to benzyl chlorides 392 and 395 to give our precursors 422 and 
423 respectively (Scheme 104). By introducing an additional carbon into the C3 side 
chains we hoped to prevent fragmentation and indole formation, and facilitate 6-
exo/endo-trig cyclisation to the proximal arenes. 
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Scheme 104: Synthesis of model system 3. 
Reagents and conditions: (a) NaH (2.5 equiv.), DMF, 2-phenylethyl bromide (2.5 equiv.), RT, 16 h, 
42%; (b) TFA, CH2Cl2, RT, 6 h, 99%; (c) LiAlH4 (1.0 M in THF), THF, 60 °C, 16 h, 68%; (d) 
K2CO3, KI, 392, acetone, , 16 h, 57%; (e) K2CO3, KI, 395, acetone, , 16 h, 41%. 
 
Unfortunately, treatment of mono-iodide 422 under radical forming conditions (n-
Bu3SnH, VAZO) produced indoline 424 as the major product together with traces of 
indole 425 (Scheme 105). The result showed that the rate of H-atom abstraction from 
n-Bu3SnH outpaced addition of the C2-indoline radical to the pendant arene, as 
indeed did loss of a homobenzyl radical from C3. 
 
 
 
 
 
 
 
Scheme 105 
Reagents and conditions: (a) n-Bu3SnH (2.2 equiv.), VAZO (20 mol%), PhMe, 120 °C, 3 h. 
 
Treatment of di-iodide 423 under radical forming conditions provided a complex 
product mixture from which the reduction product 426 was isolated in 26% yield 
(Scheme 106).  
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Scheme 106 
Reagents and conditions: (a) n-Bu3SnH (4.4 equiv.), VAZO (20 mol%), PhMe, 120 °C, 6 h, 26%. 
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Conclusions 
  This study was undertaken to discover whether intramolecular translocation 
of an aryl radical to C2 of an indoline, by 1,5-H atom abstraction, was a feasible 
means of elaborating this centre. Having achieved this CH activation, we also wished 
to show that the C2-indoline radical could promote cyclisation to a pendant alkene 
and to determine whether this was a facile process. Pleasingly, the radical reactions 
of the initial model systems 396 and 397 showed that translocation and subsequent 
cyclisation were indeed promoted. More importantly, they showed that a doubly 
primed benzyl substituent, as in 398, promotes CH2 double activation of the C2 
centre, furnishing a propellane 401.   
  Work on the project continues, with the immediate aim of effecting the 
reduction of oxindole 360 to 361, keeping the aryl halide and E ring intact. With a 
synthesis of the indoline core realized, prospects are good for the radical induced CH 
activation and cyclisation approach to aspidospermidine 2 (hydrogenation and 
hydrogenolysis of 427 completing the total synthesis). Incorporation of a benzyl 
group with two ortho halides should also facilitate CH2 double activation of the 
indoline and a tandem radical cyclisation to install rings C and F of aspidofractinine 
4 (Scheme 107). 
 
Scheme 107: Proposed future work towards the targets. 
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Chapter 5 - Experimental 
 
General experimental 
 
All reactions were performed in oven-dried glassware and when required under an 
inert atmosphere of nitrogen or argon. Thermolysis reactions using microwave 
irradiation were carried out in a CEM Discover microwave reactor operating at a 
power of 150W.  
All solvents were distilled prior to use. Toluene, diethyl ether and THF were distilled 
from sodium with benzophenone as an indicator. Chloroform and dichloromethane 
were distilled from calcium hydride immediately prior to use. Other solvents and 
reagents were purified according to standard laboratory methods. 
Thin Layer Chromatography (Analytical TLC) was performed using aluminium-
backed plates coated with silica gel 60 containing a fluorescence indicator active at 
254 nm. The plates were visualised under a UV lamp (254 nm) and by staining with 
either 20% phosphomolybdic acid in ethanol or 10% aqueous potassium 
permanganate. Column chromatography was achieved using Apollo silica gel 
(0.040-0.063 mm, 230-400 mesh), which was slurry packed and run under low 
pressure. 
Infrared spectroscopy was performed using a Bio-Rad FT-IR goldengate 
spectrometer. Absorption maxima (max) are quoted as wavenumbers (cm
-1) and the 
following abbreviations used to describe their intensity: w - weak, m – medium, s – 
strong, b - broad, v- very. 
Nuclear magnetic resonance spectroscopy was performed using a Bruker Avance 
300 MHz spectrometer or a Bruker DPX 400 MHz spectrometer, run in dry CDCl3, 
CD3OD or d
6-DMSO. Chemical shifts are quoted as -values in ppm downfield of 
TMS (0 ppm) and referenced to the solvent peak – 7.27 ppm for 
1H spectra and 
77.20 ppm for 
13C spectra for CDCl3. Coupling constants (J) are given in Hz and 
signals are described using the notation: s – singlet, d – doublet, t – triplet, q – 
quartet, quin. – quintet, m – multiplet, b – broad, app. – apparent and obsc. – 
obscured.  86 
 
Mass spectrometry was performed using electron ionisation (EI) and chemical 
ionisation (CI) on a Thermoquest Trace GCMS spectrometer; and by electrospray 
positive (ES
+) ionisation on a Waters ZMD spectrometer. High resolution EIMS was 
performed on a VG Analytical 70-250-Se spectrometer and high resolution ESMS 
performed on a Bruker Apex III spectrometer.  
Melting points were determined using a Griffin melting point apparatus and are 
uncorrected. 
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Synthetic Procedures–Chapter 2 
2,3-Dihydro-1H-indole-3-carboxylic acid (246a). 
 
 
 
 
 
 
Sodium metal (8.06 mmol, 1.85 g) was added to a rapidly refluxing solution of 
indole-3-carboxylic acid 247a (6.20 mmol, 1.00 g) in anhydrous ethanol (40 mL). 
The mixture was heated at reflux under nitrogen for 16 h, allowed to cool and 
quenched by the careful drop-wise addition of water (40 mL). The volatiles were 
removed in vacuo before acidifying the aqueous residue to pH 1 (2 M HCl) and 
extracting with ethyl acetate (3 x 30 mL). The aqueous phase was then adjusted to 
pH 4 (2 M NaOH) and extracted with ethyl acetate (5 x 30 mL). The combined 
organic phases were washed with brine (100 mL), dried (MgSO4), and concentrated 
in vacuo to provide the indoline product 246a (2.34 mmol, 0.38 g, 38%) as a light 
brown solid. Data consistent with the literature.
46 
 
IR (ATR / golden gate):   3296 (m), 3126 (w), 3013 (w), 3062 (w), 2847 (w), 
1622 (s), 1519 (m), 1442 (m). 
1H NMR (300 MHz, DMSO-d6)  
 ppm 7.16 (1H, m, aromatic CH), 6.97 (1H, m, 
aromatic CH), 6.56 (1H, dd, J=7.7, 0.9 Hz, aromatic 
CH), 6.51 (1H, d, J=7.7 Hz, aromatic CH), 4.07 (1H, 
app. td, J=8.0, 1.0 Hz, CHCO2H), 3.67 (1H, dd, J=9.6, 
7.8 Hz, NCHHCHCO2H), 3.57 (1H, app t, J=9.6 Hz, 
CHHCHCO2H), 1.91 (1H, s, NH). 
13C NMR + DEPT (75 MHz, DMSO-d6)  
  ppm 173.5 (C=O), 152.0 (C), 128.1 (CH), 126.3 (C), 
    124.6  (CH), 116.8 (CH), 108.8 (CH), 48.5 (CH2), 46.6 
    ( CH). 
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(3,4-Dimethoxyphenyl)-(2-hydoxy-indol-1-yl)-methanone (253).  
 
 
 
 
 
 
 
To a solution of oxindole (251) (1.5 mmol, 0.20 g) and triethylamine (1.5 mmol, 
0.21 mL) in anhydrous dichloromethane (20 mL) under nitrogen at room temperature 
was added a solution of 3,4-dimethoxybenzoyl chloride (252) (1.5 mmol, 0.30 g) in 
anhydrous dichloromethane (20 mL). The reaction mixture was stirred for 48 h at 
room temperature, then washed with water (50 mL). The organic phase was dried 
(MgSO4), concentrated in vacuo and purified by column chromatography (silica, 
25% diethyl ether in petroleum ether) to give the indole (253) (0.5 mmol, 0.15 g, 
34%) as a white solid. 
 
Novel 
Mpt:       172–173  °C  (Et2O). 
IR (ATR / golden gate):  3343 (s), 3134 (w), 3077 (w), 2978 (w), 2933  
    (w),  1736  (s). 
1H NMR (300 MHz, CHLOROFORM-d):  
    δ ppm 8.84 (1H, b s, NH), 7.86 (1H, dd, J=8.3, 2.0 Hz, 
    a r o m a t i c   C H), 7.65 (1H, d, J=2.0 Hz, aromatic CH), 
    7.57  (1H,  d,  J=8.3 Hz, aromatic CH), 7.32 (1H, d,  
    J=7.7  Hz, aromatic CH), 7.21–7.11 (2H, m, 2 x  
    a r o m a t i c   C H), 6.95 (1H, d, J=8.6 Hz, aromatic CH), 
    6.28  (1H,  d,  J=1.5 Hz, aromatic CH), 3.97 (6H, s,  
    2   x   O C H3).
 
13C NMR + DEPT (75 MHz, CHLOROFORM-d):  
    δ ppm 163.8 (C=O), 154.5 (C), 149.3 (C), 143.9 (C), 
    131.7  (C), 127.0 (C), 125.1 (CH), 121.1 (CH), 121.0 
    ( C), 120.7 (CH), 120.6 (CH), 112.8 (CH), 111.1 (CH), 
    110.9  (CH), 88.1 (CH), 56.5 (2xOCH3). 
N
H
O O
Cl
OMe
OMe
N
H
O
O
OMe
OMe
CH2Cl2, NEt3, RT +
48 h, 34%
   251
C8H7NO
(133.15)
    252
C9H9ClO3
 (200.62)
    253
C17H15NO4
 (297.31)89 
 
ESMS: m/z (%):   320 [M+Na]
+ (100), 298 [M+H]
+ (40).  
HRMS (ES +ve):     C17H15NNaO4 [M+Na]
+ 320.0893, found 320.0891. 
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Methyl-oxiranylmethyl-phenylamine (255).  
 
 
 
 
 
N-Methylaniline (0.93 mmol, 0.1 mL) (254) was dissolved in ethanol (10 mL) with 
potassium carbonate (1.86 mmol, 0.26 g) and stirred under nitrogen at room 
temperature for 1 h. Epibromohydrin 429 (2.79 mmol, 0.24 mL) was added to the 
reaction mixture drop-wise and then stirred at reflux for 5 h. Ethanol was removed in 
vacuo and the crude material partitioned between water (10 mL) and ethyl acetate 
(10 mL). The organic layer was separated and the aqueous phase extracted with ethyl 
acetate (3 x 20 mL). The combined organic phases were washed with brine (30 mL), 
dried (MgSO4), concentrated in vacuo and purified by column chromatography 
(silica, 10% ethyl acetate in hexanes) to give the epoxide 255 as a yellow oil (0.67 
mmol, 0.11 g, 73%). Data consistent with the literature.
64 
 
1H NMR (300 MHz, CHLOROFORM-d):  
δ ppm 7.29–7.22 (2H, m, 2 x aromatic CH), 6.79–6.73 
(3H, m, 3 x aromatic CH), 3.65 (1H, dd, J=15.7, 3.2 
Hz, OCH2CHCH2N), 3.41 (1H, dd, J=15.7, 4.8 Hz, 
OCH2CHCH2N), 3.17 (1H, m, OCH2CHCH2N),  3.01 
(3H, s, NCH3), 2.79 (1H, app. t, J=4.8 
Hz,OCH2CHCHHN), 2.57 (1H, dd, J=4.8, 2.7 Hz, 
OCH2CHCHHN). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d):  
    δ ppm 149.9 (C), 129.6 (2xCH), 117.3 (CH), 112.8 
    ( 2 x CH), 54.6 (CH2), 50.9 (CH), 45.5 (CH2), 39.4  
    ( N CH3). 
EIMS: m/z (%):     163 [M]
+· (80), 120 [M-C2H3O]
+· (100), 104 (80), 77 
    (65). 
 
 
 
NH
O
Br
N
O
+ K2CO3, EtOH
, 5 h, 73%
   254
 C7H9N
(107.16)
   429
C3H5BrO
(136.98)
    255
C10H13NO
 (163.22)91 
 
2-Bromomethyl-1,2-dimethoxy-benzene (261). 
 
 
 
 
 
 
To a solution of 3,4-dimethoxybenzyl alcohol (390) (2.5 mmol, 0.36 mL) in 
anhydrous ether (30 mL) at 0 °C was added a solution of phosphorus tribromide (5.0 
mmol, 0.49 mL) in dry ether (5 mL) drop-wise. The reaction mixture was stirred at 
room temperature for 3 h before pouring slowly into water (20 mL) and extracting 
with dichloromethane (3 x 20 mL). The dried (MgSO4) organic phase was 
concentrated in vacuo to give a white solid that was washed with hexane to give 
benzyl bromide (261) (1.9 mmol, 0.44 g, 76%) as a white solid with no further need 
for purification. Data consistent with the literature.
65 
 
IR (ATR / golden gate):   3007 (w), 2932 (w), 2834 (w), 1602 (m), 1511 (s). 
1H NMR (300 MHz, CHLOROFORM-d):  
δ ppm 6.94 (1H, dd, J=8.1, 2.1 Hz, aromatic CH), 6.92 
(1H, app. s, aromatic CH), 6.51 (1H, d, J=8.1 Hz, 
aromatic CH), 4.50 (2H, s, BrCH2Ar), 3.89 (3H, s, 
OCH3), 3.88 (3H, s, OCH3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d):  
    δ ppm 149.0 (C), 148.9 (C), 130.0 (C), 121.3 (CH), 
    111.9  (CH), 110.8 (CH), 55.7 (OCH3), 55.6 (OCH3), 
    34.1  (CH2). 
EIMS: m/z (%):    230:232 {1:1} [M]
+· Br
79:Br
81 (20), 151 [M-Br]
+· (100), 
        137 (20), 107 (50), 77 (45). 
 
 
 
 
 
 
OH
MeO
MeO
Br
MeO
MeO
PBr3, Et2O, RT
 3 h, 76%
   390
C9H12O3
(168.19)
    261
C9H11BrO2
 (231.09)92 
 
(2-Bromophenyl)-(3,4,dimethoxy-benzyl)-amine (258).  
 
 
 
 
 
 
To a solution of 2-bromoaniline (257) (2.90 mmol, 0.50 g) in anhydrous DMF (40 
mL) at room temperature under nitrogen was added sodium hydride (60% dispersion 
in mineral oil, 5.33 mmol, 0.13 g) and the reaction mixture stirred for 3 h. To the 
reaction mixture (purple/brown solution) was added a solution of benzyl bromide 
261  (3.77 mmol, 0.87 g) in anhydrous DMF (10 mL) drop-wise. The reaction 
mixture was heated at 90 °C for 16 h, then cooled to 0 °C and partitioned between 
water (20 mL) and ethyl acetate (20 mL). The organic phases were washed with 
water (4 x 20 mL) and brine (20 mL), dried (MgSO4) and purified by column 
chromatography (silica, 10% diethyl ether in petroleum ether) to give 258 as a pale 
yellow solid (1.96 mmol, 0.63 g, 67%). 
 
Novel 
Mpt:       86–87  °C  (EtOH). 
IR (ATR / golden gate):   3387 (m), 3003 (w), 2958 (w), 2929 (w), 2827 (w),  
    1509  (s). 
1H NMR (300 MHz, CHLOROFORM-d):  
    δ ppm 7.44 (1H, dd, J=7.9, 1.4 Hz, aromatic CH), 7.14 
    (1H,  app.  td,  J=8.4, 1.4 Hz, aromatic CH), 6.93–6.83 
    (3H,  m,  3  x  aromatic  CH), 6.65–6.55 (2H, m, 2 x  
    a r o m a t i c   C H), 4.68 (1H, b s, NH), 4.33 (2H, b d, J=5.1 
    H z ,   N C H2), 3.88 (3H, s, OCH3), 3.87 (3H, s, OCH3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d):  
    δ ppm 149.6 (C), 148.7 (C), 145.1 (C), 132.7 (CH), 
    131.5  (C), 128.8 (CH), 119.8 (CH), 118.4 (CH), 112.2 
    ( C H), 111.7 (CH), 110.9 (CH), 110.1 (C-Br), 56.3  
    ( O C H3), 56.2 (OCH3), 48.3 (NHCH2). 
Br
NH2
Br
OMe
OMe
NH
Br
OMe
OMe
+ 1) NaH, DMF, 3 h, RT
2) 90 °C, 16 h, 67%
   257
C6H6BrN
(172.03)
    261
C9H11BrO2
 (231.09)
      258
C15H16BrNO2
   (322.20)93 
 
EIMS: m/z (%):     321:323 {1:1} [M]
+· Br
79:Br
81 (20), 151    
    [ M −C6H4BrNH]
+· (100), 135 (10), 121 (16), 107 (26), 
    91  (19),  77  (23). 
HRMS (ES +ve):     C15H16BrNNaO2 [M+Na]
+ 344.0256, found 344.0250. 
CHN:        Calcd for C15H16BrNO2: C, 55.92, H, 5.01, N, 4.35.  
        Found: C, 55.69, H, 5.04, N, 4.18. 
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(2-Bromophenyl)-(3,4-dimethoxy-benzyl)-prop-2-ynyl-amine (259).  
 
 
 
 
 
 
Aniline 258 (2.9 mmol, 0.94 g) was added to a suspension of sodium hydride (60% 
in mineral oil, 3.2 mmol, 0.13 g) in anhydrous DMF (30 mL) at 0 °C and the dark 
brown solution stirred at room temperature for 4 h. Propargyl bromide solution (80% 
in toluene, 5.8 mmol, 0.65 mL) was added drop-wise to the reaction mixture which 
was then heated to 60 °C for 72 h. Water (50 mL) was carefully added to the reaction 
mixture and the aqueous extracted with ethyl acetate (2 x 50 mL). The organic 
phases were combined, washed with water (5 x 30 mL) and brine (60 mL), dried 
(MgSO4) and concentrated in vacuo to give the crude material as a dark brown oil. 
The crude was purified by column chromatography (silica, 10% diethyl ether in 
petroleum ether) to give an inseparable 1:1.5 mixture of the alkyne (259) and starting 
material (258) as a pale yellow solid (1.6 mmol, 0.58 g, 55%).  
 
Novel 
IR (ATR / golden gate):  3395 (w), 3285 (w), 3068 (w), 3003 (w), 2958 (w),  
        (w), 2827 (w), 2353 (m), 1512 (s). 
1H NMR (300 MHz, CHLOROFORM-d): (Mixture of 258:259, 1.5:1) 
Data for 259:  
δ ppm 7.60 (1H, dd, J=8.0, 1.4 Hz, aromatic CH), 
7.34–7.24 (2H, m, 2 x aromatic CH), 7.17–7.11 (2H, 
m, aromatic CH), 7.00–6.79 (2H, m, 2 x aromatic 
CH), 4.27 (2H, s, CH2Ar), 3.88–3.86 (6H, m, 2 x 
OCH3), 3.80 (2H, app. d, J=2.4 Hz, NCH2C≡CH), 
2.25 (1H, app. t, J=2.3 Hz, NCH2C≡CH). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d): (Mixture of 258:259, 1.5:1) 
Data for 259:  
δ ppm 149.2 (C), 148.5 (C), 133.7 (CH), 131.4 (C), 
130.5 (C), 128.0 (CH), 125.7 (CH), 125.0 (CH), 121.5 
Br
NH
OMe
OMe
Br
N
OMe
OMe
NaH, DMF, RT, 4 h.
Propargyl Bromide, 
 60 °C, 72 h, 55%
      258
C15H16BrNO2
   (322.20)
      259
C18H18BrNO2
   (360.25)95 
 
(C), 120.9 (CH), 111.9 (CH), 110.8 (CH), 79.1 (C), 
73.5 (CH), 56.1 (OCH3), 56.0 (OCH3), 55.5 (CH2), 
41.9 (CH2). 
ESMS: m/z (%):     382:384 {1:1} [M + Na]
+ Br
79:Br
81 (80).  
HRMS (ES +ve):     C18H18BrNNaO2 [M+Na]
+ 382.0413, found 382.0421. 
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1-(3,4-dimethoxy-benzyl)-3-mehtyl-1H-indole (260).  
 
 
 
 
 
 
The crude mixture of alkyne 259 and 258 (1:1.5) (0.20 g) was dissolved in 
anhydrous toluene (30 mL) along with tributyltin hydride (1.17 mmol, 0.31 mL) and 
VAZO (3 mg) and stirred under nitrogen at reflux for 16 h. The reaction mixture was 
cooled and further tributyltin hydride (1.17 mmol, 0.31 mL) and VAZO (3 mg) 
added. The reaction mixture was again heated to reflux and stirred under nitrogen for 
a further 24 h. Once cooled, the solvent was removed in vacuo and the crude residue 
re-dissolved in ether (30 mL) and stirred vigorously with a saturated aqueous 
solution of KF (50 mL) for 30 min. The organic phase was separated and washed 
with water (50 mL) and brine (50 mL) and dried (MgSO4). The crude residue was 
purified by column chromatography (10% anhydrous K2CO3: 90% silica, 10% 
diethyl ether in petroleum ether) to give indole (260)
63 (0.28 mmol, 0.08 g, 90% 
based on available starting material) as a brown solid.   
 
Mpt:       58–60  °C  (EtOAc). 
IR (ATR / golden gate):   3395 (m), 3354 (w), 3068 (w), 2995 (w), 2958 (w),  
    2929  (w). 
1H NMR (300 MHz, CHLOROFORM-d):  
δ ppm 7.27 (1H, m, aromatic CH), 7.19 (1H, m, 
aromatic CH), 7.10 (1H, dd, J=7.4, 1.7 Hz, aromatic 
CH), 6.96-6.92 (2H, m, 2 x aromatic CH), 6.78 (1H, 
app. td, J=7.4, 1.0 Hz, aromatic CH), 6.73-6.65 (2H, 
m, 2 x aromatic CH), 3.93 (3H, s, OCH3), 3.89 (3H, s, 
OCH3), 3.89-3.88 (2H, obsc. m, CH2Ar), 2.81 (3H, s, 
CH3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d):  
δ ppm 149.6 (C), 148.6 (C), 146.8 (C), 132.4 (C), 
130.3   (CH), 129.6 (CH), 128.9 (CH), 127.8 (C), 
Br
N
OMe
OMe
N
OMe
OMe
n-Bu3SnH, VAZO
PhMe, , 48 h, 90%
       259
C18H18BrNO2
    (360.25)
    260
C18H19NO2
 (281.36)97 
 
121.9 (CH), 117.1 (CH), 113.3 (CH), 111.9 (CH), 
110.1 (CH), 56.3 (OCH3), 56.2 (OCH3), 48.6 (NCH2), 
31.2 (CH3). 
N.B. 1 x aromatic (C) not observed. 
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N-(2-Bromophenyl)-3,4-dimethoxybenzamide (262).  
 
 
 
 
 
To a solution of 2-bromoaniline (257) (1.16 mmol, 0.20 g) and triethylamine (1.16 
mmol, 0.16 mL) in anhydrous dichloromethane (20 mL) under nitrogen at room 
temperature was added a solution of 3,4-dimethoxybenzoyl chloride (430) (1.16 
mmol, 0.23 g) in anhydrous dichloromethane (20 mL). The reaction mixture was 
stirred for 16 h at room temperature, then washed with water (50 mL). The organic 
phase was separated, dried (MgSO4), concentrated in vacuo and purified by column 
chromatography (silica, 25% diethyl ether in petroleum ether) to give the aniline 
(262) (0.94 mmol, 0.32 g, 81%) as a white solid. Data consistent with the literature.
66 
 
IR (ATR / golden gate):   3560  (w),  3269  (w), 3019 (w), 2946 (w), 1647 (s), 
1509       (s). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 8.54 (1H, dd, J=8.3, 1.4 Hz, aromatic CH), 8.43 
(1H, b s, NH), 7.58 (1H, dd, J=8.2, 1.5 Hz, aromatic 
CH), 7.55 (1H, d, J=2.1 Hz, aromatic CH), 7.49 (1H, 
dd, J=8.3, 2.1 Hz, aromatic CH), 7.42 (1H, app. td, 
J=7.8, 1.4 Hz, aromatic CH), 7.01 (1H, app. td, J=7.8, 
1.5 Hz, aromatic CH), 6.96 (1H, d, J=8.2 Hz, aromatic 
CH), 3.98 (3H, s, OCH3), 3.96 (3H, s, OCH3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d):  
    δ ppm 165.0 (C=O), 152.6 (C), 149.5 (C), 136.2 (C), 
    132.4  (CH), 128.7 (CH), 127.4 (C), 125.2 (CH), 
    121.8  (CH), 119.8 (CH), 113.8 (C), 111.0 (CH), 110.8 
    ( CH), 56.3 (2xOCH3). 
ESMS: m/z (%):     358:360 {1:1} [M + Na]
+ Br
79:Br
81 (100).  
HRMS (ES +ve):     C15H15BrNO3 [M+H]
+ 336.0230, found 336.0233. 
 
Br
NH
O
OMe
OMe
Br
NH2
O
Cl
OMe
OMe
CH2Cl2, NEt3, RT +
16 h, 81%
    257
C6H6BrN
(172.03)
   430
C9H9ClO3
(200.62)
      262
C15H14BrNO3
   (336.19)99 
 
N-(2-Bromophenyl)-3,4-dimethoxy-N-prop-2-ynyl-benzamide (263).  
 
 
 
 
 
 
To a suspension of sodium hydride (60% in mineral oil, 0.94 mmol, 0.04 g) in 
anhydrous DMF (10 mL) under nitrogen was added aniline 262 (0.63 mmol, 0.21 g). 
The reaction mixture was stirred for 4 h at room temperature then propargyl bromide 
(80% solution in toluene, 0.94 mmol, 0.08 mL) was added drop-wise. After 16 h 
water (20 mL) was added and the aqueous phase extracted with ethyl acetate (2 x 20 
mL). The combined organic phases were washed with water (5 x 20 mL), brine (30 
mL), (MgSO4), concentrated in vacuo and purified by column chromatography 
(silica, 50% diethyl ether in petroleum ether) to give the alkyne (263) as a white 
solid (0.54 mmol, 0.20 g, 86%). 
 
Novel 
Mpt:       145-146  °C  (EtOH). 
IR (ATR / golden gate):   3253 (m), 3085 (w), 3056 (w), 2999 (w), 2954 (w),  
        2929 (w), 2353 (m), 1644 (s). 
1H NMR (300 MHz, CHLOROFORM-d):  
δ ppm 7.60 (1H, d, J=8.2 Hz, aromatic CH), 7.23-6.95 
(5H, m, 5 x aromatic CH), 6.65 (1H, d, J=8.2 Hz, 
aromatic CH), 5.09 (1H, b d, J=17.4 Hz, HC≡CCHH), 
4.12 (1H, dd, J= 17.4, 2.4 Hz, HC≡CCHH), 3.80 (3H, 
s, OCH3), 3.70 (3H, s, OCH3), 2.21 (1H, t, J=2.4 Hz, 
HC≡CCH2).
 
13C NMR + DEPT (75 MHz, CHLOROFORM-d):  
    δ ppm 170.3 (C=O), 151.0 (C), 148.3 (C), 141.9 
       ( C), 133.9 (CH), 132.5 (CH), 129.7 (CH), 128.7 (CH), 
    127.3  (C), 123.2 (CH), 122.6 (C), 112.1 (CH), 110.3 
    ( CH), 78.2 (C), 72.8 (C≡CH), 56.1 (2xOCH3), 38.7 
    ( N CH2C≡CH). 
Br
NH
O
OMe
OMe
Br
N
O
OMe
OMe
1) NaH, DMF, RT, 4 h
2) Propargyl bromide
     RT, 16 h, 86%
       262
C15H14BrNO3
    (336.19)
      263
C18H16BrNO3
   (374.24)100 
 
EIMS: m/z (%):     373:375 {1:1} [M]
+· Br
79:Br
81 (20), 294 [M-Br]
+· (50), 
    165  [COC6H3(OCH3)2]
+· (100), 137 (45), 122 (29), 107 
    (24),  92  (27),  77  (65). 
HRMS (ES +ve):     C18H16BrNNaO3 [M+Na]
+ 396.0206, found 396.0197. 
CHN:        Calcd for C18H16BrNO3: C, 57.77, H, 4.31, N, 3.74.  
        Found: C, 57.84, H, 4.38, N, 3.61. 
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8,9-Dimethoxy-5-((E)-3-tributylstannyl-allyl)-5H-phenanthridin-6-one (264).  
 
 
 
 
 
 
 
Alkyne  263 (0.27 mmol, 0.10 g), tributyltin hydride (0.56 mmol, 0.16 mL) and 
VAZO (3 mg) in toluene (30 mL) was heated at reflux under nitrogen for 16 h then 
cooled to room temperature. Further tributyltin hydride (0.56 mmol, 0.16 mL) and 
VAZO (3 mg) were added. After 48 h at reflux the reaction mixture was cooled to 
room temperature, concentrated, re-dissolved in ether (30 mL) and stirred vigorously 
with a saturated aqueous solution of KF (50 mL) for 30 min. The organic phase was 
separated, washed with water (50 mL) and brine (50 mL) and dried (MgSO4). The 
crude residue was purified by column chromatography (10% anhydrous K2CO3: 90% 
silica, 25% diethyl ether in petroleum ether) to give tricycle 264 as a white oil (0.09 
mmol, 55 mg, 32%). 
 
Novel 
IR (ATR / golden gate):   2954 (s), 2922 (s), 2872 (m), 2852 (m), 1645 (s), 1609 
    ( s ) .  
1H NMR (300 MHz, CHLOROFORM-d):  
    δ ppm 8.03 (1H, d, J=8.0 Hz, aromatic CH), 7.85 (1H, 
    s ,   a r o m a t i c   C H), 7.50 (1H, s, aromatic CH), 7.33–7.24 
    (2H,  m,  2  x  aromatic  CH), 7.16 (1H, m, aromatic CH), 
    5.97–5.96  (2H,  m,  CH=CH), 4.99 (2H, b s, NCH2),  
    3.97  (3H,  s,  OCH3), 3.92 (3H, s, OCH3), 1.34–1.26  
    ( 6 H ,   m ,   S n ( C H2CH2CH2CH3)3), 1.16–1.09 (6H, m,  
    S n ( C H 2CH2CH2CH3)3), 0.76–0.69 (15H, m,   
    S n ( C H 2CH2CH2CH3)3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d):  
    δ ppm 161.2 (C=O), 153.7 (C), 150.2 (C), 141.8 (CH), 
    137.3  (C), 131.2 (CH), 128.9 (C), 128.7 (CH), 122.9 
Br
N
O
OMe
OMe
N
O
Bu3Sn
OMe
OMe
n-Bu3SnH, VAZO, PhMe
, 48 h, 32%
      263
C18H16BrNO3
   (374.24)
      264
C30H43NO3Sn
   (584.37)102 
 
    ( CH), 122.5 (CH), 120.0 (C), 119.6 (C), 116.7 (CH), 
    109.6  (CH), 103.0 (CH), 56.5 (OCH3), 56.5 (OCH3), 
    48.4  (NCH2), 29.4 (3xCH2), 27.5 (3xCH2), 14.0  
    ( 3 x CH3), 9.8 (3xCH2). 
ESMS: m/z (%):    1192 [M2+Na]
+ (20), 608 [M+Na]
+ (20). 
HRMS (ES +ve):     C30H43NNaO3Sn [M+Na]
+ 608.2157, found 608.2161. 
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Methyl 3-allyl-2-oxo-2,3-dihydro-1H-indol-3-carboxylate (266). 
 
 
 
 
 
 
To a solution of methyl indole-3-carboxylate (265) (57.1 mmol, 10.0 g) in anhydrous 
DCM (300 mL) at 0 °C under nitrogen was added sequentially dimethyl piperazine 
(32.0 mmol, 4.3 mL) and NCS (62.7 mmol, 8.4 g). After 2 h the reaction mixture 
was added to a solution of allyl alcohol (114.2 mmol, 7.8 mL) and TFA (13.7 mmol, 
1.0 mL) in dry DCM (150 mL),at a rate sufficient to maintain the reaction 
temperature below 25 °C. After 2 h at room temperature the reaction mixture was 
washed with NaHCO3 (10%, 2 x 100 mL) and HCl (0.5 M, 2 x 100 mL). The organic 
phases were dried (MgSO4), concentrated in vacuo, then re-dissolved in anhydrous 
toluene (300 mL) and stirred with silica gel at room temperature under nitrogen for 4 
days. The reaction mixture was filtered, concentrated in vacuo to a brown oil then 
recrystallised from 40% ethyl acetate in hexane to give the desired product (266) as 
white crystals (19.5 mmol, 4.50 g, 61%). Data consistent with the literature.
54 
 
Mpt:         129–131 °C (EtOAc and hexanes) (Lit.
54 130–132 °C) 
IR (ATR / golden gate):   3158 (b m), 3093 (b m), 3036 (w), 2942 (w), 2876  
        (w), 2819 (w), 1739 (s), 1719 (s), 1681 (s), 1619 (s). 
1H NMR (300 MHz, CHLOROFORM-d):  
δ ppm 9.03 (1H, b s, NH), 7.31–7.27 (2H, m, 2 x CH 
aromatic), 7.08 (1H, app. t, J=7.5 Hz, CH aromatic), 
6.97 (1H, d, J=8.3 Hz, CH aromatic), 5.48 (1H, ddt, 
J=17.1, 10.1, 7.5 Hz, CH2=CH), 5.09 (1H, d, J=17.1 
Hz, CHH=CH), 4.99 (1H, dd, J=10.1, 0.6 Hz,   
CHH=CHCH2C), 3.72 (3H, s, COOCH3), 3.09-2.96 
(2H, m, =CHCH2C).  
13C NMR + DEPT (75 MHz, CHLOROFORM-d):  
δ ppm 176.5 (C=O), 169.7 (C=O), 141.7 (C), 131.1 
(CH), 129.5 (CH), 128.4 (C), 124.3 (CH), 123.1 (CH), 
N
H
O
O
O
N
H
O
O 1) Dimethyl piperazine, NCS, CH2Cl2
                       0 °C, 2 h
2) Allyl alcohol, TFA, CH2Cl2, RT, 2 h
     PhMe, silica gel, RT, 48 h, 61%
   265
C10H9NO2
(175.19)
    266
C13H13NO3
 (231.25)104 
 
120.3 (CH2), 110.6 (CH), 60.0 (C), 53.4 (OCH3), 38.8 
(CH2). 
ESMS: m/z (%):     254 [M+Na]
+ (100).  
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(3-Allyl-2,3-dihydro-1H-indol-3-yl)-methanol (271).  
 
 
 
 
 
 
To anhydrous THF (150 mL) at 0 °C under nitrogen was added sequentially LiAlH4 
(73.5 mmol, 2.79 g) and a solution of amide 266 (14.7 mmol, 3.4 g) in dry THF (100 
mL) drop-wise over 10 min. The reaction mixture was refluxed under nitrogen for 16 
h then cooled to 0 °C and water (50 mL) added cautiously. The reaction mixture was 
concentrated to half its volume then filtered and partitioned between ether (50 mL) 
and water (50 mL). The aqueous phase was extracted with ether (3 x 70 mL), then 
the combined organic phases were washed with brine (50 mL), dried (MgSO4), 
concentrated in vacuo and purified by column chromatography (silica, 25% diethyl 
ether in petroleum ether) to give the alcohol (271) (6.34 mmol, 1.20 g, 43%) as a 
pale brown oil. 
 
Novel 
IR (ATR / golden gate):   3334 (b m), 2905 (m), 2868 (m), 2353 (m), 2333 (m), 
    1605  (s). 
1H NMR (300 MHz, CHLOROFORM-d):  
δ ppm 7.11–7.05 (2H, m, 2 x aromatic CH), 6.76 (1H, 
app. td, J=7.5, 0.8 Hz, aromatic CH), 6.65 (1H, dd, 
J=7.5, 0.9 Hz, aromatic CH), 5.75 (1H, ddt, J=17.2, 
10.1, 7.3 Hz, CH2=CH), 5.14–5.06 (2H, m, CH2=CH), 
3.71 (1H, d, J=10.9 Hz, CHHOH or CHHNH), 3.65 
(1H, d, J=10.9 Hz, CHHOH or CHHNH), 3.48 (1H, d, 
J=9.4 Hz, CHHOH or CHHNH), 3.44 (1H, d, J=9.4 
Hz, CHHOH or CHHNH), 2.49 (2H, d, J=7.3 Hz, 
=CHCH2C). 
 
 
 
N
H
OH
N
H
O
O
O
LiAlH4, THF, 
24 h, 43%
    266
C13H13NO3
 (231.25)
    271
C12H15NO
 (189.26)106 
 
13C NMR + DEPT (75 MHz, CHLOROFORM-d):  
δ ppm 152.1 (C), 134.6 (CH), 132.1 (C), 128.6 (CH), 
123.9 (CH), 118.9 (CH), 118.3 (CH2), 110.2 (CH), 
68.0 (CH2), 54.3 (CH2), 51.3 (C), 40.3 (CH2). 
ESMS: m/z (%):     190 [M+H]
+ (40), 212 [M+Na]
+ (100).  
HRMS (ES +ve):     C12H16NO [M+H]
+ 190.1226, found 190.1225. 
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Methyl 3-allyl-1-(3,4-dimethoxy-benzoyl)-2-oxo-2,3-dihydro-1H-indole-3-
carboxylate (273).  
 
 
 
 
 
 
To a solution of amide (266) (0.87 mmol, 0.20 g) and triethylamine (0.87 mmol, 
0.12 mL) in anhydrous DCM (50 mL) at room temperature under nitrogen was added 
a solution of 3,4-dimethoxybenzoyl chloride (0.87 mmol, 0.18 g) in DCM (50 mL). 
After 16 h the reaction mixture was washed with water (50 mL) and the aqueous 
phase extracted with DCM (3 x 50 mL). The combined organic phasess were washed 
with brine (50 mL), dried (MgSO4), concentrated in vacuo and purified by column 
chromatography (silica, 20% diethyl ether in petroleum ether) to give amide (273) 
(0.08 mmol, 33 mg, 10%) as a white solid. 
 
Novel 
Mpt:       103-105  °C  (EtOAc). 
IR (ATR / golden gate):   3166 (w), 3089 (w), 3007 (w), 2357 (w), 2329 (w),  
    1740  (s),  1723  (s),  1671  (s). 
1H NMR (300 MHz, CHLOROFORM-d):  
δ ppm 7.69 (1H, d, J=7.9 Hz, aromatic CH), 7.52 (1H, 
dd, J=8.4, 2.2 Hz, aromatic CH), 7.43–7.36 (3H, m, 3 
x aromatic CH), 7.23 (1H, app. dt, J=7.6, 1.0 Hz, 
aromatic CH), 6.92 (1H, d, J=8.4 Hz, aromatic CH), 
5.45 (1H, dddd, J=16.9, 9.9, 8.2, 6.4 Hz, CH2=CH), 
5.12 (1H, dd, J=16.9, 1.2 Hz, CHH=CH), 5.04 (1H, b 
d,  J=9.9 Hz, CHH=CH), 3.96 (3H, s, OCH3), 3.94 
(3H, s, OCH3), 3.75 (3H, s, COOCH3), 3.14-2.97 (2H, 
m, =CHCH2). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d):  
    δ ppm 173.7 (C=O), 169.4 (C=O), 168.5 (C=O), 154.1 
    ( C), 149.1 (C), 141.3 (C), 131.0 (CH), 129.8 (CH),  
N
H
O
O
O
N
O
O
O
O
O
O
3,4-dimethoxybenzoyl chloride
NEt3, CH2Cl2, RT, 16 h, 10%
    266
C13H13NO3
 (231.25)
    273
C22H21NO6
 (395.42)108 
 
    127.2  (C), 125.9 (C), 125.2 (2xCH), 123.9 (CH),  
    120.9  (CH2), 115.0 (CH), 113.0 (CH), 110.8 (CH),  
    60.4  (C), 56.4 (OCH3), 56.4 (OCH3), 53.7 (OCH3),  
    38.7  (CH2).  
ESMS: m/z (%):     418 [M+Na]
+ (40).  
HRMS (ES +ve):     C22H21NNaO6 [M+Na]
+ 418.1261, found 418.1253. 
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[3-Allyl-1-(3,4-dimethoxy-benzyl)-2,3-dihydro-1H-indol-3-yl]-methanol (272).  
 
Method A: 
 
 
 
 
 
 
 
Method B: 
 
 
 
 
 
 
 
Method A:  To a solution of amine (271) (1.06 mmol, 0.20 g) in dry DMF (30 mL) 
under nitrogen at 0 °C was added sodium hydride (60% dispersion in mineral oil, 
2.11 mmol, 85 mg). The reaction mixture was allowed to warm to room temperature 
over 2 h (reaction mixture turns from purple to brown) then benzyl bromide (261) 
(1.06 mmol, 0.25 g) in dry DMF (20 mL) was added drop-wise. After 16 h water (50 
mL) was added. The aqueous phase was extracted with ethyl acetate (4 x 50 mL) and 
the combined organic phases washed with water (4 x 50 mL), brine (50 mL), dried 
(MgSO4) and purified by column chromatography (silica, 25% diethyl ether in 
petroleum ether) to give the alcohol (272) (0.19 mmol, 65 mg, 18%) as a colourless 
oil. 
 
Method B: To anhydrous THF (20 mL) at 0 °C under nitrogen was added 
sequentially LiAlH4 (0.63 mmol, 24 mg) and a solution of amide (273) (0.08 mmol, 
33 mg) in dry THF (5 mL) drop-wise over 3 min. The reaction mixture refluxed 
under nitrogen for 16 h then cooled to 0 °C and water (20 mL) added cautiously. The 
N
H
OH
N
OH
O
O
Br
O
O
+
NaH (2 equiv.), DMF
RT, 16 h, 18%
     271
C12H15NO
 (189.26)
    261
C9H11BrO2
 (231.09)
    272
C21H25NO3
 (339.44)
N
O
O
O
O
O
O
N
OH
O
O
N
H
OH LiAlH4, THF
, 16 h
    273
C22H21NO6
 (395.42)
 272, 11%
C21H25NO3
 (339.44)
 271, 63%
C15H15NO
 (189.26)
+110 
 
reaction mixture was concentrated in vacuo to half its original volume, filtered and 
partitioned between ether (20 mL) and water (20 mL). The aqueous phase was 
extracted with ether (3 x 30 mL), the combined organic phases washed with brine 
(40 mL), dried (MgSO4), concentrated in vacuo and purified by column 
chromatography (silica, 25% diethyl ether in petroleum ether) to give firstly the 
alcohol (272) (0.01 mmol, 3 mg, 11%) and then the alcohol 271 (0.05 mmol, 10 mg, 
63%) as colourless oils. 
 
Novel 
IR (ATR / golden gate):   3195 (s), 1690 (w), 1610 (w), 1435 (s). 
1H NMR (300 MHz, CHLOROFORM-d):  
δ ppm 7.54 (1H, app. t, J=7.7 Hz, aromatic CH), 7.50 
(1H, d, J=7.3 Hz, aromatic CH), 7.31–7.25 (3H, m, 3 x 
aromatic CH), 7.14 (1H, app. t, J=7.3 Hz, aromatic 
CH), 6.96 (1H, d, J=8.0 Hz, aromatic CH), 6.15 (1H, 
ddt,  J=17.1, 10.0, 7.3 Hz, CH2CH=CH2), 5.53–5.46 
(2H, m, CH=CH2), 4.68 (1H, d, J=14.8 Hz, NCHHAr), 
4.62 (1H, d, J=14.8 Hz, NCHHAr), 4.31 (3H, s, 
OCH3), 4.28 (3H, s,OCH3), 4.13 (1H, d, J=10.8 Hz, 
CHHOH), 4.07 (1H, d, J=10.8 Hz, CHHOH), 3.69 
(1H, d, J=9.3 Hz, NCHHC), 3.64 (1H, d, J=9.3 Hz, 
NCHHC), 2.95–2.85 (2H, m, CH2=CHCH2). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d):  
    δ ppm 152.8 (C), 149.5 (C), 148.5 (C), 134.6 (CH), 
    132.5  (C), 131.1 (C), 128.8 (CH), 123.7 (CH), 120.1 
    ( CH), 118.2 (CH2), 117.9 (CH), 111.5 (CH), 111.1  
    ( CH), 107.4 (CH), 68.0 (CH2), 60.5 (CH2), 56.2  
    ( O CH3), 56.2 (OCH3), 52.9 (CH2), 49.7 (C), 40.3  
    ( CH2). 
ESMS: m/z (%):    362 [M+Na]
+ (100), 340 [M+H]
+ (35). 
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2-Iodo-4,5-dimethoxybenzyl alcohol (391).  
 
 
 
 
 
To a solution of 3,4-dimethoxybenzyl alcohol (390) (2.0 mmol, 0.3 mL) in 
anhydrous chloroform (10 mL) at room temperature was added silver trifluoroacetate 
(2.0 mmol, 0.6 g). To this suspension was added a solution of iodine (2.0 mmol, 0.5 
g) in dry chloroform (60 mL) drop-wise. The reaction mixture turned a yellow/green 
colour and after 1 h the AgI precipitate was filtered. The resulting solution washed 
with Na2S2O3 (10 mL) and concentrated in vacuo to afford iodide 291 as a white 
solid (1.3 mmol, 0.4 g, 68%). Data consistent with the literature.
67 
 
IR (ATR / golden gate):   3258 (m), 2903 (w), 2831 (w), 1595 (m), 1498 (s). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.22 (1H, s, aromatic CH), 7.01 (1H, s, 
aromatic CH), 4.61 (2H, s, CH2OH), 3.89 (3H, s, 
OCH3), 3.86 (3H, s, OCH3), 2.02 (1H, b s, OH). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 149.9 (C), 149.3 (C), 135.6 (C), 121.9 (CH), 
112.1 (CH), 85.8 (CI), 69.5 (CH2), 56.6 (OCH3), 56.3 
(OCH3). 
EIMS: m/z (%):    294 [M]
+· (100), 166 (15), 139 (68), 124 (28), 95 (18), 
    77  (20). 
 
 
 
 
 
 
 
 
OH
OMe
OMe
OH
I
OMe
OMe
I2, CF3COOAg 
CHCl3, RT, 1 h, 68%
   390
C9H12O3
(168.19)
   391
C9H11IO3
(294.09)112 
 
2-Iodo-4,5-dimethoxybenzyl bromide (271). 
 
 
 
 
 
To a solution of alcohol (391) (2.95 mmol, 0.87 g) in anhydrous DCM (30 mL) 
under nitrogen at 0 °C was added a solution of phosphorous tribromide (5.90 mmol, 
0.65 mL) in dry DCM (30 mL) drop-wise. After 16 h the reaction mixture was 
cooled to 0 °C water (30 mL) added, drop-wise at first. The aqueous phase was 
separated and extracted with DCM (3 x 30 mL). The combined organic phases were 
concnetrated in vacuo to give bromide 274 as a yellow powder (2.03 mmol, 0.73 g, 
69%), which was stored in the dark at -4 °C. Data consistent with the literature.
67 
 
Mpt:       73–75  °C  (Et2O) (Lit.
67 74–75°C). 
IR (ATR / golden gate):  3003 (w), 2954 (w), 2929 (w), 2901 (w), 2835 (w),  
    1589  (m),  1500  (s). 
1H NMR (300 MHz, CHLOROFORM-d):  
    δ ppm 7.30 (1H, s, CH aromatic), 7.01 (1H, s, CH  
    aromatic),  4.63  (2H,  s,  CH2Br), 3.92 (3H, s, OCH3), 
    3.91  (3H,  s,  OCH3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d):  
    δ ppm 150.0 (2xC), 132.9 (C), 122.3 (CH), 113.2  
    ( CH), 88.9 (CI), 56.6 (OCH3), 56.4 (OCH3), 39.8  
    ( CH2). 
EIMS: m/z (%):     356:358 {1:1} [M]
+· Br
79:Br
81 (5), 277 [M−Br]
+· (100), 
        150 (11), 92 (11), 77 (11). 
 
 
 
 
OH
I
OMe
OMe
Br
I
OMe
OMe
PBr3, CH2Cl2, RT
16 h, 69%.
   391
C9H11IO3
(294.09)
    274
C9H10BrIO2
 (356.99)113 
 
Methyl 3-allyl-1-(2-iodo-4,5-dimethoxy-benzyl)-2-oxo-2,3-dihydro-1H-indole-3-
carboxylate (275) and 3-allyl-3-(2-iodo-4,5-dimethoxy-benzyl)-1,3-dihydro-
indol-2-one (276). 
 
To a solution of amide (266) (2.16 mmol, 0.50 g) in dry DMF (60 mL) at 0 °C was 
added sodium hydride (60% dispersion in mineral oil, 3.24 mmol, 0.13 g) in one 
portion. The resulting orange / yellow solution was stirred at room temperature under 
nitrogen for 3 h then a solution of benzyl bromide (274) (2.16 mmol, 0.77 g) in dry 
DMF (50 mL) was added. After 16 h in the dark, water (50 mL) was added along 
with ether (50 mL). The separated organic phase was washed with water (5 x 50 mL) 
and brine (50 mL), then dried (MgSO4) and concentrated in vacuo and purified by 
column chromatography (silica, 20% diethyl ether in petroleum ether) to give firstly 
the desired product (275) (0.52 mmol, 0.26 g, 24%) as a white solid then 276 (0.45 
mmol, 0.20 g, 21%) as a colourless oil. 
 
Data for 275.  
Novel 
Mpt:       127–130  °C  (EtOAc). 
IR (ATR / golden gate):   2995 (w), 2966 (w), 2938 (w), 2917 (w), 2831 (w),  
        1742 (s), 1698 (s), 1597 (m), 1502 (m). 
1H NMR (300 MHz, CHLOROFORM-d):  
δ ppm 7.30–7.27 (2H, m, 2 x aromatic CH), 7.22 (1H, 
app. td,   J=7.8, 1.3 Hz, aromatic CH), 7.06 (1H, app. 
td, J=7.5, 0.9 Hz, aromatic CH), 6.70 (1H, s, aromatic 
CH), 6.68 (1H, s, aromatic CH), 5.45 (1H, ddt, J=17.0, 
10.1, 7.5 Hz, CH2=CH), 5.13–4.94 (2H, m, CH2=CH), 
5.03 (1H, d, J=16.3 Hz, NCHH), 4.82 (1H, d, J=16.3 
N
O
O
O
I
OMe
OMe
N
H
O
O
O Br
I
OMe
OMe
N
H
O
I
OMe
MeO
+
NaH, DMF 
RT, 16 h
    266
C13H13NO3
 (231.25)
     274
C9H10BrIO2
  (356.99)
  275, 24%
C22H22INO5
  (507.33)
+
  276, 21%
C20H20INO3
 (449.29)114 
 
Hz, NCHH),  3.85 (3H, s, COOCH3), 3.70 (3H, s, 
OCH3), 3.67 (3H, s, OCH3), 3.09–3.06 (2H, m, 
CH2=CHCH2).  
13C NMR + DEPT (75 MHz, CHLOROFORM-d):  
    δ ppm 174.1 (C=O), 169.7 (C=O), 150.2 (C), 149.4 
    ( C), 143.3 (C), 131.2 (CH), 129.9 (C), 129.5 (CH),  
    127.5  (C), 123.8 (CH), 123.3 (CH), 121.9 (CH), 120.3 
    ( CH2), 111.0 (CH), 110.2 (CH), 86.1 (C-I),   
    59.7  (C), 56.5 (OCH3), 56.2 (OCH3), 53.4 (COOCH3), 
    48.9  (CH2), 38.3 (CH2). 
ESMS: m/z (%):     530 [M+Na]
+ (100), 508 [M+H]
+ (5).  
HRMS (ES +ve):     C22H22INNaO5 [M+Na]
+ 530.0435, found 530.0428. 
 
Data for 276.  
Novel 
IR (ATR / golden gate):   3322 (m), 2974 (w), 2933 (w), 2905 (w), 2840 (w), 
2128 (w), 1704 (s), 1618 (m), 1503 (s). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 8.99 (1H, s, NH), 7.24 (1H, d, J=7.6 Hz, 
aromatic CH), 7.15 (1H, app. td, J=7.5, 1.0 Hz, 
aromatic CH), 7.06 (1H, s, aromatic CH), 6.99 (1H, 
app. td, J=7.5, 1.0 Hz, aromatic CH), 6.81 (1H, d, 
J=7.6 Hz, aromatic CH), 6.52 (1H, s, aromatic CH), 
5.41 (1H, m, CH=CH2), 5.03 (1H, dd, J=17.0, 1.8 Hz, 
CH=CHH), 4.92 (1H, dd, J=10.1, 1.8 Hz, CH=CHH), 
3.72 (3H, s, OCH3), 3.55 (3H, s, OCH3), 3.30–3.36 
(2H, m, CH2Ar), 2.64–2.82 (2H, m, CH2CH=CH2). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
  ppm 181.7 (C=O), 148.7 (C), 148.1 (C), 141.1 (C), 
    132.1  (CH), 131.9 (C), 131.1 (C), 128.1 (CH), 125.2 
    ( CH), 122.1 (CH), 121.6 (CH), 119.3 (CH2), 112.5  
    ( CH), 109.9 (CH), 90.5 (CI), 56.0 (OCH3), 55.5  
    ( O CH3), 54.9 (C), 45.7 (CH2), 41.9 (CH2). 115 
 
ESMS: m/z (%):    472 [M+Na]
+ (472), 921[M2+Na]
+ (100). 
HRMS (ES +ve):     C20H20INNaO3 [M+Na]
+ 472.0380, found 472.0372. 
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3-Allyl-1-methyl-1,3-dihydro-indol-2-one (281). 
 
 
 
 
 
 
A solution of ester 266 (2.16 mmol, 0.50 g) and NaBr (4.32 mmol, 0.45 g) in DMF 
(100 mL), was heated at reflux for 2 h under nitrogen.  Once cool the reaction 
mixture was diluted with water (100 mL) and extracted with diethyl ether (3 x 60 
mL). The organic phases were combined, washed with water (4 x 50 mL) and brine 
(100 mL), dried (MgSO4), and concentrated in vacuo. The crude residue was purified 
by column chromatography (silica, 20% diethyl ether in petroleum ether) to give 281 
(1.09 mmol, 0.20 g, 51%) as colourless clear oil. Data consistent with the literature.
68 
 
IR (ATR / golden gate):   3383 (w), 3054 (w), 2979 (w), 2937 (w), 2915 (w), 
1701 (s), 1611 (s), 1493 (m), 1469 (s). 
1H NMR (300 MHz, CHLOROFORM-d)  
  ppm 7.23–7.31 (2H, m, 2 x aromatic CH), 7.03 (1H, 
    app.  td,  J=7.5, 0.9 Hz, aromatic CH), 6.82 (1H, dd,  
    J=8.1, 0.6 Hz, aromatic CH), 5.76 (1H, dddd, J=17.0, 
    10.1,  7.9,  6.1  Hz,  CH2CH=CH2), 5.00–5.15 (2H, m, 
    C H 2CH=CH2), 3.48 (1H, dd, J=7.6, 4.9 Hz,   
    A r C H), 3.20 (3H, s, NCH3), 2.83 (1H, m,    
    C HHCH=CH2), 2.55 (1H, m, CHHCH=CH2). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
  ppm 177.3 (C=O), 144.5 (C), 134.3 (CH), 128.8 (C), 
    128.1  (CH), 124.3 (CH), 122.4 (CH), 118.0 (CH2),  
    108.0  (CH), 45.3 (NCH3), 35.1 (CH2), 26.3 (CH). 
ESMS: m/z (%):    188 [M+H]
+ (100), 210 [M+Na]
+ (80). 
 
 
 
N
H
O
O
O
N
O
    266
C13H13NO3
 (231.25)
    281
C12H13NO
 (187.24)
NaBr, DMF, 
2 h, 51%117 
 
(1-Methyl-2-oxo-2,3-dihydro-1H-indol-3-yl)-acetaldehyde (282). 
 
 
 
 
 
 
A flow of 1–2% O3 in O2 was bubbled through a solution of alkene 281 (1.09 mmol, 
0.20 g) in anhydrous DCM (25 mL) at −78 °C for 30 min where a blue solution 
persisted. The mixture was then purged with O2 for 1 h when the blue colour had 
faded, then PPh3 (2.73 mmol, 0.72 g) added. After warming to room temperature, the 
mixture was tested for peroxides with starch-iodide paper then concentrated in vacuo 
and purified by column chromatography (silica, 25% diethyl ether in petroleum 
ether) to give aldehyde 282 (0.60 mmol, 0.11 g, 55%) as a colourless oil. The 
aldehyde was analyzed by NMR and used immediately in the subsequent reaction.  
 
Novel 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 9.89 (1H, t, J=0.8 Hz, CH2CHO), 7.30 (1H, 
app. td, J=7.8, 1.0 Hz, aromatic CH), 7.21 (1H, dd, 
J=7.5, 0.6 Hz, aromatic CH), 7.03 (1H, app. td, J=7.5, 
1.0 Hz, aromatic CH), 6.85 (1H, d, J=7.8 Hz, aromatic 
CH), 3.91 (1H, dd, J=8.5, 4.0 Hz, CHCH2CHO), 3.24 
(3H, s, NCH3), 3.25 (1H, ddd, J=18.7, 4.0, 0.8 Hz, 
CHHCHO), 2.88 (1H, ddd, J=18.7, 8.5, 0.8 Hz, 
CHHCHO). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
  ppm 199.1 (CHO), 177.0 (C=O), 144.4 (C), 128.5 
    ( CH), 128.4 (C), 124.4 (CH), 122.8 (CH), 108.3 (CH), 
    44.9  (CH2), 40.0 (NCH3), 26.5 (CH). 
 
 
 
N
O
N
O
O
    281
C12H13NO
 (187.24)
    282
C11H11NO2
 (189.22)
O3, CH2Cl2, -78 °C
PPh3, 1 h, 55%118 
 
3-(2-Hydroxy-ethyl)-1-methyl-1,3-dihydro-indol-2-one (283). 
 
 
 
 
 
 
 
To a solution of aldehyde 282 (0.53 mmol, 0.10 g) in anhydrous MeOH (10 mL) at 0 
°C under nitrogen was added NaBH4 (0.58 mmol, 22 mg). The reaction mixture was 
allowed to warm to room temperature, stirred for 1 h then water (20 mL) was added. 
The aqueous phase was separated and extracted with ether (3 x 20 mL) then the 
combined organic phases were washed with brine (50 mL), dried (MgSO4), filtered 
and concentrated in vacuo to give alcohol 283 (0.31 mmol, 59 mg, 58%) as a 
colourless oil, without need for purification. Data consistent with the literature.
69 
 
IR (ATR  /  golden  gate):    3383 (m), 3060 (w), 2921 (w), 2884 (w), 1685 (s), 
1610 (s), 1493 (m), 1469 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.31 (1H, app. td, J=7.9, 1.0 Hz, aromatic CH), 
7.26 (1H, dd, J=7.9, 0.9 Hz, aromatic CH), 7.08 (1H, 
app. td, J=7.7, 0.9 Hz, aromatic CH), 6.84 (1H, d, 
J=7.7 Hz, aromatic CH), 3.92 (2H, t, J=5.8 Hz, 
CH2OH), 3.60 (1H, dd, J=8.8, 5.2 Hz, ArCH), 3.22 
(3H, s, NCH3), 2.22 (1H, m, CHHCH2OH), 2.03 (1H, 
m, CHHCH2OH). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 179.0 (C=O), 144.3 (C), 129.1 (C), 128.3 (CH), 
123.8 (CH), 122.9 (CH), 108.4 (CH), 61.2 (CH2), 44.7 
(NCH3), 33.6 (CH2), 26.5 (CH). 
ESMS: m/z (%):    214 [M+Na]
+ (50), 230 [M+K]
+ (100). 
 
 
N
O
O
N
O
OH
    282
C11H11NO2
 (189.22)
    283
C11H13NO2
 (191.23)
NaBH4, MeOH
RT, 1 h, 58%119 
 
1′-Methyl-spiro[cyclopropane-1,3′-indol-2′-one] (285). 
 
 
 
 
 
 
To a solution of alcohol 283 (0.21 mmol, 40 mg) and amine 284 (0.23 mmol, 29 
mg), in anhydrous THF (10 mL) at 0 °C under nitrogen was added PPh3 (0.21 mmol, 
55 mg) and DIAD (0.21 mmol, 41 μL). The reaction mixture was allowed to warm to 
room temperature, stirred for 16 h under nitrogen then filtered through silica and 
concentrated  in vacuo. Purification by column chromatography (silica, 20→75% 
diethyl ether in petroleum ether) gave cyclopropane 285 (0.12 mmol, 20 mg, 55%) as 
a colourless oil. Data consistent with the literature.
70 
 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.27 (1H, ddd, J=7.9, 7.6, 1.2 Hz, aromatic 
CH), 7.03 (1H, app. td, J=7.6, 1.0 Hz, aromatic CH), 
6.91 (1H, d, J=7.9 Hz, aromatic CH), 6.85 (1H, dd, 
J=7.6, 0.6 Hz, aromatic CH), 3.31 (3H, s, NCH3), 1.75 
(2H, dd, J=7.9, 4.3 Hz, -CHHCHH-), 1.49–1.5 (2H, m, 
CHHCHH-). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
  ppm 177.2 (C=O), 143.8 (C), 131.1 (C), 126.9 (CH), 
    122.1  (CH), 118.4 (CH), 108.1 (CH), 27.2 (C), 26.7 
    ( N CH3), 19.3 (2xCH2). 
 
 
 
 
 
 
 
N
O
OH
N
O
N
H
O
    283
C11H13NO2
 (191.23)
    285
C11H11NO
 (173.22)
DIAD, PPh3, THF 
RT, 16 h, 55%
   284
C7H11NO
(125.17)
+120 
 
1-Benzyl-1H-indole-2,3-dione (294). 
 
 
 
 
 
 
To a solution if isatin 293 (54.4 mmol, 8.00 g) in anhydrous DMF (200 mL) under 
nitrogen at 0 ºC was added sodium hydride (60% in mineral oil, 59.8 mmol, 2.40 g) 
portion-wise. The resulting dark purple reaction mixture was allowed to warm to 
room temperature and after 30 min benzyl bromide (59.8 mmol, 7.11 mL) was 
added. After a further 1 h the orange reaction mixture was added cold water (500 
mL) and the extracted with DCM (3 x 150 mL). The combined organic phases were 
washed with brine (500 mL), dried (MgSO4), filtered and concentrated in vacuo to 
give  N-benzyl isatin (294) as an orange solid (49.7 mmol, 11.78 g, 91%). Data 
consistent with the literature.
71 
 
Mpt:       127-128  °C  (Et2O) (Lit.
71 126-127 °C). 
IR (ATR / golden gate):   2958  (w),  2917  (w), 2852 (w), 2840 (w), 1731 (s), 
1608 (s). 
1H NMR (400 MHz, CHLOROFORM-d)  
 ppm 7.54 (1H, dd, J=7.5, 1.3 Hz, aromatic CH), 7.41 
(1H, app. td, J=7.8, 1.3 Hz, aromatic CH), 7.18–7.33 
(5H m, 5 x aromatic CH), 7.02 (1H, app. t, J=7.5 Hz, 
aromatic CH), 6.71 (1H, d, J=7.8 Hz, aromatic CH), 
4.86 (2H, s, NCH2Ph). 
13C NMR + DEPT (100 MHz, CHLOROFORM-d)  
  ppm  183.4 (C=O), 158.5 (C=O), 150.9 (C), 138.4 
    ( CH), 134.7 (C), 129.2 (2xCH), 128.3 (CH), 127.6  
    ( 2 x CH), 125.6 (CH), 124.0 (CH), 117.9 (C), 111.2  
    ( CH), 44.2 (CH2). 
ESMS: m/z (%):     238 [M+H]
+ (100), 260 [M+Na]
+ (50), 497 [M2+Na]
+ 
    (60). 
N
H
O
O
N
O
O
Ph
NaH, BnBr, DMF
RT, 1 h, 91%
   293
C8H5NO2
(147.13)
     294
C15H11NO2
  (237.26)121 
 
1-Benzyl-1,3-dihydro-indol-2-one (295). 
 
 
 
 
 
 
N-Benzyl isatin (294) (25.3 mmol, 6.00 g) was stirred in hydrazine mono-hydrate (25 
mL) at reflux under nitrogen for 2 h. On cooling to room temperature the reaction 
mixture was poured onto iced water (100 mL) and extracted with ethyl acetate (4 x 
50 mL). The combined organic phases were washed with brine (100 mL), dried 
(MgSO4) and concentrated in vacuo to give the product as a viscous yellow oil (295) 
(25.1 mmol, 5.60 g, 99%). Data consistent with the literature.
72 
 
IR (ATR / golden gate):   3322  (w),  3060  (w), 3023 (w), 2917 (w), 1701 (s), 
1613 (s). 
1H NMR (400 MHz, CHLOROFORM-d)  
 ppm 7.18–7.31 (6H, m, 6 x aromatic CH), 7.13 (1H, 
app. t, J=7.6 Hz, aromatic CH), 6.97 (1H, app. t, J=7.2 
Hz, aromatic CH), 6.69 (1H, d, J=7.8 Hz, aromatic 
CH), 4.88 (2H, s, NCH2Ph), 3.58 (2H, s, COCH2). 
13C NMR + DEPT (100 MHz, CHLOROFORM-d)  
 ppm 175.3 (C=O), 144.5 (C), 136.1 (C), 128.9 
(2xCH), 128.0 (CH), 127.7 (CH), 127.5 (2xCH), 
124.6 (C), 124.6 (CH), 122.5 (CH), 109.2 (CH), 43.9 
(CH2), 35.9 (CH2). 
ESMS: m/z (%):     246 [M+Na]
+ (100), 224 [M+H]
+ (20). 
 
 
 
 
 
 
N
O
Ph
N
O
O
Ph
NH2NH2, 
16 h, 99%
     294 
C15H11NO2
  (237.26)
     295
C15H13NO
 (223.28)122 
 
1′-Benzyl-spiro[cyclopropane-1,3′-indol-2′-one] (287). 
 
 
 
 
 
To a cooled (0 ºC) solution of oxindole 295 (51.6 mmol, 11.53 g) in anhydrous DMF 
(250 mL) under nitrogen was added sodium hydride (60% in mineral oil, 113.6 
mmol, 4.50 g) portion-wise. The resulting dark red reaction mixture was stirred at 
room temperature for 1 h then a solution of 1,2-dibromoethane (206.4 mmol, 17.80 
mL) in anhydrous DMF (50 mL) was added drop-wise. The reaction mixture was 
allowed to warm to room temperature and after 18 h was cooled on ice, and 
quenched with water (300 mL). The aqueous phase was extracted with ethyl acetate 
(3 x 70 mL) then the combined organic phases were washed with water (4 x 100 mL) 
and brine (200 mL), dried (MgSO4), filtered, and concentrated in vacuo and purified 
by column chromatography (silica, 10% ethyl acetate in hexanes) to give the desired 
compound (287) as a white solid (34.7 mmol, 8.64 g, 67%). Data consistent with the 
literature.
57 
 
IR (ATR / golden gate):   3056 (w), 3019 (w), 2987 (w), 2921 (w), 1701 (s). 
1H NMR (400 MHz, CHLOROFORM-d)  
 ppm 7.17–7.29 (5H, m, 5 x aromatic CH), 7.08 (1H, 
app. t, J=7.7 Hz, aromatic CH), 6.94 (1H, app. t, J=7.4 
Hz, aromatic CH), 6.79 (1H, d, J=7.4 Hz, aromatic 
CH), 6.74 (1H, d, J=7.7 Hz, aromatic CH), 4.95 (2H, 
s, NCH2Ph), 1.76 (2H, dd, J=7.8, 4.0 Hz, -CHHCHH), 
1.51 (2H, dd, J=7.8, 4.0 Hz, -CHHCHH-). 
13C NMR + DEPT (100 MHz, CHLOROFORM-d)  
 ppm 177.3 (C=O), 142.9 (C), 136.4 (C), 131.0 (C), 
128.9 (2xCH), 127.7 (CH), 127.5 (2xCH), 126.8 
(CH), 122.2 (CH), 118.5 (CH), 109.2 (CH), 44.3 
(CH2), 27.2 (C), 19.6 (2xCH2). 
ESMS: m/z (%):     250 [M+H]
+ (100), 272 [M+Na]
+ (45). 
N
O
Ph
N
O
Ph
NaH, DMF
BrCH2CH2Br, RT
    16 h, 67%
     295
C15H13NO
 (223.28)
     287
C17H15NO
  (249.32)123 
 
1-Benzyl-3-(2-bromoethyl)-2,3-dihydro-1H-indol-2-one (431).  
 
 
 
 
 
 
Cyclopropane 287 (2.19 mmol, 0.55 g) was dissolved in a solution of HBr in acetic 
acid (30%, 20 mL). After 6 h at room temperature water (40 mL) and ether (40 mL) 
were added. The aqueous phase was extracted with ether (3 x 40 mL) and the 
combined organic phases were washed with water (3 x 40 mL) and brine (100 mL), 
dried (MgSO4) and concentrated in vacuo. Azeotropic removal of acetic acid with 
toluene (3 x 100 mL) gave bromide 431 (1.82 mmol, 0.60 g, 83%) as a colourless 
oil. 
 
Novel 
IR (ATR / golden gate):   3060 (w), 3027 (w), 2917 (w), 1702 (s), 1611 (s), 1487 
(s), 1466 (s). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.19–7.33 (6H, m, 6 x aromatic CH), 7.16 (1H, 
app. td, J=7.8, 1.0 Hz, aromatic CH), 7.01 (1H, app. 
td, J=7.6, 1.0 Hz, aromatic CH), 6.72 (1H, d, J=7.8 
Hz, aromatic CH), 4.88 (2H, s, NCH2Ph), 3.67–3.77 
(2H, m, CHCH2CH2Br), 3.58 (1H, dd, J=7.4, 6.5 Hz, 
CHCH2CH2Br), 2.44 (2H, m, CHCH2CH2Br). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
  ppm 177.2 (C=O), 143.6 (C), 136.0 (C), 129.0  
    ( 2 x CH), 128.4 (CH), 128.0 (C), 127.8 (CH), 127.5  
    ( 2 x CH), 124.1 (CH), 122.8 (CH), 109.4 (CH), 44.1  
    ( CH), 43.9 (CH2), 34.4 (CH2), 30.1 (CH2). 
ESMS: m/z (%):      330:332 {1:1} [M+H]
+ Br
79:Br
81 (100), 352:354 {1:1} 
    [ M + N a ]
+ Br
79:Br
81 (80).  
 
N
O
Ph
N
O
Ph
Br
     287
C17H15NO
  (249.32)
     431
C17H16BrNO
  (330.22)
HBr, AcOH
RT, 6 h, 83%124 
 
N N
H
N
N
N
2) KOH, MeOH, MTBE, RT, 16 h, 17% 
1) Ca(OCl)2, MTBE, AcOH, H2O, -10 °C
   296
C5H11N
 (85.15)
  297
C5H9N
(83.13)
   298
C15H27N3
(249.40)
2,3,4,5-Tetrahydro-pyridine (297) and its cyclic trimer (298). 
 
 
 
 
 
To a solution of piperidine 296 (47.0 mmol, 4.60 mL) in water (4 mL) was added 
glacial acetic acid (61.6 mmol, 3.80 mL). The resulting solution was added drop-
wise over 10 min to a slurry of calcium hypochlorite (32.4 mmol, 4.64 g) stirred in 
water (10 mL) and methyl t-butyl ether (10 mL) at −10 ºC behind a blast screen. 
After 30 min the organic phase was separated and added drop-wise to a solution of 
potassium hydroxide (68.8 mmol, 3.80 g) in methanol (10 mL) 0 ºC. The reaction 
mixture was allowed to warm to room temperature and after 16 h the precipitate 
formed was collected by filtration, washed with methanol. The filtrate and combined 
washings were concentrated in vacuo and partitioned between water (100 mL) and 
ether (80 mL). The aqueous phase was extracted with ether (3 x 80 mL) then the 
combined organic phases were washed with brine (100 mL), dried (MgSO4), filtered 
and concentrated in vacuo. The resulting oil was dissolved in acetone (10 mL) and 
cooled to –20 ºC overnight. The white crystals formed were collected by filtration, 
washed with cold acetone, and dried under vacuum to give imine 298 (7.82 mmol, 
1.95 g, 17%) as its cyclic trimer (a white solid). Data consistent with the literature.
58 
 
IR (ATR  /  golden  gate):    3215 (w), 2962 (m), 2923 (s), 2844 (m), 2807 (m), 
2774 (m), 2713 (m), 2586 (w), 2529 (w). 
1H NMR (400 MHz, CHLOROFORM-d)  
 ppm 3.06–3.19 (3H, m, 3 x NCH), 2.73–2.87 (3H, 
m, 3 x NCHH), 1.95–2.09 (3H, m, 3 x NCHH), 1.52–
1.82 (15H, m, 3 x CH2CH2CHHCH), 1.19–1.40 (3H, 
m, CH2’s in ring). 
13C NMR + DEPT (100 MHz, CHLOROFORM-d)  
 ppm 82.2 (CH), 46.6 (CH2), 29.4 (CH2), 26.0 (CH2), 
22.5 (CH2). 
 125 
 
1′-Benzyloctahydrospiro[indolizine-1,3′-indol-2′-one] (299).  
 
 
 
 
 
 
 
Cyclopropane (287) (0.40 mmol, 100 mg), imine (297) (0.35 mmol, 87 mg) and 
MgI2 (0.17 mmol, 47 mg) were dissolved in anhydrous THF (2 mL). The reaction 
vessel was flushed with nitrogen, heated under microwave irradiation (150 W, 125 
°C) for 5 h, then cooled to room temperature. Water (10 mL) was added and the 
phases separated. The aqueous phase was extracted with ethyl acetate (3 x 10 mL), 
then the combined organic phases were washed with brine (20 mL), dried (MgSO4), 
concentrated in vacuo and purified by column chromatography (silica, 5-10% ethyl 
acetate in hexanes) to give the desired product (299) (0.28 mmol, 93 mg, 70%) as a 
colourless oil. Data consistent with the literature.
57 
 
IR (ATR / golden gate):   2958 (w), 2929 (w), 2901 (w), 2848 (w), 2803 (w), 
2770 (w), 2721 (w), 1698 (s), 1609 (m). 
1H NMR (400 MHz, CHLOROFORM-d)  
 ppm 7.45 (1H, d, J=7.4 Hz, aromatic CH), 7.22–7.35 
(5H, m, 5 x aromatic CH), 7.13 (1H, app. td, J=7.8, 1.0 
Hz, aromatic CH), 7.02 (1H, app. td, J=7.4, 1.0 Hz, 
aromatic CH), 6.70 (1H, d, J=7.8 Hz, aromatic CH), 
5.05 (1H, d, J=15.7 Hz, NCHHPh), 4.80 (1H, d, 
J=15.7 Hz, NCHHPh), 3.31 (1H, td, J=8.6, 2.2 Hz, 
NCHH), 3.21 (1H, d, J=10.8 Hz, NCHH), 2.36–2.51 
(3H, m, NCH+NCHH+NCHH), 1.98–2.15 (2H, m, 
2xCHH), 1.57–1.72 (2H, m, 2xCHH), 1.47 (1H, dddd, 
J=12.8, 12.7, 12.7, 4.1, Hz, CHH), 1.09–1.25 (2H, m, 
2xCHH), 0.90 (1H, qd, J=12.8, 3.5 Hz, CHH). 
 
N
O
Ph
N
O
Ph
N H
N
+
 µwave, 5 h, 70%
MgI2,THF, 125 °C
     287
C17H15NO
 (249.32)
  297
C5H9N
(83.13)
     299
C22H24N2O
  (332.45)126 
 
13C NMR + DEPT (100 MHz, CHLOROFORM-d)  
 ppm 180.0 (C=O), 142.4 (C), 136.3 (C), 133.9 (C), 
128.9 (2xCH), 127.7 (CH), 127.5 (2xCH), 127.3 
(CH), 125.1 (CH), 122.5 (CH), 108.8 (CH), 72.3 
(CH), 56.8 (C), 54.4 (CH2), 53.8 (CH2), 44.0 (CH2), 
35.1 (CH2), 26.6 (CH2), 25.4 (CH2), 23.9 (CH2). 
1H-
1H and 
1H-
13C correlations obtained to confirm above NMR assignments. 
ESMS: m/z (%):     333 [M+H]
+ (90), 355 [M+Na]
+ (30), 688 [M2+Na]
+ 
      (100). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 127 
 
1′-Benzyl-2,2′,3,3′,4,5,6,7,8,8a-decahydrospiro[indolizine-1,3′-indole] (300). 
 
 
 
 
 
 
 
To a solution of oxindole 299 (0.27 mmol, 90 mg) in anhydrous THF (20 mL) at 
room temperature, under nitrogen, was added a solution of LiAlH4 (1.0 M in THF, 
0.81 mmol, 0.81 mL) drop-wise. The reaction mixture was stirred at room 
temperature for 30 min, heated to 70 °C for 2 h, then cooled to 0 °C. Water (30 mL) 
was added carefully then the reaction mixture was extracted with ethyl acetate (3 x 
30 mL). The combined organic phases were washed with brine (100 mL), dried 
(MgSO4), filtered, concentrated in vacuo and purified by column chromatography 
(silica, 1% MeOH in CHCl3) to give 300 (0.21 mmol, 68 mg, 79%) as a brown oil.  
 
Novel 
IR (ATR / golden gate):   3066 (w), 3032 (w), 3002 (w), 2926 (w), 2854 (w), 
2778 (w), 1603 (m), 1486 (m), 1452 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.24–7.37 (6H, m, 6 x aromatic CH), 7.08 (1H, 
app. td, J=7.7, 1.2 Hz, aromatic CH), 6.72 (1H, app. t, 
J=7.4 Hz, aromatic CH), 6.50 (1H, d, J=7.8 Hz, 
aromatic CH), 4.33 (1H, d, J=14.8 Hz, NCHHPh), 
4.16 (1H, d, J=14.8 Hz, NCHHPh), 3.30 (1H, d, J=9.0 
Hz, NCHH), 3.23 (1H, d, J=9.0 Hz, NCHH), 3.11–
3.20 (2H, m, 2xNCHH), 2.10–2.27 (2H, m, 2xNCHH), 
1.64–2.04 (3H, m, 2xCHH and NCH), 1.40–1.63 (2H, 
m, 2xCHH), 0.82–1.23 (4H, m, 4xCHH). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
  ppm 152.2 (C), 138.8 (C), 128.7 (2xCH), 128.0  
    ( 2 x CH), 127.7 (CH), 127.2 (CH), 125.2 (CH), 118.0 
N
O
Ph
N H
N
Ph
N H
     299
C22H24N2O
  (332.45)
   300
C22H26N2
(318.47)
LiAlH4 (1.0 M), THF
70 °C, 2 h, 79%128 
 
    ( CH), 107.0 (CH), 74.6 (NCH), 65.8 (NCH2), 54.3  
    ( N CH2), 54.0 (NCH2), 53.7 (NCH2Ph), 52.5 (C), 38.3 
    ( CH2), 26.6 (CH2), 25.4 (CH2), 24.4 (CH2). 
    NB.  1  (C) not observed. 
1H-
1H and 
1H-
13C correlations obtained to confirm above NMR assignments. 
ESMS: m/z (%):    319 [M+H]
+ (100). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 129 
 
Synthetic Procedures–Chapter 3 
2-(Trimethylsilyl)ethyl 2-oxo-piperid-1-yl carbonate (304). 
NH
O
O O
O
Si
NO2
N
O O
O
Si LiHMDS, THF, -78 °C - RT,  23%
   305
C5H9NO
 (99.13)
     304
C11H21NO3Si
  (243.38)
 
To a solution of LiHMDS (2.55 mmol, 1.20 mL) in anhydrous THF (10 mL) under 
argon at −78 °C was added n-BuLi (2.2 M, 5.55 mmol, 1.20 mL). The reaction 
mixture was warmed to 0 °C and stirred for 30 min before being cooled to −78 °C.  
A solution of δ-valerolactam (305) (5.00 mmol, 0.50 g) in anhydrous THF (6 mL) 
was added drop-wise and the solution stirred at −78  °C for 30 min. 2-
(Trimethylsilyl)ethyl 4-nitrophenyl carbonate (5.00 mmol, 1.43 g) in anhydrous THF 
(10 mL) was added and the reaction mixture was allowed to warm to room 
temperature overnight. Water (100 mL) was added and the reaction mixture 
extracted with ethyl acetate (3 x 100 mL). The combined organic phases were 
washed with brine (200 mL), dried (MgSO4), filtered and concentrated in vacuo to 
give 304 (1.16 mmol, 0.28 g, 23% crude) as a colourless oil. 
Novel 
IR (ATR / golden gate):   2945 (m), 2892 (w), 1733 (m), 1709 (s). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 4.29–4.36 (2H, m, OCH2CH2Si(CH3)3), 3.71 
(2H, t, J=6.2 Hz, NCH2CH2CH2CH2), 2.49–2.56 (2H, 
m, NCH2CH2CH2CH2), 1.78–1.86 (4H, m, 
NCH2CH2CH2CH2), 1.07–1.14 (2H, m, 
OCH2CH2Si(CH3)3), 0.04 (9 H, s, 
OCH2CH2Si(CH3)3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 171.4 (C=O), 154.6 (C=O), 65.7 (CH2), 46.5 
(CH2), 35.0 (CH2), 22.9 (CH2), 20.6 (CH2), 17.7 
(CH2), −1.4 (3 x CH3). 
ESMS: m/z (%):    509 [M2+Na]
+ (100), 266 [M+Na]
+ (20). 
HRMS (ES +ve):     C11H21NNaO3Si [M+Na]
+ 266.1188, found 266.1183. 130 
 
1-Allyl-piperidin-2-one (308), 1,3-diallyl-piperidin-2-one (309) and 1,3,3-triallyl-
piperidin-2-one (310). 
 
To a solution of δ–valerolactam 305 (5.04 mmol, 0.50 g) in anhydrous THF (30 mL) 
under nitrogen at −78°C, was added a solution of n-BuLi (1.6 M in hexanes, 5.09 
mmol, 3.18 mL). The reaction mixture was warmed to 0 °C over 1 h, then 
trimethylsilyl chloride (5.54 mmol, 0.70 mL) was added. After 2 h LDA (2.0 M in 
THF, 15.12 mmol, 7.60 mL) was added, and the resulting red solution stirred for 1 h 
then cooled to −78°C. Allyl bromide (60.48 mmol, 5.20 mL) was added drop-wise 
and the reaction mixture allowed to slowly warm to room temperature. After 16 h a 
saturated solution of NH4Cl (50 mL) was added and the mixture extracted with DCM 
(3 x 50 mL). The combined organic phases were washed with HCl (1 M, 100 mL), 
water (100 mL) and brine (100 mL), dried (MgSO4), concentrated in vacuo and 
purified by column chromatography (silica, 20% ethyl acetate in hexanes) to give 
firstly 308 (2.32 mmol, 0.32 g, 46%), then 309 (1.37 mmol, 0.25 g, 27%) and finally 
310 (0.36 mmol, 78 mg, 7%) each as colourless oils. 
 
Data for 308 consistent with the literature.
73 
IR (ATR / golden gate):   3079  (w),  3013  (w), 2928 (w), 2855 (w), 1631 (s), 
1470 (w). 
1H NMR (300 MHz, CHLOROFORM-d)  
  ppm 5.76 (1H, ddt, J=16.7, 10.6, 6.0 Hz,    
    N C H 2CH=CH2), 5.21–4.99 (2H, m, NCH2CH=CH2), 
    4.00  (2H,  m,  NCH2CH=CH2), 3.28–3.20 (2H, m,  
    N C H2CH2CH2CH2), 2.45–2.36 (2H, m,    
    N C H 2CH2CH2CH2), 1.78–1.85 (4H, m,      
    N C H 2CH2CH2CH2). 
 
N H
O
N
O
N
O
N
O
+ +
1) n-BuLi, TMSCl, THF
    -78 °C to 0 °C, 3 h
2) LDA, allyl bromide, THF
    -78 °C to RT, 16 h
   305
C5H9NO
 (99.13)
 308, 46%
C8H13NO
 (139.20)
 309, 27%
C11H17NO
 (179.26)
 310, 7%
C14H21NO
 (219.33)131 
 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
  ppm 169.6 (C=O), 132.9 (CH=CH2), 117.1  
    ( C H = CH2), 49.3 (CH2), 47.2 (CH2), 32.3 (CH2), 23.2 
    ( CH2), 21.4 (CH2). 
 
Data for 309. 
Novel 
IR (ATR / golden gate):  3452 (w), 3081 (w), 2974 (w), 2933 (w), 2860 (w), 
1634 (s), 1491 (m), 1462 (m), 1442 (m), 1413 (m).   
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 5.85–5.69 (2H, m, 2 x CH=CH2), 5.20–5.01 
(4H, m, 2 x CH=CH2), 4.06-3.91 (2H, m, 
NCH2CH=CH2), 3.27-3.18 (2H, m, NCH2CH2CH2), 
2.67 (1H, m, CHCH2CH=CH2), 2.40 (1H, m, 
CHCHHCH=CH2), 2.28 (1H, m, CHCHHCH=CH2), 
1.97–1.82 (2H, m, 2 x CHH), 1.74 (1H, m, CHH), 
1.57 (1H, m, CHH). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
  ppm 171.8 (C=O), 136.7 (CH), 133.2 (CH), 117.1 
    ( CH2), 116.9 (CH2), 49.8 (CH2), 47.7 (CH2), 41.4  
    ( CH), 36.6 (CH2), 26.3 (CH2), 21.9 (CH2). 
ESMS: m/z (%):    202 [M+Na]
+ (100), 381 [M2+Na]
+ (20). 
 
Data for 310. 
Novel 
IR (ATR / golden gate):  3077 (w), 3013 (w), 2975 (w), 2930 (m), 2850 (w), 
1631 (s), 1488 (m), 1439 (m), 1415 (m).    
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 5.83–5.66 (3H, m, NCH2CH=CH2 and 2 x 
CH2CH=CH2), 5.19–5.00 (6H, m, NCH2CH=CH2 and 
2 x CH2CH=CH2), 3.97 (2H, dd, J=5.9, 1.4 Hz, 
NCH2CH=CH2), 3.20 (2H, t, J=5.6 Hz, 
NCH2CH2CH2), 2.60-2.50 (2H, m, 2 x CHHCH=CH2), 132 
 
2.12–2.23 (2H, m, 2 x CHHCH=CH2), 1.69–1.84 (4H, 
m, NCH2CH2CH2). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
  ppm 173.7 (C=O), 134.8 (2xCH), 133.3 (CH), 118.1 
    ( 2 x CH2), 117.0 (CH2), 50.1 (CH2), 47.9 (CH2),  
    45.0  (C), 43.5 (2xCH2), 29.3 (CH2), 19.8 (CH2). 
ESMS: m/z (%):    220 [M+H]
+ (30), 242 [M+Na]
+ (100), 462 [M2+Na]
+ 
    (50). 
HRMS (EI):      C14H21NO [M]
+. 219.1618, found 219.1619. 
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Diethyl 2-(2-cyano-ethyl)-2-ethoxycarbonyl-malonate (314). 
 
O
O
O
O
O O
O
O
O
O
O O CN
CN
K2CO3, Bu4NHSO4
Toluene, RT, 72 h, 46%
    314
C13H19NO6
 (285.30)
    315
C10H16O6
 (232.24)
 
To a mixture of triethyl methanetricarboxylate (315) (16.00 mmol, 3.4 mL) in 
toluene (3 mL) at room temperature was added acrylonitrile (14.00 mmol, 0.9 mL), 
K2CO3 (4.20 mmol, 0.58 g) and Bu4NHSO4 (0.70 mmol, 0.24 g). After 24 h the 
reaction mixture was washed with water (20 mL) and the aqueous phase extracted 
with ether (3 x 10 mL). The combined organic phases were washed with brine (20 
mL), dried (MgSO4), concentrated in vacuo and purified by column chromatography 
(silica, 20% diethyl ether in petroleum ether) to give the desired compound (314) as 
a yellow oil (6.49 mmol, 1.93 g, 46%). Data consistent with the literature.
60 
 
1H NMR (300 MHz, CHLOROFORM-d):    
 ppm 4.26 (6H, q, J=7.1 Hz, 3 x COOCH2CH3), 
2.72–2.63 (2H, m, CH2CH2CN), 2.53–2.44 (2H, m, 
CH2CH2CN), 1.27 (9H, t, J=7.1 Hz, 3 x 
COOCH2CH3).
 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 166.1 (3xC=O), 118.9 (CN), 64.3 (C), 62.8 
(3xCH2), 28.9 (CH2), 13.9 (3xCH3), 13.5 (CH2). 
ESMS: m/z (%):    308 [M+Na]
+ (100). 
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Ethyl 2-oxo-piperidine-3-carboxylate (320). 
 
 
 
 
 
 
To anhydrous THF (20 mL) under argon at 0 °C was added LiAlH4 (1.0 M in THF, 
2.35 mmol, 2.4 mL) drop-wise. To this was added a solution of nitrile (314) (0.47 
mmol, 0.14 g) in anhydrous THF (2 mL). After 24 h at room temperature the 
reaction mixture was heated to reflux for 1 h then cooled to room temperature and 
water (10 mL) added carefully. The aqueous phase was extracted with ether (3 x 30 
mL) then continuously extracted for 16 h with hot ethyl acetate (80 mL). The 
combined organic phases were dried (MgSO4) and concentrated in vacuo to give the 
title compound (320) (0.37 mmol, 64 mg, 80%) as a yellow oil. Data consistent with 
the literature.
60 
 
IR (ATR / golden gate):   3304  (w),  3225  (w), 2941 (w), 2873 (w), 1731 (s), 
1655 (s). 
1H NMR (300 MHz, CHLOROFORM-d):    
 ppm 6.56 (1H, b s, NH), 4.22 (2H, m, CO2CH2CH3), 
3.43–3.28 (3H, m, CHCH2CH2CH2N), 2.17–2.01 (2H, 
m, 2xCHH), 1.93 (1H, m, CHH), 1.75 (1H, m, CHH), 
1.29 (3H, t, J=7.1 Hz, CO2CH2CH3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
  ppm 170.9 (C=O), 168.3 (C=O), 61.6 (CH2), 48.8 
       ( CH), 42.4 (CH2), 25.0 (CH2), 20.5 (CH2), 14.3 (CH3). 
ESMS: m/z (%):    194 [M+Na]
+ (100). 
 
 
 
 
 
N H O
O O
O
O
O
O
O O CN
LiAlH4 (1.0 M in THF), THF
RT, 24 h, , 1 h, 80%
     314
C13H19NO6
  (285.30)
    320
C8H13NO3
 (171.20)135 
 
Diethyl 2-(3-ethoxycarbonylamino-propyl)-malonate (322) and diethyl 2-oxo-
piperidine-3,3-dicarboxylate (312). 
 
 
 
 
 
 
 
To a solution of nitrile (315) (0.70 mmol, 0.20 g) in EtOH (5 mL) was added 
Adams’ catalyst (PtO2, 0.07 mmol, 16 mg). The reaction flask was evacuated and 
refilled with argon (x3) before being evacuated and refilled with hydrogen (x3). The 
reaction mixture was stirred under a hydrogen atmosphere (balloon) at room 
temperature for 16 h before being filtered through Celite
® and washed with ethanol. 
The filtrate was concentrated in vacuo and purified by column chromatography 
(silica, 20→50% ethyl acetate in hexanes then 1–5% MeOH in ethyl acetate) to give 
firstly 322 (0.25 mmol, 73 mg, 36%) as a clear oil then lactam (312) (0.19 mmol, 29 
mg, 17%) as a cream solid.  
 
Data for 322 
Novel 
IR (ATR / golden gate):   3387 (w), 3330 (w), 2979 (w), 2933 (w), 2907 (w), 
2862 (w), 1720 (s), 1693 (s), 1526 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 4.81 (1H, b s, NH), 4.16 (4H, q, J=7.2 Hz, 
2xCOOCH2CH3), 4.07 (2H, q, J=6.6 Hz, 
NHCOOCH2CH3), 3.30 (1H, t, J=7.5 Hz, 
CHCH2CH2CH2NH), 3.16 (2H, app. q, J=5.9 Hz, 
CHCH2CH2CH2NH), 1.89 (2H, m, 2 x CHH), 1.57–
1.47 (2H, m, 2 x CHH), 1.23 (6H, t, J=7.2 Hz, 2 x 
COOCH2CH3), 1.19 (3H, t, J=6.6 Hz, 
NHCOOCH2CH3). 
 
O O
O CN
EtO OEt
OEt
O O
N
H
O
OEt
EtO OEt
N H
O CO2Et
CO2Et +
PtO2, H2, EtOH
RT, 16 h
     315
C13H19NO6
  (285.30)
 322, 36%
C13H23NO6
 (289.33)
 312, 17%
C11H17NO5
 (243.26)136 
 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 169.4 (2xC=O), 156.8 (C=O), 61.5 
(2xOCH2CH3), 60.8 (OCH2CH3), 51.7 (CH), 40.5 
(CH2), 27.8 (CH2), 25.9 (CH2), 14.7 (OCH2CH3), 14.2 
(2xOCH2CH3). 
ESMS: m/z (%):    312 [M+Na]
+ (100). 
HRMS (ES +ve):     C13H23NNaO6 [M+Na]
+ 312.1423, found 312.1418. 
 
Data for 312 consistent with the literature.
60 
IR (ATR / golden gate):  3194 (w), 3073 (w), 2971 (w), 2945 (w), 2899 (w), 
1746 (m), 1724 (s), 1675 (s). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 6.51 (1H, b s, NH), 4.28 (4H, q, J=7.1 Hz, 2 x 
COOCH2CH3), 3.36 (2H, td, J=6.3, 2.1 Hz, 
NHCH2CH2CH2), 2.48–2.42 (2H, m, 2 x CHH), 1.82–
1.73 (2H, m, 2 x CHH), 1.30 (6H, t, J=7.1 Hz, 2 x 
COOCH2CH3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 168.1 (2xC=O), 166.0 (C=O), 63.5 (C), 62.5 
(2xOCH2CH3), 42.2 (CH2), 28.7 (CH2), 19.0 (CH2), 
14.1 (2xOCH2CH3). 
ESMS: m/z (%):    266 [M+Na]
+ (40), 509 [M2+Na]
+ (100). 
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Dimethyl 2-(2-phenylsulfonyl-ethyl)-malonate (327). 
 
 
 
 
 
 
 
To a solution of dimethyl malonate (326) (2.27 mmol, 0.26 mL) in anhydrous DMF 
(10 mL) at 0 °C under argon was added sodium hydride (60% in mineral oil, 5.68 
mmol, 0.23 g). The reaction mixture was allowed to warm to room temperature and 
after 30 min 2-chloroethyl phenyl sulfide (5.68 mmol, 0.84 mL) was added 
dropwise. After 6 h at room temperature the temperature was raised to 60 °C for 16 
h then reduced to room temperature. Water (20 mL) was added and the reaction 
mixture extracted with ether (3 x 20 mL). The combined organic phases were 
washed with water (4 x 20 mL) and brine (50 mL), dried (MgSO4), concentrated in 
vacuo and purified by column chromatography (silica, 5% diethyl ether in petroleum 
ether) to give the mono-alkylated material 327 (0.82 mmol, 0.22 g, 36%) as a 
colourless liquid. Data consistent with the literature.
74 
 
IR (ATR / golden gate):   3002 (w), 2949 (w), 1729 (s), 1436 (m). 
1H NMR (300 MHz, CHLOROFORM-d):    
 ppm 7.39–7.28 (3H, m, 3 x aromatic CH), 7.24–7.15 
(2H, m, 2 x aromatic CH), 3.74 (6H, s, 2 x OCH3), 
3.66   (1H, t, J=7.2 Hz, CHCH2CH2SPh), 2.97 (2H, t, 
J=7.2 Hz, CH2CH2SPh), 2.26-2.19 (2H, app. q, J=7.2 
Hz, CHCH2CH2SPh). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 169.5 (2xC=O), 135.6 (C), 129.9 (2xCH), 
129.2 (2xCH), 126.5 (CH), 52.8 (2xOCH3), 50.4 
(CH), 31.6 (CH2), 28.5 (CH2). 
ESMS: m/z (%):    291 [M+Na]
+ (100). 
 
O O
MeO OMe
O O
MeO OMe
S
1) NaH, DMF, RT, 30 min
2) PhSCH2CH2Cl, 60 °C, 
          16 h, 36%
   326
 C5H8O4
(132.12)
     327
C13H16O4S
  (268.33)138 
 
Dimethyl 2,2-bis-(2-benzylsulfonyl-ethyl)-malonate (328) and dimethyl 2-(2-
benzylsulfonyl-ethyl)-malonate (328a). 
 
 
 
 
 
 
 
To a solution of dimethyl malonate (326) (3.78 mmol, 0.43 mL) in acetonitrile (10 
mL) was added phenyl vinyl sulfone (11.40 mmol, 1.90 g) and 
dihydridotetrakis(triphenylphosphine)-ruthenium(II) (0.11 mmol, 0.13 g). The dark 
green solution was stirred at room temperature for 4 d, filtered, concentrated in 
vacuo and purified by column chromatography (silica, 30→70% ethyl acetate in 
hexanes) to give firstly bis-alkylated material (328) (3.58 mmol, 1.68 g, 95%) then 
the mono-alkylation material (328a) (0.11 mmol, 19 mg, 3%), both as a clear oils. 
 
Data for 328 consistent with the literature.
61 
IR (ATR / golden gate):   3002 (w), 3960 (w), 2933 (w), 1731 (s), 1444 (m). 
1H NMR (300 MHz, CHLOROFORM-d):      
 ppm 7.87–7.94 (4H, m, 4 x aromatic CH), 7.56–7.74 
(6H, m, 6 x aromatic CH), 3.67 (6H, s, 2 x OCH3), 
3.14–3.04 (4H, m, 2 x CH2CH2SO2Ph), 2.27–2.17 (4H, 
m, 2 x CH2CH2SO2Ph).
 
13C NMR + DEPT (75 MHz, CHLOROFORM-d):  
 ppm 169.8 (2xC=O), 138.8 (2xC), 134.2 (2xCH), 
129.7 (4xCH), 128.2 (4xCH), 55.4 (C), 53.3 
(2xOCH3), 51.7 (2xCH2), 26.8 (2xCH2). 
ESMS: m/z (%):    491 [M+Na]
+ (70), 959 [M2+Na]
+ (100). 
   
 
 
  
O O
MeO OMe
SO2Ph
O O
MeO OMe
SO2Ph PhO2S
O O
MeO OMe
SO2Ph
+
[RuH2(PPh3)4]
MeCN, RT, 4 d
+
    326
 C5H8O4
(132.12)
    432
C8H8O2S
 (168.22)
  328, 95%
C21H24O8S2
 (468.55)
  328a, 3%
C13H16O6S
  (300.33)139 
 
Data for 328a consistent with the literature.
75 
IR (ATR / golden gate):   2956 (w), 2359 (w), 2340 (w), 1730 (s), 1446 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.94–7.88 (2H, m, 2 x aromatic CH), 7.71–7.53 
(3H, m, 3 x aromatic CH), 3.72 (6H, s, 2 x OCH3), 
3.58 (1H, t, J=7.1 Hz, CHCH2CH2SO2Ph), 3.27–3.16 
(2H, m, CHCH2CH2SO2Ph), 2.28 (2H, m, 
CHCH2CH2SO2Ph). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 168.7 (2xC=O), 138.8 (C), 134.1 (CH), 129.5 
(2xCH), 128.2 (2xCH), 53.5 (CH2), 52.9 (2xOCH3), 
49.5 (CH), 22.2 (CH2). 
ESMS: m/z (%):    323 [M+Na]
+ (100). 
HRMS (ES +ve):     C13H16NaO6S [M+Na]
+ 323.05653, found 323.0560. 
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Methyl 2,2-bis-(2-benzylsulfonyl-ethyl)-4-cyano-butyrate (329) and methyl 4-
benzenesulfonyl-2-(2-benzenesulfonyl-ethyl)-butyrate (330).   
 
 
 
 
 
 
To a solution of malonate (328) (0.64 mmol, 0.30 g) in anhydrous DMF (10 mL) at 
room temperature under argon was added NaI (1.28 mmol, 0.19 g) and acrylonitrile 
(3.20 mmol, 0.21 mL). The reaction mixture was heated to 130 °C for 16 h, then 
cooled to room temperature and water (15 mL) added. The reaction mixture was 
extracted with ethyl acetate (3 x 10 mL) and the combined organic phases washed 
with water (4 x 10 mL) and brine (20 mL), dried (MgSO4), concentrated in vacuo 
and purified by column chromatography (silica, 50% ethyl acetate in hexanes) to 
give an inseparable 1:1 mixture of the desired product 329 and the decarboxylated 
product 330 (133 mg) as a brown solid. 
 
Novel 
IR (ATR / golden gate):   3066 (w), 3020 (w), 2949 (w), 2930 (w), 2253 (w), 
1727 (s), 1448 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.93–7.85 (4H+4H, m, 2 x 4 x aromatic CH), 
7.71–7.64 (2H+2H, m, 2 x 2 x aromatic CH), 7.63–
7.54 (4H+4H, m, 2 x 4 x aromatic CH), 3.63 (3H, s, 
OCH3), 3.62 (3H, s, OCH3), 3.12–3.05 (2H+2H, m, 2 
x CH2CH2SO2Ph), 3.01-2.94 (2H+2H, m, 2 x 
CH2CH2SO2Ph), 2.64 (1H, m, CH(CH2CH2SO2Ph)2, 
330), 2.22 (2H, t, J=7.8 Hz, CH2CH2CN, 329), 2.07-
1.84 (4H+4H+2H, m, 4 x CH2CH2SO2Ph and 
CH2CH2CN (329)). 
 
 
O O
MeO OMe
SO2Ph PhO2S
O
MeO
SO2Ph PhO2S
CN
O
MeO
SO2Ph
SO2Ph
     328
C21H24O8S2
 (468.55)
+
      329
C22H25NO6S2
   (463.58)
     330
C19H22O6S2
  (410.51)
NaI, DMF, 
acyrlonitrile, 16h141 
 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
  ppm 173.5 (C=O), 173.2 (C=O), 138.9 (C), 138.6 
    ( C), 134.3 (CH), 134.1 (CH), 129.7 (CH), 129.6 (CH), 
    128.1  (CH), 128.1 (CH), 118.5 (CN), 53.7 (CH2), 53.0 
    ( O CH3), 52.3 (OCH3), 51.1 (CH2), 46.8 (C), 42.1 
(CH),       30.8  (CH2), 26.5 (CH2), 24.7 (CH2), 12.5 (CH2). 
ESMS: m/z (%):    433 [M(330)+Na]
+ (100), 486 [M(329)+Na]
+ (40). 
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Dimethyl 2,2-bis-(2-benzenesulfinyl-ethyl)-malonate (332) and dimethyl 2-(2-
benzenesulfinyl-ethyl)-malonate (333). 
 
 
 
 
 
 
To a solution of dimethyl malonate (326) (6.00 mmol, 0.69 mL) in anhydrous DMF 
(30 mL) under argon was added NaH (60% dispersion in mineral oil, 1.20 mmol, 48 
mg). The reaction mixture was stirred at room temperature for 15 min then phenyl 
vinyl sulfoxide (433) (13.20 mmol, 1.80 mL) added drop-wise. After 48 h water (50 
mL) was added and the reaction mixture extracted with diethyl ether (2 x 40 mL). 
The combined organic phases were washed with water (4 x 40 mL) and brine (100 
mL), dried (MgSO4), concentrated in vacuo and purified by column chromatography 
(silica, 30% ethyl acetate in hexanes→100% ethyl acetate) to give firstly the bis-
alkylated material (322) as a yellow oil (4.62 mmol, 2.02 g, 77%, 1:1 mixture of 
diasteroisomers) and then the mono-alkylated material (333) (0.54 mmol, 94 mg, 
9%) as a clear oil.  
 
Data for 322 
Novel 
IR (ATR / golden gate):  3054 (w), 2949 (w), 1730 (s), 1440 (m).    
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.61–7.49 (10H, m, 10 x aromatic CH), 3.70–
3.63 (6H, m, 2 x OCH3), 2.84 (2H, m, CH2CH2SOPh), 
2.62 (2H, m, CH2CH2SOPh), 2.36–2.22 (2H, m, 
CH2CH2SOPh), 2.05 (2H, m, CH2CH2SOPh). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 170.5 (2xC=O), 143.2+143.2 (2xC), 131.3 
(2xCH), 129.5 (4xCH), 124.2 (4xCH), 56.1+56.0 (C), 
53.1 (2xOCH3), 51.3+51.2 (2xCH2), 25.6+25.5 
(2xCH2). 
O O
MeO OMe
SOPh
O O
MeO OMe
SOPh PhOS
O O
MeO OMe
SOPh
+ +
NaH (0.2 equiv.)
DMF, RT, 48h
   326
 C5H8O4
(132.12)
   433
C8H8OS
(152.22)
 332, 77%
C21H24O6S2
  (436.55)
  333, 9%
C13H16O5S
  (284.33)143 
 
ESMS: m/z (%):    459 [M+Na]
+ (90), 895 [M2+Na]
+ (100). 
HRMS (ES +ve):     C21H24NaO6S2 [M+Na]
+ 459.0906, found 459.0907. 
 
 
Data for 333 consistent with the literature.
76 
IR (ATR / golden gate):   3054 (w), 3005 (w), 2949 (w), 1733 (s), 1422 (m). 
1H NMR (300 MHz, CHLOROFORM-d)    
 ppm 7.65–7.45 (5H, m, 5 x aromatic CH), 3.72 (3H, 
s, OCH3), 3.71 (3H, s, OCH3), 3.52 (1H, t, J=7.2 Hz, 
CHCH2CH2SOPh), 2.94 (1H, m, CHHSOPh), 2.81 
(1H, m, CHHSOPh), 2.35 (1H, m, CHHCH2SOPh), 
2.19 (1H, m, CHHCH2SOPh). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 169.0+168.9 (2xC=O), 143.3+143.2 (C), 131.3 
(CH), 129.5 (2xCH), 124.2 (2xCH), 53.9 (CH2), 52.9 
(2xOCH3), 50.3 (CH), 21.6 (CH2). 
ESMS: m/z (%):    307 [M+Na]
+ (100). 
HRMS (ES +ve):     C13H16NaO5S [M+Na]
+ 307.0616, found 307.0611. 
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Methyl 4-cyano-2,2-divinyl-butanoate (331), methyl 2-(2-benzenesulfinyl-ethyl)-
but-2-enoate (334), methyl 2-2(2-benzenesulfinyl-ethyl)-4-cyano-2-vinyl-
butanoate (335), methyl 2,2,-bis-(2-benzenesulfinyl-ethyl)-4-cyano-butanoate  
(336) and methyl 4-benzenesulfinyl-2-(2-benzenesulfinyl-ethyl)-butanoate (337). 
 
To a solution of malonate (332) (0.52 mmol, 0.23 g) in anhydrous DMF (5 mL) at 
room temperature under argon was added NaI (1.04 mmol, 42 mg) and acrylonitrile 
(2.60 mmol, 0.17 mL). The reaction mixture was heated to 130 °C for 16 h then 
cooled to room temperature and water (10 mL) added. After extraction with ethyl 
acetate (2 x 10 mL), the combined organic phases were washed with water (4 x 10 
mL) and brine (30 mL), dried (MgSO4), concentrated in vacuo and purified by 
column chromatography (silica, 20→50% ethyl acetate in hexanes to 1% MeOH in 
ethyl acetate) to give a mixture of compounds (331, 334, 335, 336 and 337). Yields 
of each product varied with reaction conditions (temperature and time).  
 
Data for 331 
Novel     Clear  oil. 
IR (ATR / golden gate):   3085  (w),  3009  (w), 2952 (w), 2250 (w), 1728 (s), 
1433 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 5.97 (2H, dd, J=17.6, 10.8 Hz, 2 x CH=CH2), 
5.35 (2H, d, J=10.8 Hz, 2 x CH=CHH), 5.18 (2H, d, 
O O
MeO OMe
SOPh PhOS
O
MeO
CN
O
MeO
SOPh
O
MeO
CN
SOPh
O
MeO
CN
SOPh PhSO
O
MeO
SOPh
SOPh
NaI, DMF
 acrylonitrile
130 °C, 16 h
+ +
+ +
     332
C21H24O6S2
  (436.55)
    331
C10H13NO2
 (179.22)
     334
C13H16O3S
  (252.33)
     335
C16H19NO3S
  (305.40)
        336
C22H25NO4S2
    (431.58)
     337
C19H22O4S2
  (378.51)145 
 
J=17.6 Hz, 2 x CH=CHH), 3.75 (3H, s, OCH3), 2.39 
(2H, t, J=8.1 Hz, CH2CH2CN), 2.23 (2H, t, J=8.1 Hz, 
CH2CH2CN). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 173.0 (C=O), 137.0 (2xCH), 119.7 (CN), 117.4 
(2xCH2), 54.8 (C), 52.8 (OCH3), 31.5 (CH2), 13.2 
(CH2). 
ESMS: m/z (%):    202 [M+Na]
+ (100). 
HRMS (ES +ve):     C10H13NNaO2 [M+Na]
+ 202.0844, found 202.0838. 
 
 
Data for 334 
Novel     Clear  oil. 
IR (ATR / golden gate):   3058  (w),  2990  (w), 2952 (w), 2850 (w), 1706 (s), 
1644 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.65–7.60 (2H, m, 2 x aromatic CH), 7.56–7.49 
(3H, m, 3 x aromatic CH), 6.97 (1H, q, J=7.2 Hz, 
C=CHCH3), 3.71 (3H, s, OCH3), 3.00 (1H, m, 
CH2CHHSOPh), 2.88–2.76 (2H, m, CHHCHHSOPh), 
2.59 (1H, m, CHHCH2SOPh), 1.82 (3H, d, J=7.2 Hz, 
C=CHCH3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 167.6 (C=O), 143.9 (C), 140.5 (CH), 131.1 
(CH), 130.0 (C), 129.4 (2xCH), 124.2 (2xCH), 55.8 
(CH2), 52.0 (OCH3), 19.6 (CH2), 14.5 (CH3). 
ESMS: m/z (%):  253 [M+H]
+ (20), 275 [M+Na]
+ (80), 527 [M2+Na]
+ 
(100). 
HRMS (ES +ve):     C13H16NaO3S [M+Na]
+ 275.0718, found 275.0712. 
 
Data for 335 
Novel        Brown oil, 1:1 mixture of diastereoisomers. 
IR (ATR / golden gate):   3047 (w), 2956 (w), 2245 (w), 1726 (s), 1443 (m). 146 
 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm  7.63–7.48 (5H+5H, m, 2 x (5 x aromatic CH)), 
5.876 (1H, dd, J=17.9, 11.0 Hz, CH=CH2), 5.872 (1H, 
dd, J=17.9, 11.0 Hz, CH=CH2), 5.35 (1H, d, J=11.0 
Hz, CH=CHH), 5.29 (1H, d, J=11.0 Hz, CH=CHH), 
5.15 (1H, d, J=17.9 Hz, CH=CHH), 5.06 (1H, d, 
J=17.9 Hz, CH=CHH), 3.71 (3H, s, OCH3), 3.69 (3H, 
s, OCH3), 2.85 (1H+1H, m, 2 x CHH), 2.64 (1H+1H, 
m, 2 x CHH), 2.32–2.06 (4H+4H, m, 2 x 4 x CHH), 
2.04–1.85 (2H+2H, m, 2 x 2 CHH). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 173.4 (C=O), 143.4+143.3 (C), 136.7+136.7 
(CH), 131.3 (CH), 129.5 (2xCH), 124.2 (2xCH), 
119.2 (CN), 117.9+117.8 (CH2), 52.8+52.7 (OCH3), 
51.7+51.5 (CH2), 51.1 (C), 32.5+32.3 (CH2), 
28.1+27.8 (CH2), 13.0+12.9 (CH2). 
ESMS: m/z (%):    328 [M+Na]
+ (100), 633 [M2+Na]
+ (60). 
HRMS (ES +ve):     C16H19NNaO3S [M+Na]
+ 328.0977, found 328.0978. 
 
Data for 336 
Novel        Brown oil (1:2:1 mixture of diastereoisomers). 
IR (ATR / golden gate):   3058 (w), 2945 (w), 2249 (w), 1725 (m), 1443 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.61–7.48 (10H, m, 10 x aromatic CH), 3.66–
3.58 (3H, m, OCH3), 2.77–2.72 (2H, m, 
CH2CH2SOPh), 2.58–2.43 (2H, m, CH2CH2SOPh), 
2.26–1.92 (4H, m, 4 x CHH), 1.91–1.83 (2H, m, 2 x 
CHH), 1.67–1.77 (2H, m, 2 x CHH). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 173.9 (C=O), 143.0+143.0+142.9+142.8 (2xC), 
131.4 (2xCH), 129.5 (4xCH), 124.1 (4xCH), 118.8 
(CN), 52.7 (OCH3), 50.7+50.6+50.5+50.3 (2xCH2), 147 
 
47.3+47.2 (C), 30.8+30.7+30.6 (CH2), 25.8+25.5+25.3 
(2xCH2), 12.4 (CH2). 
ESMS: m/z (%):    454 [M+Na]
+ (100), 885 [M2+Na]
+ (100). 
HRMS (ES +ve):     C22H25NNaO4S2 [M+Na]
+ 454.1123, found 454.1117. 
 
Data for 337 
Novel        Brown oil (1:1 mixture of diastereoisomers). 
IR (ATR / golden gate):   3054  (w),  2952  (w), 2930 (w), 2847 (w), 1726 (s), 
1443 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.62–7.46 (10H, m, 10 x aromatic CH), 3.64 
(3H, s, OCH3), 2.88–2.42 (4H, m, 4 x CHH), 2.25–
1.64 (5H, m, CHCH2CH2SOPh and 4 x CHH). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
  ppm 174.2+173.8 (C=O), 143.5+143.3 (2xC), 131.4 
    +131.3+131.2  (2xCH), 129.5+129.5+124.2 (4xCH), 
    124.1  (4xCH), 54.2+54.1+54.0+53.9 (2xCH2), 52.2 
    ( O CH3), 43.5+43.3+43.2 (CH), 24.3+24.3+24.1+23.9 
    ( 2 x CH2). 
ESMS: m/z (%):    401 [M+Na]
+ (50), 779 [M2+Na]
+ (100). 
HRMS (ES +ve):     C19H22NaO4S2 [M+Na]
+ 401.0857, found 401.0822. 
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6-Benzenesulfinyl-4-(2-benzenesulfinyl-ethyl)-4-formyl-hexanenitrile (340). 
 
 
 
 
 
 
To anhydrous THF (15 mL) under argon at −78 °C was added sequentially LiAlH4 
(1.0 M, 0.46 mmol, 0.46 mL) and a solution of nitrile (336) (0.23 mmol, 0.10 g), in 
anhydrous THF (5 mL) drop-wise. After 2 h the reaction was quenched by the drop-
wise addition of water (30 mL) and the solution was extracted with ethyl acetate (3 x 
20 mL). The combined organic phases were washed with brine (100 mL), dried 
(MgSO4), concentrated in vacuo and purified by column chromatography (silica, 
100% ethyl acetate→5% MeOH in ethyl acetate) to give the aldehyde (441) (0.13 
mmol, 52 mg, 56%) as a colourless oil. 
 
Novel   1:2:1 mixture of diastereoisomers. 
IR (ATR / golden gate):  3062 (w), 2952 (w), 2865 (w), 2249 (w), 1715 (m), 
1443(m).    
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 9.30 (1H, m, CHO), 7.59–7.46 (10H, m, 10 x 
aromatic CH), 2.80–2.63 (2H, m, 2 x CHH), 2.39–2.54 
(2H, m, 2 x CHH), 2.21–1.92 (4H, m, 4 x CHH), 
1.88–1.77 (2H, m, 2 x CHH), 1.72–1.59 (2H, m, 2 x 
CHH). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 202.3 (CHO), 142.7+142.6+142.6 (2xC), 131.5 
(2xCH), 129.6 (4xCH), 124.0 (4xCH), 118.7 (CN), 
50.4+50.4 (C), 49.8+49.7+49.6+49.5 (2xCH2), 27.7 
(CH2), 23.0+22.8+22.7 (2xCH2), 11.9 (CH2). 
ESMS: m/z (%):    456 [M+Na+MeOH]
+ (100). 
 
 
O
CN
SOPh PhOS
MeO O
PhOS SOPh
CN
LiAlH4 (1.0 M in THF), THF
-78 °C, 2 h, 56%
       336
C22H25NO4S2
   (431.58)
       340
C21H23NO3S2
   (401.55)149 
 
Methyl 4-cyano-2,2-divinyl-butanoate (331). 
 
 
 
 
 
 
A solution of nitrile (332) (0.63 mmol, 0.27 g) in anhydrous DMF (12 mL) was 
degassed with argon for 30 min. The solution was separated into 3 mL batches and 
heated under microwave irradiation (100 W, 150 °C) for 2–3 h. The dark brown 
solutions were combined and partitioned between water (20 mL) and ethyl acetate 
(20 mL). The aqueous phase was extracted with ethyl acetate (20 mL), and the 
combined organic phases were washed with water (4 x 20 mL) and brine (50 mL), 
dried (MgSO4), concentrated in vacuo and purified by column chromatography 
(silica, 100% petroleum ether→25% diethyl ether in petroleum ether) to give divinyl 
ester (331) (0.47 mmol, 84 mg, 75%) as a yellow oil. 
 
Data previously reported 331. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O
CN
MeO
O
SOPh PhOS
CN
MeO
 DMF, microwave
110 W, 150 °C, 2 h, 75% 
      332
C22H25NO4S2
   (431.58)
    331
C10H13NO2
 (179.22)150 
 
Methyl 4-cyano-2,2-divinyl-butanoate (331). 
 
 
 
 
 
A solution of nitrile (335) (0.53 mmol, 0.15 g) in anhydrous DMF (6 mL) was 
degassed with argon for 30 min. The solution was separated into 3 mL batches and 
heated under microwave irradiation (100 W, 140 °C) for 30 min. The dark brown 
solutions were combined and partitioned between water (10 mL) and ethyl acetate 
(10 mL). The aqueous phase was extracted with ethyl acetate (1 x 10 mL) and the 
combined organic phases combined were washed with water (4 x 20 mL) and brine 
(50 mL), dried (MgSO4), concentrated in vacuo and purified by column 
chromatography (silica, 100% petroleum ether→25% diethyl ether in petroleum 
ether) to give the divinyl ester (331) (0.34 mmol, 61 mg, 64%) as a yellow oil. 
 
Data previously reported 331. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O
CN
MeO
O
SOPH
CN
MeO DMF, microwave, 100 W
140 °C, 30 min, 64% 
      335
C16H19NO3S
   (305.40)
    331
C10H13NO2
 (179.22)151 
 
Methyl 4-cyano-2,2-divinyl-butanoate (331) and methyl 4,6-dicyano-2,2-divinyl-
hexanoate (435). 
 
A crude mixture (2:1) of nitrile (336) and nitrile (434) (100 mg) was dissolved in 
anhydrous DMF (3 mL) and heated under microwave irradiation (100 W, 130 °C) 
for 1 h. The resulting dark brown solution was partitioned between water (10 mL) 
and ethyl acetate (10 mL). The aqueous phase was extracted with ethyl acetate (10 
mL), and the combined organic phases were washed with water (4 x 10 mL) and 
brine (50 mL), dried (MgSO4), concentrated in vacuo and purified by column 
chromatography (silica, 100% petroleum ether→50% diethyl ether in petroleum 
ether) to give firstly the divinyl ester (331) (0.06 mmol, 10 mg) as a yellow oil and 
then the bis-nitrile compound (435) as a brown oil (0.13 mmol, 3 mg, 1:1 mixture of 
diastereoisomers). 
 
Data previously reported for 331. 
 
Data for 435 
Novel  
IR (ATR / golden gate):  3088 (w), 2952 (w), 2922 (w), 2847 (w), 2238 (w), 
1726 (s).   
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 6.08 (2H, dd, J=17.6, 10.7 Hz, 2 x CH=CH2), 
6.00 (2H, dd, J=17.6, 10.7 Hz, 2x CH=CH2), 5.38 
(2H+2H, dd, J=10.7, 3.5 Hz, 2 x CH=CHH), 5.22 
(2H+2H, dd, J=17.6, 3.5 Hz, 2 x CH=CHH), 3.77 
(3H+3H, s, OCH3), 2.82 (1H+1H, m, CHHCHCN), 
2.68–2.48 (2H+2H, m, CHCH2CH2CN), 2.35 (1H+1H, 
O
CN
MeO
O
CN
PhOS SOPh
MeO
O
PhOS
CN
CN PhOS
MeO
O
CN
CN
MeO DMF, 100 W
 microwave
150 °C, 2 h 
+ +
      336
C22H25NO4S2
   (431.58)
      434
C25H28N2O4S2
   (484.64)
    435
C13H16N2O2
 (232.28)
    331
C10H13NO2
 (179.22)152 
 
dd, J=14.1, 9.4 Hz, CHHCH2CN), 1.97–2.05 (3H+3H, 
m, CHCH2CH2CN). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 173.1 (C=O), 137.1+137.0 (2xCH), 126.6 
(CN), 120.6 (CN), 118.0+117.9 (2xCH2), 54.9 (C), 
52.9 (OCH3), 38.5 (CH2), 29.9 (CH2), 27.2 (CH), 15.4 
(CH2). 
ESMS: m/z (%):    255 [M+Na]
+ (100). 
HRMS (ES +ve):     C13H16N2NaO2 [M+Na]
+ 255.1109, found 255.1104. 
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4-Hydroxymethyl-4-vinyl-hex-5-enenitrile (341). 
 
 
 
 
 
To a solution of ester (331) (1.42 mmol, 0.25 g) in anhydrous THF (20 mL), under 
argon at −78 °C, was added LiAlH4 (1.0 M in THF, 2.84 mmol, 2.8 mL) drop-wise. 
After 6 h water (5 mL) was added, the reaction mixture was warmed to room 
temperature and partitioned between HCl (2 M, 10 mL) and ether (20 mL). The 
aqueous phase was extracted with ether (2 x 20 mL) and the combined organic 
phases were washed with brine (60 mL), dried (MgSO4), concentrated in vacuo to 
give alcohol (341) (1.19 mmol, 0.18 g, 84%) as a yellow oil. 
 
Novel  
IR (ATR / golden gate):  3444 (m), 3092 (w), 2930 (w), 2869 (w), 2245 (m), 
1716 (w), 1629 (w). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 5.74 (2H, dd, J=17.7, 10.9 Hz, 2 x CH=CH2), 
5.33 (2H, dd, J=10.9, 0.6 Hz, 2 x CH=CHH), 5.15 
(2H, dd, J=17.7, 0.6 Hz, 2 x CH=CHH), 3.53 (2H, s, 
CH2OH), 2.32 (2H, t, J=8.2 Hz, CH2CH2CN), 1.97 
(2H, t, J=8.2 Hz, CH2CH2CN), 1.65 (1H, b s, 
CH2OH). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 139.2 (2xCH), 120.3 (2xCH2), 117.4 (CN), 
67.1 (OCH2), 48.5 (C), 30.1 (CH2), 12.6 (CH2). 
CIMS: m/z (%):  169 [M+NH4]
+· (50), 152 [M+H]
+· (10), 134 [M-OH]
+· 
(50), 121 [M−CH2OH]
+· (70). 
 
 
 
O
CN
MeO O H
CN LiAlH4 (1.0 M, in THF), THF
-78 °C, 6 h, 84%
    331
C10H13NO2
 (179.22)
    341
C9H13NO
 (151.21)154 
 
3-Amino-6-hydroxymethyl-2-(2-hydroxymethyl-2-vinyl-but-3-enyl)-6-vinyl-oct-
7-enenitrile (342). 
 
 
 
 
 
 
To a solution of ester (331) (0.67 mmol, 0.12 g) in anhydrous THF (10 mL), under 
argon at −78°C, was added LiAlH4 (1.0 M in THF, 2.68 mmol, 2.7 mL) drop-wise. 
After 2 h the reaction mixture was allowed to warm to 0 °C. After 4 h water (20 mL) 
was added, and the reaction mixture warmed to room temperature and extracted with 
ether (3 x 20 mL). The combined organic phases were washed with brine (50 mL), 
dried (MgSO4), concentrated in vacuo and purified by column chromatography 
(silica, 5% MeOH in ethyl acetate) to give firstly RSM (331) (0.05 mmol, 8 mg, 7%) 
and then (342) (0.03 mmol, 10 mg, 5%, 1:1 mixture of stereoisomers) as a yellow 
oil. 
 
Novel  
IR (ATR / golden gate):  3357 (w), 3077 (w), 3002 (w), 2922 (w), 2858 (w), 
2234 (w), 1625 (w).   
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 5.89 - 5.70 (4H, m, 4 x CH=CH2), 5.36–5.06 
(8H, m, 4 x CH=CH2), 3.63 (2H, s, CH2OH), 3.58–
3.54 (2H, m, CH2OH), 2.81 (1H, m, CHCN or 
CHNH2), 2.62 (1H, m, CHCN or CHNH2), 2.11–1.61 
(6H, m, 2 x CH2, and 2 x OH), 1.60–1.22 (2H, m, 
CH2). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 141.1+141.0+140.9+140.8 (2x(2xCH)), 
140.2+140.0+139.9+139.8 (2x(2xCH)), 122.1+121.4 
(2xCN), 117.0+116.9+116.9+116.8 (2x(2xCH2)), 
116.2+116.1+116.1 (2x(2xCH2)), 66.9+66.8+66.7 
O H
CN
O H
NH2
OH
CN
LiAlH4 (1.0 M in THF), THF
-78 °C, 2 h then 0 °C, 4h, 5%
    331
C9H13NO
 (151.21)
     342
C18H28N2O2
  (304.44)155 
 
+66.2 (2x(2xCH2)), 55.1 (2xCH), 48.7+48.6 (2xC), 
48.5 (2xC), 35.4+34.8 (2xCH), 34.4 (2xCH2), 
31.5+31.3 (2xCH2), 30.4+28.6 (2xCH2). 
ESMS: m/z (%):    327 [M+Na]
+ (100), 305 [M+H]
+ (60). 
HRMS (ES +ve):     C18H29N2O2 [M+H]
+ 305.2229, found 305.2222. 
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O H
CN
O
Si CN Imidazole, TBDMSCl
DMF, RT, 20 h, 65%
    341
C9H13NO
 (151.21)
     343
C15H27NOSi
   (265.47)
4-(tert-Butyl-dimethyl-silanyloxymethyl)-4-vinyl-hex-5-enenitrile (343). 
 
 
 
 
To a solution of alcohol (341) (1.19 mmol, 0.18 g) and imidazole (2.38 mmol, 0.15 
g) in anhydrous DMF (5 mL) at room temperature under argon was added a solution 
of TBDMSCl (1.43 mmol, 0.22 g) in anhydrous DMF (1 mL). After 16 h further 
imidazole (2.38 mmol, 0.15 g) and TBDMSCl (1.43 mmol, 0.22 g) were added, 
followed after 4 h by HCl (2 M, 10 mL). The reaction mixture was extracted with 
ether (3 x 10 mL) and the combined organic phases were washed with brine (50 mL), 
dried (MgSO4), concentrated in vacuo and purified by column chromatography 
(silica, 5% diethyl ether in petroleum ether) to give the silyl ether (343) (0.77 mmol, 
0.21 g, 65%) as a colourless oil. 
 
Novel  
IR (ATR / golden gate):  3081 (w), 3952 (w), 2933 (w), 2892 (w), 2854 (w), 
1470 (w), 1459 (w).   
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 5.76 (2H, dd, J=17.8, 11.0 Hz, 2 x CH=CH2), 
5.23 (2H, dd, J=11.0, 1.0 Hz, 2 x CH=CHH), 5.06 
(2H, dd, J=17.8, 1.0 Hz, 2 x CH=CHH), 3.49 (2H, s, 
CH2OSi(CH3)2C(CH3)3), 2.34–2.25 (2H, m, 
CH2CH2CN), 1.93–2.03 (2H, m, CH2CH2CN), 0.90 
(9H, s, OSi(CH3)2C(CH3)3), 0.04 (6H, s, 
OSi(CH3)2C(CH3)3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 139.8 (2xCH), 120.6 (CN), 116.2 (2xCH2), 
68.3 (CH2), 48.0 (C), 30.3 (CH2), 26.0 (3xCH3), 18.4 
(C), 12.7 (CH2), −5.4 (2xCH3). 
ESMS: m/z (%):    288 [M+Na]
+ (100). 
HRMS (ES +ve):     C15H27NNaOSi [M+Na]
+ 288.1759, found 288.1754. 
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4-(tert-Butyl-dimethyl-silanyloxymethyl)-4-vinyl-hex-5-enylamine (344). 
 
 
 
 
 
To a solution of nitrile (343) (0.61 mmol, 0.16 g) in anhydrous THF (20 mL) at 0 °C 
under argon was added a solution of LiAlH4 (1.0 M in THF, 1.20 mmol, 1.2 mL) 
drop-wise. After 5 h water (10 mL) was added and the reaction mixture extracted 
with ether (3 x 10 mL). The combined organic phases were washed with brine (50 
mL), dried (MgSO4), concentrated in vacuo and purified by column chromatography 
(silica, 100% ethyl acetate then 1:9:90, NH4OH: MeOH: ethyl acetate) to give amine 
(344) as a colourless oil (0.44 mmol, 0.12 g, 72%). 
 
Novel  
IR (ATR / golden gate):  3081 (w), 2949 (m), 2930 (m), 2888 (m), 2850 (m), 
1637 (w), 1565 (w).   
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 5.80 (2H, dd, J=17.8, 10.9 Hz, 2 x CH=CH2), 
5.11 (2H, dd, J=10.9, 1.4 Hz, 2 x CH=CHH), 5.01 
(2H, dd, J=17.8, 1.4 Hz, 2 x CH=CHH), 3.51 (2H, s, 
OCH2), 2.67 (2H, t, J=7.0 Hz, CH2NH2), 1.60 (2H, b 
s, CH2NH2), 1.56–1.49 (2H, m, CHHCHHCH2NH2), 
1.45–1.35 (2H, m, CHHCHHCH2NH2), 0.88 (9H, s, 
(CH3)3), 0.02 (6H, s, Si(CH3)2). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 142.2 (2xCH), 114.4 (2xCH2), 68.2 (CH2), 48.1 
(CH2), 43.0 (CH2), 32.0 (CH2), 28.2 (C), 26.1 
(3xCH3), 18.5 (C), −5.3 (2xCH3). 
CIMS: m/z (%):    270 [M+H]
+· (100), 212 [(M−
tBu)+H]
+· (70), 138 (20), 
    89  (20),  73  (50).   
HRMS (ES +ve):     C15H32NOSi [M+H]
+ 270.2253, found 270.2248. 
 
O
Si CN
NH2 O
Si LiAlH4 (1.0 M in THF)
THF, 0 °C, 5 h, 72%
      343
C15H27NOSi
   (265.47)
     344
C15H31NOSi
  (269.51)158 
 
o-Iodoxybenzoic acid (IBX) (437). 
 
 
 
 
 
 
To a suspension of 2-iodobenzoic acid (436) (40.3 mmol, 10.00g) in H2SO4 (0.73 M, 
100 mL) was added potassium bromate (52.4 mmol, 8.75 g). The reaction mixture 
was heated to 75 °C for 4.5 h with reaction gasses scrubbed through a saturated 
solution of sodium thiosulfate. The reaction mixture was cooled to room temperature 
and stirred for 16 h. The resulting precipitate was collected by filtration, washing 
with water (200 mL) and ethanol (100 mL). The white solid product (437) was dried 
under vacuum to give the desired product (35.7 mmol, 9.99 g, 89%). Data consistent 
with the literature.
77 
 
IR (ATR / golden gate):   2896 (m), 1633 (s), 1564 (s). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 8.15 (1H, d, J=7.9 Hz, aromatic CH), 8.07–7.96 
(2H, m, 2 x aromatic CH), 7.84 (1H, app. t, J=7.2 Hz, 
aromatic CH). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 167.5 (C=O), 146.6 (C), 133.4 (CH), 133.0 
(CH), 131.4 (C), 130.1 (CH), 125.0 (CH). 
 
 
 
 
 
 
 
 
 
I
CO2H
O
I
O
O
O H
KBrO3, H2O, H2SO4
75 °C, 4.5 h, 89%
   436
C7H5IO2
(248.02)
  437
C7H5IO4
(280.02)159 
 
4-Formyl-4-vinyl-hex-5-enenitrile (347). 
 
O H
CN
O
CN
    341
C9H13NO
 (151.21)
    347
C9H11NO
 (149.19)
Dess-Martin Periodinane
CHCl3, RT, 3 h, 95%
 
To a solution of Dess-Martin periodinane (0.18 mmol, 77 mg) in CHCl3 (2 mL), at 
room temperature was added a solution of alcohol 341 (0.17 mmol, 25 mg) in CHCl3 
(0.5 mL). After 3 h the reaction mixture was concentrated in vacuo with silica (2 g) 
and purified by column chromatography (dry loaded, silica, 30% diethyl ether in 
petroleum ether) to give the aldehyde (347) as a yellow oil (0.16 mmol, 24 mg, 
95%).  
 
Novel  
IR (ATR / golden gate):   3085 (w), 3020 (w), 2941 (w), 2824 (w), 2722 (w), 
2245 (w), 1722 (s), 1633 (w). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 9.31 (1H, s, CHO), 5.77 (2H, dd, J=17.8, 10.8 
Hz, 2 x CH=CH2), 5.51 (2H, d, J=10.8 Hz, 2 x 
CH=CHH), 5.23 (2H, d, J=17.8 Hz, 2 x CH=CHH), 
2.39–2.27 (2H, m, CH2CH2CN), 2.16–2.06 (2H, m, 
CH2CH2CN). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 197.7 (CHO), 135.0 (2xCH), 120.7 (2xCH2), 
119.7 (CN), 59.3 (C), 29.6 (CH2), 12.8 (CH2). 
ESMS: m/z (%):    172 [M+Na]
+ (100). 
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4-[1,3]Dioxolan-2-yl-4-vinyl-hex-5-enenitrile (348). 
 
CN
O
O
O
CN
    348
C11H15NO2
 (193.25)
    347
C9H11NO
 (149.19)
Ethylene glycol, p-TSA (5 mol%)
Toluene, Dean-Stark, , 6 h, 98%
 
To a solution of aldehyde (347) (0.47 mmol, 70 mg) in toluene (2 mL) was added 
ethylene glycol (2.35 mmol, 0.13 mL) and p-TSA (0.03 mmol, 6 mg). The reaction 
mixture was heated to reflux under a Dean-Stark trap for 6 h then cooled to room 
temperature, diluted with ether (10 mL) and washed with sat. K2CO3 (20 mL). The 
organic phase was washed with brine (20 mL), dried (MgSO4) and concentrated in 
vacuo to give acetal 348 as a yellow oil (0.46 mmol, 89 mg, 98%). 
 
Novel  
IR (ATR / golden gate):   3088 (w), 2983 (w), 2949 (w), 2888 (m), 2245 (m), 
1735 (w), 1633 (w). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 5.84 (2H, dd, J=17.8, 11.0 Hz, 2 x CH=CH2), 
5.35 (2H, dd, J=11.0, 0.6 Hz, 2 x CH=CHH), 5.18 
(2H, dd, J=17.8, 0.6 Hz, 2 x CH=CHH), 4.73 (1H, s, 
CHCH2CH2O), 4.02–3.81 (4H, m, OCH2CH2O), 2.39–
2.29 (2H, m, CH2CH2CN), 2.09–2.00 (2H, m, 
CH2CH2CN). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 137.4 (2xCH), 120.5 (CN), 117.9 (2xCH2), 
107.6 (CH), 65.4 (2xCH2), 50.4 (C), 28.4 (CH2), 12.7 
(CH2). 
ESMS: m/z (%):    216 [M+Na]
+ (100). 
HRMS (ES +ve):     C11H15NNaO2 [M+Na]
+ 216.1000, found 216.0995. 
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4-[1,3]Dioxolan-2-yl-4-vinyl-hex-5-enylamine (349). 
 
O
O NH2
CN
O
O
    349
C11H19NO2
 (197.28)
    348
C11H15NO2
 (193.25)
LiAlH4 (1.0 M in THF), THF
60 °C, 4 h, 84%
 
To a solution of nitrile (348) (1.76 mmol, 0.34 g) in anhydrous THF (15 mL) at 0 °C 
under argon was added a solution of LiAlH4 (1.0 M in THF, 1.76 mmol, 1.76 mL) 
drop-wise. The reaction mixture was warmed to 60 °C then cooled to room 
temperature after 4 h. Water (15 mL) was added to the reaction mixture cautiously, 
followed by NaOH (2 M, 10 mL). The mixture was extracted with ether (5 x 20 mL), 
the combined organic phases were washed with brine (100 mL), dried (MgSO4), and 
concentrated in vacuo to give amine (349) (1.48 mmol, 0.29 g, 84%) as yellow oil. 
 
Novel  
IR (ATR / golden gate):   3361 (w), 3088 (w), 2949 (m), 2873 (m), 1667 (w), 
1637 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 5.89 (2H, dd, J=17.8, 11.0 Hz, 2 x CH=CH2), 
5.27 (2H, dd, J=11.0, 1.1 Hz, 2 x CH=CHH), 5.15 
(2H, dd, J=17.8, 1.1 Hz, 2 x CH=CHH), 4.81 (1H, s, 
CHOCH2CH2O), 3.99–3.82 (4H, m, OCH2CH2O), 
2.67 (2H, t, J=7.0 Hz, CH2CH2CH2NH2), 1.68–1.60 
(2H, m, CHHCHHCH2NH2), 1.50–1.38 (2H, m, 
CHHCHHCH2NH2). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 139.1 (2xCH), 116.5 (2xCH2), 108.1 (CH), 
65.5 (2xCH2), 50.6 (C), 43.2 (CH2), 30.7 (CH2), 28.5 
(CH2). 
ESMS: m/z (%):    198 [M+H]
+ (100). 
HRMS (ES +ve):     C11H20NO2 [M+H]
+ 198.1494, found 198.1489. 
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5,5-Divinyl-2,3,4,5-tetrahydropyridine (233). 
 
O
O NH2 N
    349
C11H19NO2
 (197.28)
   233
 C9H13N
(135.21)
1) 10% HCl, RT, 2 h
2) 10% NaOH, RT, 2h, 68%
 
To amine (349) (1.52 mmol, 0.30 g) was added 10% HCl (1.0 mL) and the mixture 
stirred at room temperature for 2 h. NaOH (10%) was added until the solution was 
pH 9 and after 2 h the reaction mixture was extracted with ether (4 x 10 mL). The 
combined organic phases were, dried (MgSO4) and concentrated in vacuo to give 
imine (233) as a yellow oil (1.04 mmol, 140 mg, 68%). 
 
Novel  
IR (ATR / golden gate):   3776 (w), 3077 (w), 3005 (w), 2930 (m), 2865 (m), 
1663 (m), 1633 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.53 (1H, b s, N=CH), 5.75 (2H, dd, J=17.6, 
10.5 Hz, 2 x CH=CH2), 5.21 (2H, d, J=10.5 Hz, 2 x 
CH=CHH), 5.08 (2H, d, J=17.6 Hz, 2 x CH=CHH), 
3.60–3.54 (2H, m, NCH2CH2CH2), 1.76–1.70 (2H, m, 
NCH2CHHCHH), 1.66–1.59 (2H, m, 
NCH2CHHCHH). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 164.3 (CH), 141.5 (2xCH), 115.9 (2xCH2), 
49.6 (CH2), 47.8 (C), 30.5 (CH2), 18.5 (CH2). 
ESMS: m/z (%):    136 [M+H]
+ (90). 
HRMS (ES +ve):     Compound too unstable for HRMS. 
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1′-Benzyl-8,8-divinyl-octahydrospiro[indolizine1,3′-indol-2′-one] (350). 
 
N
O
N
N
N
O
H
+
MgI2, THF, 125 °C
Microwave, 3 h, 4%
    287
C17H15NO
 (249.32)
  233
C9H13N
(135.21)
     350
C26H28N2O
  (384.53)
 
A solution of cyclopropane 287 (0.53 mmol, 0.13 g), imine 233 (0.48 mmol, 65 mg) 
and anhydrous MgI2 (0.24 mmol, 67 mg) in anhydrous THF (2 mL) was heated to 
125  °C under microwave irradiation for 3 h, cooled to room temperature, then 
partitioned between water (20 mL) and ethyl acetate (20 mL). The aqueous phase 
was extracted with ethyl acetate (4 x 20 mL), the combined organic phases were 
washed with brine (50 mL), dried (MgSO4), concentrated in vacuo and purified by 
column chromatography (silica, 20% diethyl ether in petroleum ether) to give firstly 
recovered staring material 287 (0.34 mmol, 84 mg, 64%) and then the desired 
product 350 as a colourless oil (0.002 mmol, 7 mg, 4%). 
 
Novel  
IR (ATR / golden gate):   3081 (w), 3054 (w), 3013 (w), 2933 (w), 2862 (w), 
2805 (w), 1703 (s), 1607 (m), 1486 (m), 1463 (m). 
1H NMR (400 MHz, CHLOROFORM-d)  
 ppm 7.43 (1H, d, J=7.4 Hz, aromatic CH), 7.38–7.25 
(5H, m, 5 x aromatic CH), 7.13 (1H, app. td, J=7.7, 1.1 
Hz, aromatic CH), 6.93 (1H, app. td, J=7.6, 0.9 Hz, 
aromatic CH), 6.74 (1H, d, J=7.8 Hz, aromatic CH), 
6.41 (1H, dd, J=17.8, 10.9 Hz, CH=CH2), 5.21 (1H, 
dd, J=17.8, 10.9 Hz, CH=CH2), 4.92 (1H, d, J=15.2 
Hz, NCHHPh), 4.91 (1H, dd, J=17.8, 1.3 Hz, 
CH=CHH), 4.79 (1H, d, J=15.3 Hz, NCHHPh), 4.77 
(1H, dd, J=10.9, 1.3 Hz, CH=CHH), 4.60 (1H, dd, 
J=10.9, 1.3 Hz, CH=CHH), 4.43 (1H, dd, J=17.8, 1.3 
Hz, CH=CHH), 3.42 (1H, app. td, J=8.8, 3.1 Hz, 164 
 
CCH2CHHN), 3.33 (1H, dd, J=10.8, 4.0 Hz, 
NCHHCH2CH2C), 2.59 (1H, s, NCH), 2.54 (1H, app. 
t, J=8.8 Hz, CCH2CHHN), 2.31 (1H, ddd, J=12.7, 8.8, 
3.1 Hz, CCHHCH2N), 2.18 (1H, td, J=11.7, 3.1 Hz, 
NCHHCH2CH2C), 1.99 (1H, dt, J=12.7, 8.8 Hz, 
CCHHCH2N), 1.83 (1H, ddd, J=12.7, 4.1, 4.0 Hz, 
NCH2CHHCH2C), 1.66–1.52 (2H, m, 
NCH2CHHCH2C and NCH2CH2CHHC), 1.45 (1H, m, 
NCH2CH2CHHC). 
13C NMR + DEPT (100 MHz, CHLOROFORM-d)  
 ppm 180.6 (C=O), 142.5 (C), 142.2 (CH), 141.5 
(CH), 136.2 (C), 133.1 (C), 128.8 (2xCH), 128.1 
(2xCH), 127.9 (CH), 127.8 (CH), 127.8 (CH), 121.5 
(CH), 114.9 (CH2), 112.6 (CH2), 108.5 (CH), 80.0 
(CH), 55.8 (C), 55.2 (CH2), 54.6 (CH2), 46.4 (C), 44.4 
(CH2), 38.3 (CH2), 37.1 (CH2), 21.8 (CH2). 
1H-
1H and 
1H-
13C correlations obtained to confirm above NMR assignments. 
ESMS: m/z (%):    385 [M+H]
+ (100), 407 [M+Na]
+ (10). 
HRMS (ES +ve):     C26H29N2O [M+H]
+ 385.2274, found 385.2275. 
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1-(2-Bromo-benzyl)-1H-indole-2,3-dione (351). 
N
O
O
Br
N
H
O
O
Br
Br
+
    293
C8H5NO2
(147.13)
   438
C7H6Br2
(249.93)
      351
C15H10BrNO2
   (316.16)
K2CO3, KI, MeCN
RT, 16 h, 98 %
 
To a solution of isatin (293) (13.59 mmol, 2.00 g) in acetonitrile (100 mL) at room 
temperature under argon, was added K2CO3 (27.19 mmol, 3.76 g) and KI (1.36 
mmol, 0.23 g). After 30 min 2-bromobenzyl bromide (438) (13.59 mmol, 3.40 g) in 
acetonitrile (30 mL) was added. After a further 16 h the reaction mixture was 
partitioned between ethyl acetate (100 mL) and water (100 mL). The aqueous phase 
was separated and extracted with ethyl acetate (3 x 50 mL) and the combined organic 
phases were washed with brine (150 mL), dried (MgSO4) and concentrated in vacuo 
to give 351 as an orange solid (13.27 mmol, 4.19 g, 98%). 
 
Novel  
Mpt: °C      180-182 °C (EtOH). 
IR (ATR / golden gate):   3085 (w), 3054 (w), 3026 (w), 1732 (s), 1605 (s). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.68–7.60 (2H, m, 2 x aromatic CH), 7.51 (1H, 
app. td, J=7.8, 1.3 Hz, aromatic CH), 7.31–7.09 (4H, 
m, 4 x aromatic CH), 6.75 (1H, d, J=7.8 Hz, aromatic 
CH), 5.06 (2H, s, NCH2Ar). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 183.1 (C=O), 168.2 (C=O), 158.6 (C), 150.7 
(C), 138.7 (CH), 133.4 (CH), 129.8 (CH), 128.2 (CH), 
128.2 (CH), 125.7 (CH), 124.3 (CH), 123.0 (C), 117.9 
(C), 111.3 (CH), 44.2 (CH2). 
ESMS: m/z (%):    338:340 {1:1} [M+Na]
+ Br
79:Br
81 (100). 
HRMS (ES +ve):     C15H10BrNNaO2 [M+Na]
+ 337.9793, found 337.9787. 
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1-(2-Bromo-benzyl)-1,3-dihydro-indol-2-one (352). 
N
O
O
Br
N
O
Br
       351
C15H10BrNO2
    (316.16)
NH2NH2, 
24 h, 88%
     352
C15H12BrNO
  (302.17)
 
To hydrazine mono-hydrate (20 mL) was added 351 (13.25 mmol, 4.19 g). The 
reaction mixture was stirred under argon at 125 °C for 24 h, the cooled to room 
temperature, poured onto ice water (100 mL) and extracted with ethyl acetate (4 x 
100 mL). The combined organic phases were washed with brine (200 mL), dried 
(MgSO4) and concentrated in vacuo to give 352 as a light brown solid (11.68 mmol, 
3.53 g, 88%). 
 
Novel   
Mpt:  °C    102-104  °C (EtOH). 
IR (ATR / golden gate):   3062  (w),  3036  (w), 2949 (w), 2915 (w), 1703 (s), 
1612 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.60 (1H, dd, J=7.7, 1.1 Hz, aromatic CH), 7.29 
(1H, d, J=7.3 Hz, aromatic CH), 7.24–7.01 (5H, m, 5 x 
aromatic CH), 6.66 (1H, d, J=7.7 Hz, aromatic CH), 
5.03 (2H, s, COCH2), 3.69 (2H, s, NCH2Ar). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 175.4 (C=O), 144.2 (C), 134.6 (C), 133.1 (CH), 
129.2 (CH), 128.1 (CH), 127.9 (CH), 127.8 (CH), 
124.6 (CH), 124.5 (C), 122.9 (C), 122.8 (CH), 109.3 
(CH), 43.9 (CH2), 36.0 (CH2). 
ESMS: m/z (%):    324:326 {1:1} [M+Na]
+ Br
79:Br
81 (100). 
HRMS (ES +ve):     C15H12BrNNaO [M+Na]
+ 323.9999, found 323.9994. 
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1′-(2-Bromo-benzyl)-spiro[cyclopropane-1,3′-indol-2′-one] (353). 
 
N
O
Br
N
O
Br
     352
C15H12BrNO
  (302.17)
      353
C17H14BrNO
   (328.21)
NaH, DMF, 1,2-dibromoethane
RT, 72 h, 62%
 
To a solution of 352 (11.68 mmol, 3.53 g) in anhydrous DMF (50 mL) at 0 °C under 
argon, was added NaH (60% in mineral oil, 25.70 mmol, 1.03 g). After 1 h 1,2-
dibromoethane (46.72 mmol, 4.0 mL) was added and the reaction mixture allowed to 
warm to room temperature and stirred for 72 h. Water (100 mL) and ethyl acetate 
(100 mL) were added and the aqueous separated and washed with ethyl acetate (100 
mL). The combined organic phases were washed with water (4 x 100 mL), brine 
(200 mL), dried (MgSO4), concentrated in vacuo and purified by column 
chromatography (silica, 10% ethyl acetate in hexanes) to give the cyclopropane 353 
as a red solid (7.27 mmol, 2.39 g, 62%) and recovered starting material (0.35 mmol, 
0.11 g, 3%). 
 
Novel  
Mpt:  °C    115-117  °C (EtOH). 
IR (ATR / golden gate):   3058 (w), 2990 (w), 2930 (w), 1708 (s), 1614 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.61 (1H, dd, J=7.8, 1.2 Hz, aromatic CH), 
7.25–7.00 (5H, m, 5 x aromatic CH), 6.90 (1H, d, 
J=7.3 Hz, aromatic CH), 6.75 (1H, d, J=7.8 Hz, 
aromatic CH), 5.11 (2H, s, NCH2Ar), 1.86 (2H, dd, 
J=7.8, 4.0 Hz, CHHCHH cyclopropane), 1.62 (2H, dd, 
J=7.8, 4.0 Hz, CHHCHH cyclopropane). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 177.4 (C=O), 142.5 (C), 135.0 (C), 133.0 (CH), 
130.8 (C), 129.1 (CH), 127.9 (2xCH), 127.0 (CH), 168 
 
122.8 (C), 122.4 (CH), 118.5 (CH), 109.2 (CH), 44.3 
(CH2), 27.3 (C), 19.7 (2xCH2). 
ESMS: m/z (%):    350:352 {1:1} [M+Na]
+ Br
79:Br
81 (100). 
HRMS (ES +ve):     C17H14BrNNaO [M+Na]
+ 350.0156 found 350.0151. 
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1′-(2-Bromo-benzyl)-8,8-divinyl-octahydrospiro[indolizine1,3′-indol-2′-one] 
(354). 
N
O
Br
N
N
N
O
Br
H
+
MgI2, THF, 125 °C
Microwave, 3 h, 44%
     353
C17H14BrNO
  (328.21)
   233
C9H13N
(135.21)
      354
C26H27BrN2O
   (463.42)
 
To a solution of cyclopropane 353 (1.14 mmol, 0.37 g) in anhydrous THF (5 mL) 
was added imine 233 (1.04 mmol, 0.14 g) and anhydrous MgI2 (1.14 mmol, 0.32 g). 
The reaction mixture was split into 2 portions and each was heated sequentially to 
125  °C under microwave irradiation for 3 h then cooled to room temperature, 
combined and partitioned between water (40 mL) and ethyl acetate (40 mL). The 
aqueous phase was extracted with ethyl acetate (4 x 30 mL) and the combined 
organic phases were washed with brine (100 mL), dried (MgSO4), concentrated in 
vacuo and purified by column chromatography (silica, 10→40% diethyl ether in 
petroleum ether) to give firstly recovered staring material 353 (0.39 mmol, 0.13 g, 
34%) and then the desired product 354 as a colourless oil (0.46 mmol, 0.21 g, 44%). 
 
Novel  
IR (ATR / golden gate):   3085 (w), 3058 (w), 3009 (w), 2930 (w), 2865 (w), 
2801 (w), 1705 (m), 1610 (m), 1486 (m), 1467 (m). 
1H NMR (400 MHz, CHLOROFORM-d)  
 ppm 7.60 (1H, dd, J=7.7, 1.1 Hz, aromatic CH), 7.46 
(1H, dd, J=7.4, 0.7 Hz, aromatic CH), 7.20 (1H, app. 
td, J=7.4, 1.1 Hz, aromatic CH), 7.16–7.08 (3H, m, 3 x 
aromatic CH), 6.95 (1H, app. td, J=7.7, 0.7 Hz, 
aromatic CH), 6.64 (1H, d, J=7.8 Hz, aromatic CH), 
6.43 (1H, dd, J=17.7, 10.9 Hz, CH=CH2), 5.37 (1H, 
dd,  J=17.7, 10.9 Hz, CH=CH2), 5.05–4.91 (4H, m, 
CH=CH2 and NCH2Ar), 4.66 (1H, dd, J=10.9, 1.5 Hz, 
CH=CHH), 4.52 (1H, dd, J=17.9, 1.5 Hz, CH=CHH), 
3.43 (1H, td, J=8.5, 3.1 Hz, CCH2CHHN), 3.34 (1H, 170 
 
dd,  J=10.9, 3.8 Hz, NCHHCH2CH2C), 2.64 (1H, s, 
NCH), 2.58 (1H, app. q, J=9.0 Hz, CCH2CHHN), 2.33 
(1H, ddd, J=12.7, 9.0, 3.1 Hz, CCHHCH2N), 2.20 (1H, 
td,  J=11.7, 3.1 Hz. NCHHCH2CH2C), 2.03 (1H, dt, 
J=12.7, 8.5 Hz, CCHHCH2N), 1.85 (1H, dt, J=12.6, 
3.8 Hz, NCH2CHHCH2C), 1.68–1.42 (3H, m, 
NCH2CHHCH2C and NCH2CH2CH2C). 
13C NMR + DEPT (100 MHz, CHLOROFORM-d)  
 ppm 180.9 (C=O), 142.2 (C), 142.2 (CH), 141.7 
(CH), 135.0 (C), 133.1 (CH), 132.9 (C), 129.1 (CH), 
128.6 (CH), 128.0 (CH), 127.9 (CH), 127.8 (CH), 
123.0 (C), 121.8 (CH), 115.1 (CH2), 112.8 (CH2), 
108.8 (CH), 79.9 (CH), 56.0 (C), 55.2 (CH2), 54.5 
(CH2), 46.5 (C), 44.3 (CH2), 38.5 (CH2), 37.3 (CH2), 
21.9 (CH2). 
1H-
1H and 
1H-
13C correlations obtained to confirm above NMR assignments. 
ESMS: m/z (%):    463:465 {1:1} [M+H]
+ Br
79:Br
81 (100). 
HRMS (ES +ve):     C26H28BrN2O [M+H]
+ 463.1378, found 463.1380. 
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1′-(2-Bromo-benzyl)-2′-hyrdoxy-8,8-divinyl-octahydrospiro[indolizine1,3′-
indol-2′-one]  (355). 
 
 
 
 
 
 
 
To a solution of oxindole 354 (0.32 mmol, 0.15 g) in anhydrous THF (20 mL) at 0 
°C under nitrogen was added a solution of LiAlH4 (1.0 M in THF, 0.36 mmol, 0.36 
mL) drop-wise. After 5 h water (30 mL) was added cautiously. The reaction mixture 
was extracted with ether (3 x 30 mL) and the combined organic phases were washed 
with brine (100 mL), dried (MgSO4), concentrated in vacuo and purified by column 
chromatography (silica, 1→20% MeOH in CHCl3) to give 355 (0.14 mmol, 67 mg, 
45%) as a brown oil.  
 
Novel  
IR (ATR / golden gate):   3293 (b w), 3062 (w), 3005 (w), 2930 (w), 2854 (w), 
1712 (m), 1662 (m), 1610 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.68–7.63 (1H+1H, m, 2 x aromatic CH), 7.61 
(1H+1H, m, 2 x aromatic CH), 7.24–7.09 (4H+4H, m, 
2 x 4 x aromatic CH), 7.00 (1H+1H, m, 2 x aromatic 
CH), 6.59–6.53 (1H+1H, m, 2 x aromatic CH), 6.06 
(1H, dd, J=17.8, 10.9 Hz, CH=CH2), 5.96–5.82 
(1H+2H, m, 3 x CH=CH2), 5.357 (2H, s, NCH2Ar), 
5.353 (2H, s, NCH2Ar) 5.26–4.97 (4H+4H, m, 2 x 
CH=CH2), 4.32 (1H, s, NCHOH), 3.87 (1H, s, 
NCHOH), 3.46 (1H+1H, s, 2 x NCH), 3.10–2.90 
(4H+4H, m, 2 x 2 x  CH2), 2.88–2.73 (1H+1H, m, 2 x 
CHH), 2.71–2.60 (1H+1H, m, 2 x CHH), 1.96–1.86 
N
N
O
Br
N
N
OH
Br
H
      354
C26H27BrN2O
   (463.42)
      355
C26H29BrN2O
   (465.44)
LiAlH4 (1.0 M) in THF
0 °C, 5 h, 45%, d.r. 1:1172 
 
(1H+1H, m, 2 x CHH), 1.85–1.70 (1H+1H, m, 2 x 
CHH), 1.64–1.48 (2H+2H, m, 2 x CH2). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 144.1+143.4 (CH), 142.6+142.4 (CH), 137.2+ 
136.8 (C), 132.9 (CH), 129.1 (CH), 128.5 (C), 
128.3+128.0 (CH), 126.3+126.1 (CH), 122.3 (C), 
122.0   (CH), 119.4 (CH), 119.3 (CH), 115.1+114.8 
(CH2), 114.6+113.1 (CH2), 109.8+109.7 (CH), 
98.3+87.3 (CH), 60.6 (CH), 55.9+55.2 (CH2), 
53.6+51.1 (C), 50.2   (CH2), 48.7+48.4 (C), 45.2 
(CH2), 28.3+27.5 (CH2), 24.1+23.8 (CH2), 21.5 (CH2). 
N.B. 1 x aromatic (C) not observed. 
1H-
1H and 
1H-
13C correlations obtained to confirm above NMR assignments. 
ESMS: m/z (%):    369 [M-Br-OH]
+ (100), 447:449 {1:1} [M-OH]
+  
    B r
79:Br
81 (50). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 173 
 
1-Benzyl-3-[2-(3,3-divinyl-piperidin-1-yl)-ethyl]-1H-indole (357). 
 
 
 
 
 
 
 
 
To a solution of 355 (0.05 mmol, 23 mg) in anhydrous THF (10 mL) at 0 °C under 
argon, was added a solution of LiAlH4 (1.0 M in THF, 0.15 mmol, 0.15 mL) drop-
wise. The reaction mixture was allowed to warm to room temperature and after 4.5 h 
was cooled to 0 °C and water (20 mL) was added cautiously. The aqueous phase was 
extracted with ether (4 x 20 mL) then the combined organic phases were washed 
with brine (100 mL), dried (MgSO4), concentrated in vacuo and purified by column 
chromatography (silica, 30% diethyl ether in petroleum ether) to give indole 357 
(0.02 mmol, 7 mg, 38%) as a pale brown oil.  
 
Novel  
IR (ATR / golden gate):   3085 (w), 3051 (w), 3032 (w), 2926 (w), 2862 (w), 
2801 (w), 1716 (w), 1629 (w), 1618 (w), 1466 (w). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.63 (1H, d, J=7.7 Hz, aromatic CH), 7.33–7.23 
(4H, m, 4 x aromatic CH), 7.17 (1H, app. td, J=7.5, 1.0 
Hz, aromatic CH), 7.14–7.08 (3H, m, 3 x aromatic 
CH), 6.99 (1H, s, aromatic CH), 5.85 (2H, dd, J=17.5, 
10.9 Hz, 2 x CH=CH2), 5.28 (2H, s, NCH2Ph), 5.16–
5.03 (4H, m, 2 x CH=CH2), 3.03–2.91 (2H, m, NCH2), 
2.73–2.63 (2H, m, NCH2), 2.48 (4H, b s, 2 x NCH2 
and CH2), 1.79–1.54 (4H, m, 2 x CH2). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 144.4 (CH), 138.0 (C), 136.8 (C), 128.9 
(2xCH), 128.5 (C), 127.7 (CH), 127.0 (2xCH), 126.0 
N
N
OH
Br
N
N
      355
C26H29BrN2O
   (465.44)
LiAlH4 (1.0 M) in THF
RT, 4.5 h, 45%
   357
C26H30N2
(370.54)174 
 
(CH),  121.8  (CH), 119.3 (CH), 119.0 (CH), 113.6 
(CH2), 109.8 (CH), 62.6 (CH2), 60.0 (CH2), 54.9 
(CH2), 50.1 (CH2), 43.6 (C), 33.8 (CH2), 22.8 (CH2), 
22.5 (CH2).  
    NB.  1  x  aromatic  (C) not observed. 
1H-
1H and 
1H-
13C correlations obtained to confirm above NMR assignments. 
ESMS: m/z (%):    371 [M+H]
+ (100). 
HRMS (ES +ve):     C26H31N2 [M+H]
+ 371.2482, found 371.2477. 
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Synthetic Procedures–Chapter 4 
1-(2-Iodo-4,5-dimethoxy-benzyl)-1H-indole-2,3-dione (371). 
 
 
 
 
 
A solution of isatin (293) (1.69 mmol, 0.25 g) and potassium carbonate (2.45 mmol, 
0.34 g) in anhydrous DMF (10 mL) was stirred at 50 °C for 1 h under nitrogen. 
Potassium iodide (0.34 mmol, 56 mg) and a solution of benzyl chloride (370) (1.86 
mmol, 0.58 g) in DMF (5 mL) were sequentially added. After 6 h the reaction 
mixture was cooled to room temperature and HCl (1M, 50 mL) added. The aqueous 
phase was extracted with ethyl acetate (2 x 40 mL) then the combined organic 
phasess were washed with brine (100 mL), dried (MgSO4) and concentrated in vacuo 
to give the title product (371) (1.66 mmol, 0.70 g, 98%) as an orange solid. Data 
consistent with the literature.
78 
 
IR (ATR / golden gate):  3077 (w), 3003 (w), 2950 (w), 2909 (w), 2835 (w), 
1733 (s), 1611 (s), 1503 (s), 1466 (s).    
1H NMR (300 MHz, CHLOROFORM-d)  
  ppm 7.64 (1H, dd, J=7.5, 0.8 Hz, aromatic CH), 7.52 
    (1H,  app.  td,  J=7.8, 1.5 Hz, aromatic CH), 7.30 (1H, s, 
    a r o m a t i c   C H), 7.12 (1H, app. td, J=7.5, 0.8 Hz,  
    a r o m a t i c   C H), 6.81 (1H, d, J=7.8 Hz, aromatic CH), 
    6.70  (1H,  s,  aromatic  CH), 4.96 (2H, s, NCH2Ar), 3.87 
    ( 3 H ,   s ,     O C H3), 3.72 (3H, s, OCH3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 183.5 (C=O), 158.5 (C=O), 150.5 (C), 150.1 
(C), 149.4 (C), 138.5 (CH), 128.7 (C), 125.4 (CH), 
124.1 (CH), 121.7 (CH), 117.7 (C), 111.8 (CH), 110.6 
(CH), 86.2 (CI), 56.2 (OCH3), 56.0 (OCH3), 48.9 
(CH2). 
ESMS: m/z (%):    446 [M+Na]
+ (50), 870 [M2+Na]
+ (100). 
N
H
O
O
Cl
I
OMe
OMe
I
N
O
O
OMe
OMe +
   293
C8H5NO2
(147.13)
    370
C9H10ClIO2
 (312.54)
     371
C17H14INO4
  (423.21)
K2CO3, KI, DMF
50 °C, 6 h, 98%176 
 
I
N
O
O
OMe
OMe I
N
O
OMe
OMe
     371
C17H14INO4
  (423.21)
    372
C17H16INO3
 (409.23)
H2NNH2.H2O
, 5 h, 98%
1-(2-Iodo-4,5-dimethoxy-benzyl)-1,3-dihydro-indol-2-one (372). 
 
 
 
 
 
To hydrazine mono-hydrate (10 mL) was added 371 (1.66 mmol, 0.70 g). The 
reaction mixture was heated at reflux under nitrogen for 5 h then cooled to room 
temperature, and poured onto ice water (50 mL) and extracted with ethyl acetate (4 x 
15 mL). The combined organic phases were washed with brine (100 mL), dried 
(MgSO4), concentrated in vacuo and purified by column chromatography (silica, 
20% ethyl acetate in hexanes) to give 372 (1.64 mmol, 0.67 g, 98%) as a white solid. 
 
Novel 
Mpt:     189–190  °C (EtOAc in hexanes). 
IR (ATR / golden gate):   2995  (w),  2962  (w), 2925 (w), 2835 (w), 1683 (s), 
1614 (m), 1599 (m), 1505 (s).  
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.30–7.23 (2H, m, 2 x aromatic CH), 7.18 (1H, 
app. t, J=7.7 Hz, aromatic CH), 7.03 (1H, app. t, J=7.6 
Hz, aromatic CH), 6.72 (1H, d, J=7.7 Hz, aromatic 
CH), 6.62 (1H, s, aromatic CH), 4.91 (2H, s, 
NCH2Ar),    3.89 (2H, s, NCOCH2), 3.68 (3H, s, 
OCH3), 3.67 (3H, s, OCH3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
  ppm 175.3 (C=O), 149.8 (C), 149.1 (C), 144.0 (C), 
    130.0  (C), 128.0 (CH), 124.4 (CH), 124.2 (C), 122.6 
    ( CH), 121.6 (CH), 110.6 (CH), 109.7 (CH), 86.0 (CI), 
    56.1  (OCH3), 55.9 (OCH3), 48.5 (CH2), 35.8 (CH2). 
ESMS: m/z (%):    303 [(M−I)+Na]
+ (60), 432 [M+Na]
+ (70). 
HRMS (ES +ve):     C17H16INNaO3 [M+Na]
+ 432.0067, found 432.0070. 
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1-(2-Iodo-benzyl)-1H-indole-2,3-dione (375). 
 
 
 
 
 
 
To a solution of isatin (293) (1.36 mmol, 0.20 g) in anhydrous DMF (20 mL) under 
nitrogen at room temperature was added NaH (60% dispersion in mineral oil, 11.50 
mmol, 60 mg). After 30 min 2-iodobenzyl bromide (374) (1.50 mmol, 0.45 g) was 
added followed after 1 h by water (60 mL). The reaction mixture was extracted with 
ethyl acetate (2 x 40 mL). The combined organic phases were washed with water (3 
x 50 mL) and brine (100 mL), dried (MgSO4), and concentrated in vacuo to give the 
title product 375 (1.30 mmol, 0.48 g, 97%) as an orange solid.  
Novel  
Mpt:     155–158  °C (EtOAc in hexanes). 
IR (ATR / golden gate):   2954 (w), 2921 (w), 2852 (w), 1733 (s), 1605 (s), 1460 
(s). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.91 (1H, dd, J=8.0, 1.1 Hz, aromatic CH), 7.67 
(1H, ddd, J=7.6, 1.4, 0.6 Hz, aromatic CH), 7.51 (1H, 
app. td, J=7.7, 1.4 Hz, aromatic CH), 7.30 (1H, app. 
td, J=7.7, 1.1 Hz, aromatic CH), 7.17–7.09 (2H, m, 2 x 
aromatic CH), 7.02 (1H, app. td, J=7.6, 1.7 Hz, 
aromatic CH), 6.69 (1H, d, J=8.0 Hz, aromatic CH), 
4.99 (2H, s, NCH2Ar). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
  ppm 174.8 (C=O), 158.5 (C=O), 150.6 (C), 140.1 
    ( CH), 138.7 (CH), 136.2 (C), 129.9 (CH), 129.1(CH), 
    127.3  (CH), 125.7 (CH), 124.3 (CH), 118.0 (C), 111.5 
    ( CH), 97.8 (CI), 49.4 (CH2). 
ESMS: m/z (%):    386 [M+Na]
+ (100). 
HRMS (ES +ve):     C15H10INNaO2 [M+Na]
+ 385.9648, found 385.9649. 
N
H
O
O
Br
I
I
N
O
O
+
   293
C8H5NO2
(147.13)
   374
 C7H6BrI
(296.93)
     375
C15H10INO2
  (363.16)
NaH, DMF
1 h, RT, 97%178 
 
I
N
O
O
I
N
O
     375
C15H10INO2
  (363.16)
    376
C15H12INO
 (349.17)
H2NNH2.H2O
, 16 h, 68%
1-(2-Iodo-benzyl)-1,3-dihydro-indol-2-one (376). 
 
 
 
 
 
To hydrazine mono-hydrate (10 mL) was added 375 (1.52 mmol, 0.55 g). The 
reaction mixture was heated at reflux under nitrogen for 16h then cooled to room 
temperature, poured onto ice water (50 mL) and extracted with ethyl acetate (3 x 50 
mL). The combined organic phases were washed with brine (100 mL), dried 
(MgSO4), concentrated in vacuo and purified by column chromatography (silica, 
30% ethyl acetate in hexanes) to give 376 (1.04 mmol, 0.36 g, 68%) as a brown 
solid. 
 
Novel  
Mpt:     99–102  °C (EtOAc in hexanes). 
IR (ATR / golden gate):   3056 (w), 3019 (w), 2978 (w), 2958 (w), 2942 (w), 
2917 (w), 1687 (s), 1612 (s), 1495 (m), 1465 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
  ppm 7.87 (1H, d, J=8.1 Hz, aromatic CH), 7.22 (3H, 
    m,  3  x  aromatic  CH), 6.99 (3H, m, 3 x aromatic CH), 
    6.60  (1H,  d,  J=7.7 Hz, aromatic CH), 4.92 (2H, s,  
    N C H2Ar), 3.68 (2H, s, NCOCH2). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
  ppm 175.2 (C=O), 144.0 (C), 139.6 (CH), 137.2 (C), 
    129.2  (CH), 128.6 (CH), 128.0 (CH), 127.0 (CH),  
    124.5  (CH), 124.3 (C), 122.7 (CH), 109.3 (CH), 97.7 
    ( CI), 48.9 (CH2), 35.9 (CH2). 
ESMS: m/z (%):    372 [M+Na]
+ (100), 721 [M2+Na]
+ (80). 
HRMS (ES +ve):     C15H12INNaO [M+Na]
+ 371.9856, found 371.9855. 
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3,3-Di-but-3-enyl-1-(2-iodo-benzyl)-1,3-dihydro-indol-2-one (377). 
 
 
 
 
 
 
 
To a solution of oxindole (376) (2.29 mmol, 0.80 g) in anhydrous DMF (50 mL) at 
room temperature under nitrogen was added sodium hydride (60% in mineral oil, 
5.73 mmol, 0.23 g). After 30 min a solution of 4-bromo-1-butene (5.73 mmol, 0.58 
mL) in anhydrous DMF (3 mL) was added followed after 4 h with water (50 mL). 
The reaction mixture was extracted with ethyl acetate (2 x 40 mL) and then the 
combined organic phases were washed with water (4 x 30 mL), brine (50 mL), dried 
(MgSO4), concentrated in vacuo and purified by column chromatography (silica, 2% 
ethyl acetate in hexanes) to give the desired bis-alkylated material (377) (1.05 mmol, 
0.48 g, 46%) as a white solid.  
 
Novel  
Mpt:     93–96  °C (EtOH). 
IR (ATR / golden gate):   3060 (w), 3036 (w), 2970 (w), 2913 (w), 2840 (w), 
1705 (s), 1638 (w), 1611 (m), 1487 (m), 1465 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.88 (1H, dd, J=8.2, 1.3 Hz, aromatic CH), 
7.27–7.13 (4H, m, 4 x aromatic CH), 7.09 (1H, app. td, 
J=7.6, 1.0 Hz, aromatic CH), 6.97 (1H, d, J=7.4 Hz, 
aromatic CH), 6.62 (1H, d, J=7.6 Hz, aromatic CH), 
5.75–5.62 (2H, m, 2 x CH=CH2), 4.94–4.84 (6H, m, 2 
x CH=CH2 and NCH2Ar), 2.16–2.02 (2H, m, 2 x 
CHH), 1.97–1.81 (4H, m, 4 x CHH), 1.78–1.63 (2H, 
m, 2 x CHH). 
 
 
I
N
O
I
N
O
    376
C15H12INO
 (349.17)
4-bromo-1-butene (2.5 equiv.)
            RT, 4 h, 46%
NaH (2.5 equiv.), DMF
    377
C23H24INO
 (457.36)180 
 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 179.8 (C=O), 143.0 (C), 139.6 (CH), 137.6 
(2xCH), 137.4 (C), 131.6 (C), 129.1 (CH), 128.5 
(CH), 127.9 (CH), 127.0 (CH), 122.9 (CH), 122.8 
(CH), 114.8 (2xCH2), 109.2 (CH), 97.8 (CI), 52.6 (C), 
49.1 (CH2), 37.4 (2xCH2), 28.7 (2xCH2). 
ESMS: m/z (%):    458 [M+H]
+ (100), 480 [M+Na]
+ (40). 
HRMS (ES +ve):     C23H24INNaO [M+Na]
+ 480.0795, found 480.0797. 
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1-(2-Bromo-benzyl)-3,3-di-but-3-enyl-1,3-dihydro-indol-2-one (378). 
 
 
 
 
 
 
 
To a solution of oxindole (352) (1.99 mmol, 0.60 g) in anhydrous DMF (50 mL) at 
room temperature under nitrogen was added sodium hydride (60% in mineral oil, 
5.96 mmol, 0.24 g). After 30 min a solution of 4-bromo-1-butene (5.96 mmol, 0.61 
mL) in anhydrous DMF (3 mL) was added followed after 4 h by water (100 mL). 
The reaction mixture extracted with ethyl acetate (2 x 50 mL), then the combined 
organic phases were washed with water (4 x 50 mL), brine (100 mL), dried 
(MgSO4), concentrated in vacuo and purified by column chromatography (silica, 2% 
ethyl acetate in hexanes) to give desired bis-alkylated material (378) (0.76 mmol, 
0.31 g, 38%) as a pink solid.  
 
Novel  
Mpt:     115–116°C (EtOH). 
IR (ATR / golden gate):   3068 (w), 3007 (w), 2978 (w), 2933 (w), 2905 (w), 
2835 (w), 1705 (s), 1638 (w), 1613 (m), 1487 (m), 
1464 (m), 1444 (m). 
1H NMR (400 MHz, CHLOROFORM-d)  
 ppm 7.60 (1H, dd, J=7.9, 1.3 Hz, aromatic CH), 
7.23–7.02 (6H, m, 6 x aromatic CH), 6.68 (1H, d, 
J=7.7 Hz, aromatic CH), 5.75–5.61 (2H, m, 2 x 
CH=CH2), 5.01 (2H, s, NCH2Ar), 4.93–4.84 (4H, m, 2 
x CH=CH2), 2.14–2.03 (2H, m, 2 x CHH), 1.97–1.79 
(4H, m, 4 x CHH), 1.77–1.63 (2H, m, 2 x CHH). 
13C NMR + DEPT (100 MHz, CHLOROFORM-d)  
  ppm 180.0 (C=O), 143.2 (C), 137.9 (2xCH), 135.0 
    ( C), 133.2 (CH), 131.9 (C), 129.2 (CH), 128.2 (CH), 
Br
N
O
Br
N
O
     352
C15H12BrNO
  (302.17)
4-bromo-1-butene (3 equiv.)
           RT, 4 h, 38%
NaH (3 equiv.), DMF
     378
C23H24BrNO
  (410.36)182 
 
    128.0  (CH), 127.9 (CH), 123.1 (CH), 123.0 (C), 123.0 
    ( CH), 115.0 (2xCH2), 109.3 (CH), 52.8 (C), 44.1  
    ( CH2), 37.6 (2xCH2), 28.9 (2xCH2). 
CIMS: m/z (%):    410:412 {1:1} [M+H]
+· Br
79:Br
81 (100), 355:357  
    [ ( M −CH2CH2CHCH2)+H]
+· Br
79:Br
81 (20), 332  
    [ ( M −Br)+H]
+· (30), 316 (40), 277 (10), 234 (20), 171 
    (20),  91  (20). 
HRMS (ES +ve):     C23H24BrNNaO [M+Na]
+ 432.0933, found 432.0932. 
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1-Benzyl-3,3-di-but-3-enyl-2,3-dihydro-1H-indole (379). 
 
 
 
 
 
 
 
 
To a solution of LiAlH4 (1.0 M solution in THF, 3.13 mmol, 3.13 mL) in anhydrous 
THF (25 mL) at 0 ºC under nitrogen was added a solution of oxindole (377) (1.04 
mmol, 0.48 g) in anhydrous THF (20 mL) drop-wise. The reaction was heated at 
reflux for 2 h then cooled to 0 ºC and water (50 mL) added slowly. The mixture was 
extracted with ethyl acetate (3 x 30 mL), then the combined organic phases were 
washed with brine (50 mL), dried (MgSO4), concentrated in vacuo and purified by 
column chromatography (silica, 1% ethyl acetate in hexanes) to give indoline (379) 
(0.83 mmol, 0.26 g, 80%) as a yellow oil.  
 
Novel  
IR (ATR / golden gate):   3072 (w), 3032 (w), 2921 (m), 2848 (m), 1638 (m), 
1603 (m), 1489 (m), 1453 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.35–7.22 (5H, m, 5 x aromatic CH), 7.06 (1H, 
ddd, J=7.9, 7.6, 1.0 Hz, aromatic CH), 6.97 (1H, d, 
J=7.9 Hz, aromatic CH), 6.67 (1H, app. td, J=7.6, 1.0 
Hz, aromatic CH), 6.48 (1H, d, J=7.6 Hz, aromatic 
CH), 5.83–5.70 (2H, m, 2 x CH=CH2), 4.96 (2 H, dd, 
J=17.3, 1.7 Hz, 2 x CH=CHH), 4.90 (2H, d, J=10.4 
Hz, 2 x CH=CHH), 4.26 (2H, s, NCH2Ar), 3.16 (2H, s, 
NCH2), 2.00-2.10 (2H, m, 2 x CHH), 1.84-1.91 (2H, 
m, 2 x CHH), 1.77 (2H, td, J=13.4, 4.6 Hz, 2 x CHH), 
1.65 (2H, td, J=12.6, 4.4 Hz, 2 x CHH). 
 
I
N
O
N
     377
C23H24INO
  (457.36)
   379
C23H27N
(317.48)
LiAlH4 (1.0 M in THF)
THF, , 2 h, 80%184 
 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 152.0 (C), 138.9 (2xCH), 138.5 (C), 135.3 (C), 
128.6 (CH), 128.5 (2xCH), 127.1 (2xCH), 127.1 
(CH), 123.1 (CH), 117.3 (CH), 114.2 (2xCH2), 106.7 
(CH), 63.6 (CH2), 53.1 (CH2), 46.9   (C), 38.2 
(2xCH2), 28.8 (2xCH2).  
CIMS: m/z (%):    318 [M+H]
+· (100), 262 (30), 220 (30), 172 (25), 130 
    (30),  106  (35),  91  (70). 
HRMS (ES +ve):     C23H28N [M+H]
+ 318.2216, found 318.2218. 
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tert-Butyl 2-Oxo-2,3-dihydro-indole-1-carboxylate (381). 
 
 
 
 
 
 
To a solution of oxindole (251) (3.76 mmol, 0.50 g) in anhydrous THF (30 mL) at 
room temperature under nitrogen, was added di-tert-butyl dicarbonate (9.39 mmol, 
2.05 g), and sodium carbonate (36.3 mmol, 2.79 g). after 16 h the reaction mixture 
was filtered, concentrated in vacuo and purified by column chromatography (silica, 
20% diethyl ether in petroleum ether) to give the N-Boc material (381) as a white 
solid (2.59 mmol, 0.61 g, 70%). Data consistent with the literature.
79 
 
IR (ATR / golden gate):   3052  (w),  2987  (w), 2950 (w), 2925 (w), 1787 (s), 
1760       (s),  1719  (s). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.79 (1H, d, J=8.1 Hz, aromatic CH), 7.35–7.21 
(2H, m, 2 x aromatic CH), 7.14 (1H, app. td, J=7.5, 0.9 
Hz, aromatic CH), 3.65 (2H, s, COCH2), 1.65 (9H, s, 
COOC(CH3)3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 173.2 (C=O), 149.4 (C=O), 141.2 (C), 128.2 
(CH), 124.3 (2xCH), 123.4 (C), 115.2 (CH), 84.5 (C), 
36.7 (CH2), 28.3 (3xCH3). 
     
 
 
 
 
 
 
N
H
O
N
O
O
O
RT, 16 h, 70%
Boc2O, Na2CO3, THF
   251
C8H7NO
(133.15)
    381
C13H15NO3
 (233.27)186 
 
tert-Butyl 3,3-di-but-3-enyl-2-oxo-2,3-dihydro-indole-1-carboxylate (383), tert-
Butyl 3-but-3-enyl-2-oxo-2,3-dihydro-indole-1-carboxylate (382) and tert-Butyl 
3-but-3-enyl-2-but-3-enyloxy-indole-1-carboxylate (384). 
 
To a solution of Boc-oxindole (383) (6.43 mmol, 1.50 g) in anhydrous DMF (130 
mL) at 0 ºC under nitrogen was added sodium hydride (60% in mineral oil, 19.29 
mmol, 0.77 g). After 1 h 4-bromo-1-butene (19.29 mmol, 1.96 mL) was added drop-
wise followed, after 4 h at 0 ºC and 3 h at room temperature, by water (200 mL). The 
reaction mixture was extracted with ether (2 x 100 mL), then the combined organic 
phases were washed with water (3 x 100 mL), brine (200 mL), dried (MgSO4), 
concentrated in vacuo and purified by column chromatography (silica, 10% diethyl 
ether in petroleum ether) to firstly give o-alkylated material (384) (0.16 mmol, 55 
mg, 3%), followed by the desired bis-alkylated material (383) (2.82 mmol, 0.96 g, 
44%) and then the mono-alkylated material (382) (1.31 mmol, 0.38 g, 20%) all as a 
clear oils.  
 
Data for 382 
Novel  
IR (ATR  /  golden  gate):    3077 (w), 2978 (w), 2925 (w), 1793 (m), 1764 (s), 
1727 (s).  
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.82 (1H, d, J=8.4 Hz, aromatic CH), 7.35–7.22 
(2H, m, 2 x aromatic CH), 7.16 (1H, app. dt, J=7.3, 1.1 
Hz, aromatic CH), 5.80 (1H, m, CH=CH2), 4.94–5.06 
(2H, m, CH=CH2), 3.58 (1H, t, J=5.5 Hz, 
CHCH2CH2CH=CH2), 2.24–2.04 (4H, m, 
CHCH2CH2CH=CH2), 1.65 (9H, s, CO2C(CH3)3). 
N
O
O
O
N
O
O
O
N
O
O
O
N
O
O
O
4-bromo-1-butene (2.5 equiv.),
                4 h, RT
NaH (2.5 equiv.), DMF
+
     383
C13H15NO3
  (233.27)
 383, 44%
C21H27NO3
 (341.45)
 384, 3%
C21H27NO3
 (341.45)
+
382, 20%
C17H21NO3
 (287.36)187 
 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 176.1 (C=O), 149.3 (C=O), 140.2 (C), 137.2 
(CH), 128.1 (CH), 127.8 (C), 124.2 (CH), 123.6 (CH), 
115.7 (CH2), 114.9 (CH), 84.2 (C), 45.2 (CH), 30.4 
(CH2), 29.8 (CH2), 28.1 (3xCH3). 
ESMS: m/z (%):     232 [M−
tBu+H]
+ (70), 310 [M+Na]
+ (20), 560  
    [ M 2+Na]
+ (100). 
HRMS (ES +ve):   C17H21NNaO3 [M+Na]
+ 310.1419, found 310.1414. 
 
Data for 383 
Novel  
IR (ATR / golden gate):   3072 (w), 2978 (w), 2933 (w), 2909 (w), 2848 (w), 
1973 (w), 1763 (m), 1727 (s). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.83 (1H, d, J=8.1 Hz, aromatic CH), 7.31 (1H, 
ddd, J=8.1, 7.4, 1.8 Hz, aromatic CH), 7.20 (1H, app. 
td, J=7.4, 1.0 Hz, aromatic CH), 7.16 (1H, ddd, J=7.4, 
1.8, 1.0 Hz, aromatic CH), 5.64 (2H, m, 2 x CH=CH2), 
4.90–4.80 (4H, m, 2 x CH=CH2), 2.14–2.00 (2H, m, 2 
x CHH), 1.90–1.67 (6H, m, 2 x CHH and 4 x CHH), 
1.65 (9H, s, OC(CH3)3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 178.4 (C=O), 149.1 (C=O), 140.0 (C), 137.3 
(2xCH), 130.6 (C), 128.1 (CH), 124.5 (CH), 122.6 
(CH), 114.9 (2xCH2), 114.9 (CH) 84.2 (C), 52.8 (C), 
38.1 (2xCH2), 28.6 (2xCH2), 28.1 (3xCH3). 
ESMS: m/z (%):    286 [M−
tBu+H]
+ (50), 364 [M+Na]
+ (30), 706  
    [ M 2+Na]
+ (100). 
HRMS (ES +ve):   C21H27NNaO3 [M+Na]
+ 364.1889, found 364.1883. 
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Data for 384 
Novel  
IR (ATR / golden gate):   3081 (w), 2970 (w), 2929 (w), 2852 (w), 1727 (m), 
1618 (m), 1458 (s). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 8.04 (1H, m, aromatic CH), 7.44 (1H, m, 
aromatic CH), 7.26–7.20 (2H, m, 2 x aromatic CH), 
6.03–5.84 (2H, m, 2 x CH=CH2), 5.25–4.97 (4H, m, 2 
x CH=CH2), 4.13 (2H, t, J=6.9 Hz, 
OCH2CH2CH=CH2), 2.73 (2H, dd, J=10.0, 7.5 Hz, 
CH2CH2CH=CH2), 2.60 (2H, app. qt, J=6.9, 1.3 Hz, 
OCH2CH2CH=CH2), 2.46–2.36 (2H, m, 
CH2CH2CH=CH2), 1.70 (9H, s, C(CH3)3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
  ppm 149.5 (C=O), 147.7 (C), 138.5 (CH), 134.4  
    ( CH), 132.1 (C), 128.3 (C), 123.3 (CH), 122.7 (CH), 
    118.4  (CH), 117.5 (CH2), 115.4 (CH), 115.1 (CH2), 
    105.3  (C), 83.7 (C), 75.6 (CH2), 34.4 (CH2), 33.9  
    ( CH2), 28.5 (3xCH3), 22.6 (CH2).  
ESMS: m/z (%):  286  [M−
tBu+H]
+ (100), 342 [M+H]
+ (20), 364 
[M+Na]
+ (70), 706 [M2+Na]
+ (40). 
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3,3-Di-but-3-enyl-1,3-dihydro-indol-2-one (385). 
 
 
 
 
 
 
 
To a solution of oxindole (383) (2.78 mmol, 0.95 g) in dichloromethane (50 mL) 
under nitrogen at 0 ºC was added TFA (2.5 mL). The reaction mixture was allowed 
to warm to room temperature slowly and after 16 h was concentrated in vacuo to 
give oxindole (385) as a yellow oil (2.78 mmol, 0.67 g, 100%). 
 
Novel  
IR (ATR / golden gate):   3162 (w), 3085 (w), 2974 (w), 2929 (w), 2844 (w), 
1709 (s), 1668 (s), 1642 (s), 1619 (s). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 9.25 (1H, b s, NH), 7.29 (1H, ddd, J=7.7, 7.1, 
1.8 Hz, aromatic CH), 7.25-7.20 (2H, m, 2 x aromatic 
CH), 7.15 (1H, app. dt, J=7.1, 1.0 Hz, aromatic CH), 
5.66 (2H, ddt, J=16.1, 11.1, 6.3 Hz, 2 x CH2=CH), 
4.95–4.83 (4H, m, 2 x CH2=CH), 2.11–1.60 (8H, m, 2 
x CH2=CHCH2CH2). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d) 
 
 ppm 184.8 (C=O), 140.2 (C), 137.2 (2xCH), 132.1 
(C), 128.2 (CH), 123.6 (CH), 123.2 (CH), 115.1 
(2xCH2), 110.6 (CH), 54.0 (C), 36.9 (2xCH2), 28.4 
(2xCH2). 
CIMS: m/z (%):     242  [M+H]
+· (100), 187 [M-CH2CH2CHCH2]
+· (75), 
        146 (70), 130 (10), 117 (15). 
HRMS (ES +ve):     C16H19NNaO [M+Na]
+ 264.1364, found 264.1359. 
 
 
N
H
O
N
O
O
O
RT, 16 h, 100%
TFA, CH2Cl2
    383
C21H27NO3
 (341.45)
    385
C16H19NO
 (241.34)190 
 
3,3-Di-but-3-enyl-2,3-dihydro-1H-indole (386). 
 
 
 
 
 
 
A solution of LiAlH4 (1.0 M solution in THF, 7.71 mmol, 7.71 mL) was diluted with 
anhydrous THF (80 mL) and cooled to 0 ºC under nitrogen. A solution of oxindole 
(385) (2.57 mmol, 0.62 g) in anhydrous THF (20 mL) was added drop-wise and the 
reaction mixture heated to 70 ºC for 16 h then cooled to 0 ºC. Water (100 mL) was 
added cautiously, and then the reaction mixture was extracted with ether (3 x 50 
mL). The combined organic phases were washed with brine (200 mL), dried 
(MgSO4) and concentrated in vacuo to give indoline (386) as a brown oil (2.27 
mmol, 0.52 g, 88%).  
 
Novel  
IR (ATR / golden gate):   3391 (w), 3072 (w), 2983 (w), 2921 (w), 2844 (w), 
1642 (m), 1607 (m), 1487 (m), 1462 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.05 (1H, app. td, J=7.7, 1.3 Hz, aromatic CH), 
7.00 (1H, dd, J=7.3, 0.7 Hz, aromatic CH), 6.74 (1H, 
app. td, J=7.3, 1.3 Hz, aromatic CH), 6.64 (1H, d, 
J=7.7 Hz, aromatic CH), 5.80 (2H, ddt, J=17.1, 10.3, 
6.4 Hz, 2 x CH=CH2), 5.05–4.96 (2H, m, 2 x 
CH=CHH), 4.93 (2H, d with fine splitting, J=10.3 Hz, 
2 x CH=CHH), 3.41 (2H, s, NCH2), 2.19–2.03 (2H, m, 
2 x CHH), 2.01–1.86 (2H, m, 2 x CHH), 1.86–1.64 
(4H, m, 2 x CH2CH2CH=CH2). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 151.2 (C), 138.9 (2xCH), 134.8 (C), 127.5 
(CH), 123.3 (CH), 118.4 (CH), 114.2 (2xCH2), 109.5 
N
H
N
H
O
60 °C, 16 h, 88%
LiAlH4 (1.0 M in THF), THF
     385
C16H19NO
 (241.34)
   386
C16H21N
(227.35)191 
 
(CH), 57.3 (CH2), 48.5 (C), 38.1 (2xCH2), 28.8 
(2xCH2). 
CIMS: m/z (%):   228  [M+H]
+· (70), 172 [M-CH2CH2CHCH2]
+· (50), 
130 [M-(CH2CH2CHCH2)- (CH2CHCH2)]
+· (100), 117 
(10). 
HRMS (EI):    C16H22N [M]
+ 228.1752, found 228.1747. 
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tert-Butyl 3-but-3-enyl-3-methyl-2-oxo-2,3-dihydro-indole-1-carboxylate (387). 
 
 
 
 
 
 
 
To a solution of Boc-oxindole (382) (1.04 mmol, 0.30 g) in anhydrous DMF (30 mL) 
at 0 ºC under nitrogen was added sodium hydride (60% in mineral oil, 1.57 mmol, 63 
mg). After 1.5 h methyl iodide (1.57 mmol, 0.1 mL) wad added drop-wise and 
warmed to room temperature for 4 h. Water (50 mL) was added and the reaction 
mixture extracted with ether (2 x 40 mL). The combined organic phases were 
washed with water (4 x 40 mL) and brine (100 mL), dried (MgSO4), concentrated in 
vacuo and purified by column chromatography (silica, 5% diethyl ether in petroleum 
ether) to give the title compound 387 (0.42 mmol, 0.13 g, 41%) as a colourless oil.  
 
Novel  
IR (ATR  /  golden  gate):    2974 (w), 2933 (w), 1789 (w), 1764 (m), 1727 (s), 
1646 (w), 1610 (w), 1479 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.85 (1H, d, J=8.4 Hz, aromatic CH), 7.31 (1H, 
m, aromatic CH), 7.21–7.16 (2H, m, 2 x aromatic 
CH), 5.66 (1H, ddt, J=17.6, 9.6, 6.4 Hz, CH=CH2), 
4.91–4.82 (2H, m, CH=CH2), 2.08 (1H, m, 
CH2CHHCH=CH2), 1.90–1.68 (3H, m, 
CH2CHHCH=CH2), 1.66 (9H, s, CO2C(CH3)3), 1.43 
(3H, s, CH3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
  ppm 179.1 (C=O), 149.3 (C=O), 139.2 (C), 137.3 
    ( CH), 132.6 (C), 128.0 (CH), 124.5 (CH), 122.4 (CH), 
    115.0  (CH), 114.9 (CH2), 84.2 (C), 48.5 (C), 38.4  
    ( CH2), 28.9 (CH2), 28.1 (3xCH3), 24.9 (CH3). 
N
O
O
O
N
O
O
O
     382
C17H21NO3
 (287.36)
     387
C18H23NO3
 (301.39)
NaH, DMF, MeI
RT, 4 h, 41%193 
 
ESMS: m/z (%):    246 [M−
tBu]
+ (80), 324 [M+Na]
+ (30), 626 [M2+Na]
+ 
    (100). 
HRMS (ES +ve):     C18H23NNaO3 [M+Na]
+ 324.1570, found 324.1566. 
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3-But-3-enyl-3-methyl-1,3-dihydro-indol-2-one (388). 
 
 
 
 
 
 
To a solution of oxindole (387) (0.42 mmol, 0.13 g) in dichloromethane (30 mL) 
under nitrogen at 0 ºC was added TFA (1.5 mL). The reaction mixture was allowed 
to warm to room temperature slowly and after 16 h was concentrated in vacuo to 
give oxindole (388) (0.41 mmol, 83 mg, 98%) as a yellow oil. 
 
Novel  
IR (ATR / golden gate):   3220 (b, w), 3072 (w), 3023 (w), 2974 (w), 2925 (w), 
2844 (w), 1700 (s), 1620 (m), 1471 (s). 
1H NMR (300 MHz, CHLOROFORM-d)  
  ppm 8.63 (1H, b s, NH), 7.23 (1H, app. td, J=7.7,  
    1.2  Hz,  aromatic  CH), 7.18 (1H, dd, J=7.5, 1.2 Hz,  
    a r o m a t i c   C H), 7.09 (1H, app. td, J=7.5, 0.7 Hz,  
    a r o m a t i c   C H), 6.94 (1H, d, J=7.7 Hz, aromatic CH), 
    5.68  (1H,  m,  CH=CH2), 4.96–4.84 (2H, m, CH=CH2), 
    2.13–1.61  (4H,  m,  CH2CH2CH=CH2), 1.42 (3H, s, 
    C H3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
  ppm 157.7 (C=O), 140.2 (C), 137.7 (CH), 134.5 (C), 
    128.1  (CH), 123.2 (CH), 123.1 (CH), 115.1 (CH2),  
    110.2  (CH), 47.2 (C), 37.5 (CH2), 29.0 (CH2), 24.0  
    ( CH3). 
CIMS: m/z (%):    202  [M+H]
+· (90), 147 [M-CH2CH2CHCH2]
+· (100), 
    117  (10),  91  (5). 
HRMS (ES +ve):     C13H15NNaO [M+Na]
+ 224.1046, found 224.1044. 
 
 
N
H
O
N
O
O
O
RT, 16 h, 98%
TFA, CH2Cl2
     387
C18H23NO3
 (301.39)
    388
C13H15NO
 (201.27)195 
 
3-But-3-enyl-3-methyl-2,3-dihydro-1H-indole (389). 
 
 
 
 
 
A solution of LiAlH4 (1.0 M solution in THF, 1.23 mmol, 1.23 mL) was diluted with 
anhydrous THF (10 mL) and cooled to 0 ºC under nitrogen. A solution of oxindole 
(388) (0.41 mmol, 83 mg) in anhydrous THF (2 mL) was added drop-wise and the 
reaction mixture heated to 70 ºC for 20 h then cooled to 0 ºC. Water (20 mL) was 
added cautiously and the reaction mixture was extracted with ether (3 x 20 mL). The 
combined organic phases were washed with brine (50 mL), dried (MgSO4), and 
concentrated in vacuo to give indoline (389) (0.40 mmol, 75 mg, 98%) as a yellow 
oil.  
 
Novel  
IR (ATR / golden gate):   3387 (w), 2958 (m), 2922 (m), 2856 (m), 1642 (w), 
1605 (m), 1487 (m), 1462 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.08–7.00 (2H, m, 2 x aromatic CH), 6.75 (1H, 
app. td, J=7.5, 1.0 Hz, aromatic CH), 6.65 (1H, app. 
dt, J=7.5, 0.8 Hz, aromatic CH), 5.81 (1H, ddt, J=17.0, 
10.3, 6.5 Hz, CH=CH2), 5.01 (1H, app. dq, J=17.0, 1.8 
Hz, CH=CHH), 4.93 (1H, app. ddt, J=10.3, 1.8, 1.3 
Hz, CH=CHH), 3.44 (1H, d, J=8.9 Hz, NCHH), 3.28 
(1H, d, J=8.9 Hz, NCHH), 2.22–1.89 (2H, m, 2 x 
CHH), 1.82–1.62 (2H, m, 2 x CHH), 1.33 (3H, s, 
CH3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 150.8 (C), 139.2 (CH), 137.1 (C), 127.6 (CH), 
122.8 (CH), 118.8 (CH), 114.3 (CH2), 109.8 (CH), 
59.6 (CH2), 45.2 (C), 40.0 (CH2), 29.3 (CH2), 26.0 
(CH3). 
N
H
O
N
H
    388
C13H15NO
 (201.27)
   389
C13H17N
(187.29)
LiAlH4 (1.0 M in THF), THF
, 20 h, 98%196 
 
CIMS: m/z (%):    188 [M+H]
+· (100), 172 (10), 132      
    [ M −CH2CH2CH=CH2]
+· (100), 144 (15), 117 (15). 
HRMS (ES +ve):     C13H18N [M+H]
+ 188.1434, found 188.1433. 
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1-Chloromethyl-2-iodo-4,5-dimethoxy-benzene (392). 
 
 
 
 
 
 
To a solution of benzyl alcohol (391) (5.10 mmol, 1.50 g) in dichloromethane (50 
mL), at 0 ºC under nitrogen, was added thionyl chloride (5.10 mmol, 0.37 mL) drop-
wise. After 6 h at room temperature the reaction mixture was concentrated in vacuo 
to give the benzyl chloride (392) as a green solid (4.63 mmol, 1.45 g, 91%). Data 
consistent with the literature.
80 
 
IR (ATR / golden gate):   3003 (w), 2950 (w), 2929 (w), 2827 (w), 1594 (m),  
    1503  (s). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.25 (1H, s, aromatic CH), 6.99 (1H, s, 
aromatic CH), 4.66 (2H, s, CH2Cl), 3.89 (3H, s, 
OCH3), 3.88 (3H, s, OCH3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d):  
δ ppm 150.0 (C), 132.7 (2xC), 122.2 (CH), 113.2 
(CH), 88.3 (CI), 56.6 (OCH3), 56.4 (OCH3), 51.7 
(CH2). 
EIMS: m/z (%):   312 [M]
+· (45), 277 [M−Cl]
+· (100), 263 (20), 152 (35), 
108 (35). 
 
 
 
 
 
 
 
 
OH
I
OMe
OMe
Cl
I
OMe
OMe RT, 16 h, 91%
SOCl2, CH2Cl2
    391
C9H11IO3
(294.09)
     392
C9H10ClIO2
  (312.54)198 
 
(2,6-Diiodo-3,4,5-trimethoxy-phenyl)-methanol (394). 
 
 
 
 
 
 
To a solution of 3,4,5-trimethoxybenzyl alcohol (393) (1.01 mmol, 0.20 g) in 
chloroform (20 mL), at 0 ºC under nitrogen, was added silver trifluoroacetate (2.53 
mmol, 0.56 g). To this suspension was added drop-wise a solution of iodine (2.53 
mmol, 0.64 g) in chloroform (100 mL). After 16 h at room temperature the filtered 
and the filtrate washed with a saturated solution of sodium thiosulfate (100 mL). The 
organic phase was dried (MgSO4) and concentrated in vacuo to give the benzyl 
alcohol (394) as a yellow oil (1.01 mmol, 0.45 g, 99%). 
 
Novel  
IR (ATR / golden gate):   3506 (w), 3387 (w), 2999 (w), 2929 (w), 2880 (w), 
2840 (w), 1459 (m), 1438 (m), 1398 (m), 1370 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 5.06 (2H, s, CH2OH), 3.83 (3H, s, OCH3), 3.81 
(6H, s, 2 x OCH3), 2.40 (1H, b, s, OH). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 154.2 (2xC), 145.0 (C), 139.7 (C), 92.9 (2xCI), 
75.0 (CH2), 61.3 (OCH3), 61.0 (2xOCH3). 
EIMS: m/z (%):     450 [M]
+· (100), 433 (20), 324 (15). 
HRMS (ES +ve):     C10H12I2NaO4 [M+Na]
+ 472.8723, found 472.8417. 
 
 
 
 
 
 
 
OH
OMe
OMe
OMe
OH I
I
OMe
OMe
OMe
CHCl3, RT, 16 h, 99%
CF3COOAg (2.5 equiv.) 
         I2 (2.5 equiv.)
    393
C10H14O4
 (198.22)
    394
C10H12I2O4
 (450.01)199 
 
1-Chloromethyl-2,6-diiodo-3,4,5-trimethoxy-benzene (395). 
 
OH
I
I
OMe
OMe
OMe
Cl
I
I
OMe
OMe
OMe
RT, 16 h, 100%
SOCl2, CH2Cl2
     394
C10H12I2O4
 (450.01)
      395
C10H11ClI2O3
   (468.46)
 
To a solution of benzyl alcohol (394) (0.89 mmol, 0.40 g) in DCM (40 mL), at 0 ºC 
under nitrogen, was added thionyl chloride (0.89 mmol, 0.07 mL) drop-wise. After 
16 h at room temperature the reaction mixture was concentrated in vacuo to give 
benzyl chloride (395) as a yellow oil (0.89 mmol, 0.42 g, 100%). 
 
Novel  
IR (ATR / golden gate):   3003  (w),  2966  (w), 2933 (w), 2856 (w), 1456 (s), 
1399 (s), 1371 (s), 1315 (s). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 5.13 (2H, s, ClCH2Ar), 3.92 (3H, s, OCH3), 
3.89 (6H, s, 2 x OCH3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 154.7 (2xC), 145.4 (C), 137.2 (C), 93.0 (2xCI), 
61.4 (OCH3), 61.1 (2xOCH3), 58.2 (CH2). 
EIMS: m/z (%):     468 [M]
+· (90), 434 [M−Cl]
+· (100), 419 (10), 291 (20), 
    277  (15). 
HRMS (EI):       C10H11ClI2O3 [M]
+ 467.8486, found 467.8494. 
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3-But-3-enyl-1-(2-iodo-4,5-dimethoxy-benzyl)-3-methyl-2,3-dihydro-1H-indole 
(396). 
 
 
 
 
 
 
A solution of indoline (389) (0.32 mmol, 60 mg), benzyl chloride (392) (0.27 mmol, 
83 mg) and K2CO3 (1.67 mmol, 0.23 g) in acetone (20 mL) under nitrogen was 
heated at reflux for 16 h then cooled and concentrated in vacuo. The residue was 
partitioned between water (50 mL) and ether (50 mL). The aqueous phase was 
washed with ether (2 x 30 mL) then the combined organic phases were washed with 
brine (100 mL), dried (MgSO4), concentrated in vacuo and purified by column 
chromatography (silica, 5% diethyl ether in petroleum ether) to give the desired 
product (396) as a yellow oil (0.14 mmol, 63 mg, 50%). 
 
Novel  
IR (ATR / golden gate):   3387 (b, w), 2958 (w), 2929 (w), 2827 (w), 1716 (w), 
1638 (w), 1605 (m), 1498 (s). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.29 (1H, s, aromatic CH), 7.09 (1H, app. td, 
J=7.7, 1.2 Hz, aromatic CH), 7.04 (1H, dd, J=7.4, 1.2 
Hz, aromatic CH), 6.97 (1H, s, aromatic CH), 6.74 
(1H, app. td, J=7.4, 0.9 Hz, aromatic CH), 6.48 (1H, d, 
J=7.7 Hz, aromatic CH), 5.79 (1H, ddt, J=16.9, 10.3, 
6.6 Hz, CH=CH2), 5.03–4.88 (2H, m, CH=CH2), 4.26 
(1H, d, J=15.4 Hz, NCHHAr), 4.13 (1H, d, J=15.4 Hz, 
NCHHAr), 3.89 (3H, s, OCH3), 3.78 (3H, s, OCH3),  
3.30 (1H, d, J=8.8 Hz, NCHH), 3.10 (1H, d, J=8.8 Hz, 
NCHH), 2.17 (1H, m, CH2CHHCH=CH2), 1.95 (1H, 
m, CH2CHHCH=CH2), 1.82–1.64 (2H, m, 
CH2CH2CH=CH2), 1.35 (3H, s, CH3). 
N
H
N
I
MeO
MeO
Cl
I
OMe
OMe
+
, 16 h, 50%
K2CO3, acetone
   389
C13H17N
(187.29)
     392
C9H10ClIO2
  (312.54)
    396
C22H26INO2
 (463.36)201 
 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
  ppm 151.5 (C), 149.9 (C), 149.0 (C), 139.2 (CH), 
    137.5  (C), 133.0 (C), 127.9 (CH), 122.7 (CH), 122.1 
    ( CH), 118.2 (CH), 114.5 (CH2), 112.1 (CH), 107.3  
    ( CH), 86.6 (CI), 66.2 (CH2), 58.1 (CH2), 56.6 (OCH3), 
    56.2  (OCH3), 43.9 (C), 40.5 (CH2), 29.6 (CH2), 26.3 
    ( CH3). 
ESMS: m/z (%):    464 [M+H]
+ (100), 486 [M+Na]
+ (20). 
HRMS (ES +ve):     C22H26INO2 [M+H]
+ 464.1081, found 464.1085. 
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3,3-Di-but-3-enyl-1-(2-iodo-4,5-dimethoxy-benzyl)-2,3-dihydro-1H-indole (397). 
 
 
 
 
 
 
 
 
A solution of indoline (386) (1.32 mmol, 0.30 g), benzyl chloride (392) (1.98 mmol, 
0.62 g), K2CO3 (8.18 mmol, 1.13 g) and KI (1.98 mmol, 0.33 g) in acetone (30 mL) 
under nitrogen was heated at reflux for 16 h then cooled and concentrated in vacuo. 
The residue was partitioned between water (30 mL) and ether (30 mL). The aqueous 
phase was washed with ether (2 x 30 mL) then the combined organic phases were 
washed with brine (80 mL), dried (MgSO4), concentrated in vacuo and purified by 
column chromatography (silica, 5% diethyl ether in petroleum ether) to give the 
desired product (397) as a yellow oil (1.04 mmol, 0.53 g, 79%). 
 
Novel  
IR (ATR / golden gate):   3072 (w), 2995 (w), 2929 (w), 2905 (w), 2884 (w), 
1638 (w), 1603 (m), 1497 (s), 1459 (s). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.30 (1H, s, aromatic CH), 7.09 (1H, app. td, 
J=7.7, 1.1 Hz, aromatic CH), 7.01 (1H, dd, J=7.3, 0.7 
Hz, aromatic CH), 6.95 (1H, s, aromatic CH), 6.73 
(1H, app. td, J=7.3, 1.1 Hz, aromatic CH), 6.45 (1H, d, 
J=7.7 Hz, aromatic CH), 5.80 (2H, ddt, J=17.0, 10.4, 
6.3 Hz, 2 x CH=CH2), 5.04–4.88 (4H, m, 2 x 
CH=CH2), 4.21 (2H, s, NCH2Ar), 3.89 (3H, s, OCH3), 
3.76 (3H, s, OCH3), 3.26 (2H, s, NCH2), 2.23–2.06 
(2H, m, 2 x CHH), 2.02–1.88 (2H, m, 2 x CHH), 
1.87–1.64 (4H, m, 4 x CHH). 
 
N
H
N
I
MeO
MeO
Cl
I
OMe
OMe
+
, 16 h, 79%
K2CO3, KI, acetone
   386
C16H21N
(227.35)
     392
C9H10ClIO2
  (312.54)
     397
C25H30INO2
  (503.43)203 
 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 151.7 (C), 149.6 (C), 148.6 (C), 138.7 (2xCH), 
135.0 (C), 132.6 (C), 127.7 (CH), 123.0 (CH), 121.7 
(CH), 117.7 (CH), 114.3 (2xCH2), 111.6 (CH), 106.8 
(CH), 86.1 (CI), 63.8 (CH2), 57.9 (CH2), 56.2 (OCH3), 
55.8 (OCH3), 47.0 (C), 38.5 (2xCH2), 28.9 (2xCH2). 
ESMS: m/z (%):    504 [M+H]
+ (100), 526 [M+Na]
+ (25). 
HRMS (ES +ve):     C25H31INO2 [M+H]
+ 504.1399 found 504.1394. 
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3,3-Di-but-3-enyl-1-(2,6-diiodo-3,4,5-trimethoxy-benzyl)-2,3-dihydro-1H-indole 
(398). 
 
 
 
 
 
 
 
 
A solution of indoline (386) (1.76 mmol, 0.40 g), benzyl chloride (395) (1.47 mmol, 
0.69 g), K2CO3 (9.11 mmol, 1.26 g) and KI (1.47 mmol, 0.24 g) in acetone (50 mL) 
under nitrogen was heated at reflux for 16 h then cooled and concentrated in vacuo. 
The residue was partitioned between water (40 mL) and ether (40 mL). The aqueous 
phase was washed with ether (2 x 40 mL) then the combined organic phases were 
washed with brine (100 mL), dried (MgSO4), concentrated in vacuo and purified by 
column chromatography (silica, 2% diethyl ether in petroleum ether) to give the 
desired product (398) (0.67 mmol, 0.44 g, 46%) as a light brown solid. 
 
Novel  
Mpt:  °C    79–81  °C (EtOAc in hexanes). 
IR (ATR / golden gate):   3064 (w), 3007 (w), 2962 (w), 2933 (w), 2909 (w), 
2852 (w), 1634 (w), 1603 (m), 1491 (s), 1456 (s). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.15 (1H, app. td, J=7.7, 1.1 Hz, aromatic CH), 
6.98 (1H, dd, J=7.3, 1.1 Hz, aromatic CH), 6.75–6.67 
(2H, m, 2 x aromatic CH), 5.76 (2H, ddt, J=16.9, 10.3, 
6.4 Hz, 2 x CH=CH2), 5.00–4.85 (4H, m, 2 x 
CH=CH2), 4.71 (2H, s, NCH2Ar), 3.96 (3H, s, OCH3), 
3.92 (6H, s, 2 x OCH3), 3.07 (2H, s, NCH2), 2.13–1.97 
(2H, m, 2 x CHH), 1.95–1.80 (2H, m, 2 x CHH), 
1.79–1.57 (4H, m, 4 x CHH). 
 
N
H
N
I
I
MeO
MeO
OMe
Cl
I
I
OMe
OMe
OMe
+
, 16 h, 46%
K2CO3, KI, acetone
   386
C16H21N
(227.35)
       395
C10H11ClI2O3
    (468.46)
    398
C26H31I2NO3
  (659.35)205 
 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 154.2 (2xC), 151.4 (C), 144.8 (C), 139.4 
(2xCH), 136.8 (C), 135.7 (C), 127.8 (CH), 123.3 
(CH), 117.8 (CH), 114.4 (2xCH2), 107.5 (CH), 94.3 
(2xCI), 62.0 (2xCH2), 61.4 (OCH3), 61.1 (2xOCH3), 
47.1 (C), 38.5 (2xCH2), 29.3 (2xCH2). 
ESMS: m/z (%):    660 [M+H]
+ (100), 682 [M+Na]
+ (10). 
HRMS (ES +ve):     C26H32I2NO3 [M+H]
+ 660.0472, found 660.0466. 
CHN:    Calcd for C26H31I2NO3: C, 47.36, H, 4.74, N, 2.12. 
Found: C, 47.46, H, 4.73, N, 2.02. 
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4-(3,4-Dimethoxy-benzyl)-3,8b-dimethyl-1,2,3,3a,4,8b-hexahydro-
cyclopenta[b]indole (399). 
 
 
 
 
 
 
 
 
To a solution of 396 (0.13 mmol, 60 mg) in toluene (20 mL) under nitrogen was 
added TTMSS (0.29 mmol, 88 μL) and VAZO (0.03 mmol, 6 mg). The reaction 
mixture was heated at reflux and stirred for 16 h, then cooled, concentrated in vacuo 
and purified by column chromatography (silica, 50% CHCl3 in petroleum ether) to 
give, contaminated with ~10% silicon residues that we were unable to remove, the 
desired product (399) as a brown oil (0.08 mmol, 27 mg, 62%).  
 
Novel  
IR (ATR / golden gate):   2945 (w), 2930 (w), 2892 (w), 2854 (w), 1697 (w), 
1599 (w), 1512 (w). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.02–6.94 (2H, m, 2 x aromatic CH), 6.82–6.76 
(3H, m, 3 x aromatic CH), 6.65 (1H, app. td, J=7.3, 0.9 
Hz, aromatic CH), 6.32 (1H, d, J=7.8 Hz, aromatic 
CH), 4.52 (1H, d, J=16.2 Hz, NCHHAr), 4.19 (1H, d, 
J=16.2 Hz, NCHHAr), 3.86 (3H, s, OCH3), 3.78 (3H, 
s, OCH3), 3.53 (1H, d, J=5.5 Hz, NCH), 2.17–1.84 
(3H, m, NCHCH(CH3)CH2CH2), 1.73–1.57 (2H, m, 
NCHCH(CH3)CH2CH2), 1.36 (3H, s, CCH3), 1.08 
(3H, d, J=6.9 Hz, NCHCH(CH3)CH2CH2). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 153.2 (C), 149.2 (C), 148.0 (C), 138.8 (C), 
131.9 (C), 127.5 (CH), 122.5 (CH), 119.4 (CH), 117.6 
N
I
MeO
MeO
N H
MeO
MeO
     396
C22H26INO2
 (463.36)
PhMe, 120 °C, 16 h, 62%
TTMSS (2.2 equiv.)
  VAZO (20 mol%)
     399
C22H27NO2
 (337.47)207 
 
(CH), 111.3 (CH), 110.6 (CH), 107.4 (CH), 79.4 
(NCH), 56.1 (OCH3), 55.9 (OCH3), 53.9 (CH2), 53.2 
(C), 42.4 (CH2), 41.5 (CH), 33.6 (CH2), 29.3 (CH3), 
15.1 (CH3). 
1H-
1H correlation obtained to confirm above NMR assignments. 
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8b-But-3-enyl-4-(3,4-dimethoxy-benzyl)-3-methyl-1,2,3,3a,4,8b-hexahydro-
cyclopenta[b]indole (400). 
 
 
 
 
 
 
 
 
To a solution of 397 (0.40 mmol, 0.20 g) in anhydrous toluene (20 mL) under 
nitrogen was added tributyltin hydride (0.87 mmol, 0.24 mL) and VAZO (0.08 
mmol, 20 mg). The reaction mixture was heated at reflux for 4 h then cooled and 
concentrated  in vacuo and purified by column chromatography (10% anhydrous 
K2CO3: 90% silica, 10% diethyl ether in petroleum ether) to give the desired product 
(400) as a brown oil (0.31 mmol, 0.12 g, 76%), as a 6:1 mixture of diastereoisomers. 
 
Novel  
IR (ATR / golden gate):   3077 (w), 3003 (w), 2929 (m), 2856 (m), 2827 (m), 
1601 (s), 1513 (s), 1485 (s), 1461 (s). 
1H NMR (400 MHz, CHLOROFORM-d) (Major diastereoisomer reported) 
 ppm 7.48 (1H, app. td, J=7.9, 1.1 Hz, aromatic CH), 
7.43 (1H, dd, J=7.3, 1.1 Hz, aromatic CH), 7.34–7.28 
(3H, m, 3 x aromatic CH), 7.13 (1H, app. td, J=7.3, 0.6 
Hz, aromatic CH), 6.87 (1H, d, J=7.9 Hz, aromatic 
CH), 6.16 (1H, ddt, J=16.7, 10.7, 6.1 Hz, CH2=CH), 
5.39–5.31 (2H, m, CH2=CH), 5.04 (1H, d, J=15.9 Hz, 
NCHHAr), 4.65 (1H, d, J=15.9 Hz, NCHHAr), 4.34 
(3H, s, OCH3), 4.25 (3H, s, OCH3), 4.11 (1H, d, J=5.8 
Hz, NCH), 2.59–2.46 (2H, m, CH2=CHCH2CH2), 
2.45–2.35 (2H, m, CH2=CHCH2CH2), 2.34–2.02 (4H, 
m, CH3CHCH2CH2C), 1.82 (1H, m, 
N
I
MeO
MeO
N H
MeO
MeO
PhMe, 120 °C, 16 h
    76%, d.r. 6:1
Bu3SnH (2.2 equiv.)
  VAZO (20 mol%)
     397
C25H30INO2
  (503.43)
    400
C25H31NO2
 (377.53)209 
 
CH3CHCH2CH2C), 1.57 (3H, d, J=6.9 Hz, 
CH3CHCH2CH2C).
 
13C NMR + DEPT (100 MHz, CHLOROFORM-d)  
(Major diastereoisomer reported) 
 ppm 153.2 (C), 148.9 (C), 148.0 (C), 138.8 (CH), 
136.3 (C), 131.2 (C), 127.3 (CH), 122.8 (CH), 119.8 
(CH), 117.1 (CH), 113.9 (CH2), 111.0 (CH) 110.9 
(CH), 107.0 (CH), 75.0 (CH), 56.9 (C), 55.8 (OCH3), 
55.7 (OCH3), 53.3 (CH2), 41.5 (CH), 40.9 (CH2), 40.6 
(CH2), 32.6 (CH2), 30.1 (CH2), 14.9 (CH3). 
N.B. Additional signals attributed to the minor 
diastereoisomer.
  
1H-
1H correlation obtained to confirm above NMR assignments. 
CIMS: m/z (%):     378 [M+H]
+ (30), 151 [M-CH2C6H3(OCH3)2]
+ (100). 
HRMS (EI):      C25H31NO2 [M]
+ 378.2434, found 378.5428. 
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2-Aza-2-benzyl-8,11-dimethyl benz[c]tricycle[3,3,3,0
1,5]undecane (401). 
 
 
 
 
 
 
 
 
 
To a solution of 398 (0.46 mmol, 0.30 g) in toluene (20 mL) under nitrogen was 
added tributyltin hydride (2.02 mmol, 0.55 mL) and VAZO (0.09 mmol, 23 mg). The 
reaction mixture was heated at reflux and stirred for 16 h, then cooled, concentrated 
in vacuo and purified by column chromatography (10% anhydrous K2CO3: 90% 
silica, 5-10% diethyl ether in petroleum ether) to give the desired product (401) as a 
white solid (0.41 mmol, 0.17 g, 90%), as a 1:1 mixture of diastereoisomers. 
 
Novel  
IR (ATR / golden gate):   2933 (m), 2868 (w), 2848 (w), 1687 (m), 1588 (m), 
1499(m). 
1H NMR (300 MHz, CHLOROFORM-d):  
δ ppm 7.04 (1H, dd, J=7.3, 1.0 Hz, aromatic CH), 7.05 
(1H, dd, J=7.3, 1.0 Hz, aromatic CH), 6.92 (1H, app. 
td,  J=7.7, 1.4 Hz, aromatic CH), 6.91 (1H, app. td, 
J=7.7, 1.4 Hz, aromatic CH), 6.63 (1H+1H, app. tt, 
J=7.3, 1.0 Hz, aromatic CH), 6.57 (1H+1H, b s, 
aromatic CH), 6.53 (1H+1H, b s, aromatic CH), 6.01 
(1H, d, J=7.6 Hz, aromatic CH), 5.95 (1H, d, J=7.6 
Hz, aromatic CH), 4.72 (1H, d, J=16.8 Hz, NCHHAr),  
4.44 (1H+1H, s, NCHHAr), 4.25 (1H, d, J=16.8 Hz, 
NCHHAr), 3.868 (3H, s, OCH3), 3.864 (3H, s, OCH3), 
3.788 (6H, s, 2 x OCH3), 3.786 (6H, s, 2 x OCH3), 
2.19–1.97 (4H+4H, m, 2 x 2 x CH and CHH), 1.94–
1.76   (2H+2H, m, 2 x 2 x CHH), 1.75–1.57 (2H+2H, 
N
I
I
MeO
MeO OMe
N
MeO
MeO OMe
PhMe, 120 °C, 16 h
     90%, d.r. 1:1
Bu3SnH (4.4 equiv.)
  VAZO (20 mol%)
     398
C26H31I2NO3
  (659.35)
     401
C26H33NO3
 (407.56)211 
 
m, 2 x 2 x CHH),  1.54–1.32    (2H+2H, m, 2 x 2 x 
CHH), 1.26 (3H, d, J=6.9 Hz, CHCH3), 1.11 (3H, d, 
J=6.9 Hz, CHCH3), 0.92 (3H+3H, d, J=7.0 Hz, 2 x 
CHCH3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d):  
δ ppm 153.4 (2xC), 152.6+151.8 (C), 138.5+137.9 
(C), 135.3 (C), 135.1 (C), 127.2+127.2 (CH), 
122.7+122.5 (CH), 117.3+117.0 (CH), 107.5 (CH), 
105.7 (CH), 103.8+103.7 (CH), 91.4+87.4 (C), 
67.5+64.3 (C), 61.1 (OCH3), 56.3+56.2 (2xOCH3), 
52.8+50.8 (CH2), 44.0+43.6 (2xCH), 41.5+41.1+40.1 
(2xCH2), 35.0+34.3+33.8 (2xCH2), 16.4+15.2+15.1 
(2xCH3). 
1H-
1H and 
1H-
13C correlations obtained to confirm above NMR assignments. 
ESMS: m/z (%):     408 [M+H]
+ (50), 228 [M−CH2Ar+H]
+ (100). 
HRMS (ES +ve):     C26H33NNaO3 [M+Na]
+ 430.2358, found 430.2353. 
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tert-Butyl 3,3-dibenzyl-2-oxo-2,3-dihydro-indole-1-carboxylate (404). 
 
N
O
O
O
N
O
Ph
Ph
O
O
NaH (2.5 equiv.), DMF
Benzyl bromide (2.5 equiv.) 
          RT, 16 h, 60%
    382
C13H15NO3
 (233.27)
    404
C27H27NO3
 (413.52)
 
To a solution of Boc-oxindole (382) (6.35 mmol, 1.48 g) in anhydrous DMF (100 
mL) at 0 ºC under nitrogen was added sodium hydride (60% in mineral oil, 15.86 
mmol, 0.64 g). After 2 h at 0 ºC benzyl bromide (19.05 mmol, 2.27 mL) was added 
followed after 16 h by water (100 mL). The reaction mixture was extracted with 
ether (2 x 100 mL), then the combined organic phases were washed with water (3 x 
200 mL), brine (200 mL), dried (MgSO4), concentrated in vacuo and purified by 
column chromatography (silica, 5-10% diethyl ether in petroleum ether) to give 404 
as a yellow oil (3.62 mmol, 1.50 g, 57%). 
Novel  
IR (ATR  /  golden  gate):    3085(w), 3064 (w), 3032 (w), 2987 (w), 2913 (w), 
1785 (m), 1762 (s), 1728 (s). 
1H NMR (400 MHz, CHLOROFORM-d)    
 ppm 7.39 (1H, m, aromatic CH), 7.20 (1H, m, 
aromatic CH), 7.16–7.10 (3H, m, 3 x aromatic CH), 
7.10–7.03 (5H, m, 5 x aromatic CH), 6.93 - 6.86 (4H, 
m, 4 x aromatic CH), 3.38 (2H, d, J=13.1 Hz, 2 x 
CHHAr), 3.18 (2H, d, J=13.1 Hz, 2 x CHHAr), 1.51 
(9H, s, C(CH3)3). 
13C NMR + DEPT (100 MHz, CHLOROFORM-d)  
 ppm 177.5 (C=O), 148.5 (C=O), 139.8 (C), 135.4 
(2xC), 130.0 (4xCH), 129.0 (C), 128.0 (CH), 127.7 
(4xCH), 126.6 (2xCH), 124.1 (CH), 123.5 (CH), 
114.6 (CH), 83.6 (C), 56.4 (C), 44.3 (2xCH2), 28.0 
(3xCH3).
  
ESMS: m/z (%):     436 [M+Na]
+ (50), 849 [M2+Na]
+ (100). 
HRMS (ES +ve):     C27H27NNaO3 [M+Na]
+ 436.1889, found 436.1883. 213 
 
3,3-Dibenzyl-1,3-dihydro-indol-2-one (405). 
 
N
H
O
Ph
Ph
N
O
Ph
Ph
O
O
TFA, CH2Cl2
RT, 4 h, 90%
    404
C27H27NO3
 (413.52)
    405
C22H19NO
 (313.40)
 
To a solution of N-Boc oxindole (404) (3.62 mmol, 1.50 g) in dichloromethane (200 
mL) under nitrogen at 0 ºC was added TFA (10 mL). After 4 h at room temperature 
the reaction mixture was concentrated in vacuo to give oxindole (405) as a white 
solid (3.26 mmol, 1.02 g, 90%). Data consistent with the literature.
81 
 
IR (ATR / golden gate):   3142 (w), 3077 (w), 2023 (w), 2938 (w), 2913 (w), 
2880 (w), 2856 (w), 2823 (w), 1713 (s), 1667 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 8.62 (1H, b s, NH), 7.28 (1H, m, aromatic CH), 
7.19–7.02 (8H, m, 8 x aromatic CH), 6.98–6.87 (4H, 
m, 4 x aromatic CH), 6.56 (1H, m, aromatic CH), 3.37 
(2H, d, J=13.2 Hz, 2 x CHHPh), 3.27 (2H, d, J=13.2 
Hz, 2 x CHHPh). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d) 
δ ppm 183.4 (C=O), 139.8 (C), 135.1 (2xC), 130.7 
(C), 129.9 (4xCH), 128.2 (CH), 127.8 (4xCH), 126.8 
(2xCH), 124.6 (CH), 122.8 (CH), 110.4 (CH), 57.6 
(C), 43.3 (2xCH2). 
CIMS: m/z (%):     313 [M+H]
+· (100), 222 [M−CH2Ph]
+· (100), 204 (35), 
    91  (75). 
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3,3-Dibenzyl-2,3-dihydro-1H-indole (406). 
 
N
H
Ph
Ph
N
H
O
Ph
Ph LiAlH4 (1.0M in THF), THF
60 °C, 16 h, 60%
     405
C22H19NO
 (313.40)
   406
C22H21N
(299.42)
 
A solution of LiAlH4 (1.0 M solution in THF, 9.78 mmol, 9.78 mL) was diluted with 
anhydrous THF (100 mL) and cooled to 0 ºC under nitrogen. A solution of oxindole 
(405) (3.26 mmol, 1.02 g) in anhydrous THF (20 mL) was added drop-wise and the 
reaction mixture then heated to 70 ºC for 16 h then cooled to 0 ºC. Water (200 mL) 
was then added cautiously, then the reaction mixture was extracted with ether (3 x 70 
mL). The combined organic phases were washed with brine (200 mL), dried 
(MgSO4), concentrated in vacuo and purified by column chromatography (silica, 
20% diethyl ether in petroleum ether) to give indoline (406) as a brown oil (1.91 
mmol, 0.57 g, 60%).  
 
Novel  
IR (ATR / golden gate):   3386  (m),  3081(w), 3052 (w), 3019 (w), 2917 (w), 
2852 (w), 1605 (m), 1487 (s), 1462 (m), 1453 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.24–7.17 (6H, m, 6 x aromatic CH), 7.09–6.94 
(6H, m, 6 x aromatic CH), 6.77 (1H, app. td, J=7.3, 0.9 
Hz, aromatic CH), 6.53 (1H, d, J=7.8 Hz, aromatic 
CH), 3.43 (2H, s, NHCH2), 3.10 (2H, d, J=13.4 Hz, 2 
x CHHAr), 3.00 (2H, d, J=13.5 Hz, 2 x CHHAr). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 151.7 (C), 138.6 (2xC), 134.6 (C), 131.0 
(4xCH), 128.1 (4xCH), 126.5 (3xCH), 124.6 (CH), 
118.7 (CH), 110.5 (CH), 55.6 (CH2), 51.5 (C), 45.1 
(2xCH2).  
ESMS: m/z (%):     300 [M+H]
+ (100). 
HRMS (ES +ve):     C22H21N [M+H]
+ 300.1752, found 300.1747. 
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3,3-Dibenzyl-1-(2-iodo-4,5-dimethoxy-benzyl)-2,3-dihydro-1H-indole (407). 
 
N
Ph
Ph
I
MeO
MeO
N
H
Ph
Ph
Cl
I
OMe
OMe
+
K2CO3, KI, acetone
, 16 h, 76%
   406
C22H21N
(299.42)
     392
C9H10ClIO2
  (312.54)
     407
C31H30INO2
  (575.49)
 
 
A solution of indoline (406) (0.84 mmol, 0.25 g), benzyl chloride (392) (1.25 mmol, 
0.39 g), K2CO3 (5.04 mmol, 0.70 g) and KI (1.25 mmol, 0.21 g) in acetone (60 mL) 
under nitrogen was heated at reflux for 16 h the cooled and concentrated in vacuo. 
The residue was partitioned between water (50 mL) and ether (50 mL). The aqueous 
phase was washed with ether (2 x 50 mL) then the combined organic phases were 
washed with brine (200 mL), dried (MgSO4), concentrated in vacuo and purified by 
column chromatography (silica, 5% diethyl ether in petroleum ether) to give the 
desired product (407) as a brown oil (0.64 mmol, 0.37 g, 76%). 
 
Novel  
IR (ATR / golden gate):   3064 (w), 3023 (w), 2999 (w), 2909 (w), 2848 (w), 
1711 (s), 1601 (m), 1496 (s). 
1H NMR (400 MHz, CHLOROFORM-d)  
 ppm 7.24 (1H, s, aromatic CH), 7.23–7.16 (6H, m, 6 
x aromatic CH), 7.08 (1H, app. td, J=7.6, 1.2 Hz, 
aromatic CH), 7.00–6.95 (4H, m, 4 x aromatic CH), 
6.91 (1H, dd, J=7.3, 0.9 Hz, aromatic CH), 6.71 (1H, 
app. t, J=7.4 Hz, aromatic CH), 6.69 (1H, s, aromatic 
CH), 6.37 (1H, d, J=7.8 Hz, aromatic CH), 3.98 (2H, 
s, NCH2Ar), 3.87 (3H, s, OCH3), 3.65 (3H, s, OCH3), 
3.27 (2H, s, NCH2), 3.09 (2H, d, J=13.4 Hz, 2 x 
CHHAr), 2.98 (2H, d, J=13.6 Hz, 2 x CHHAr). 
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 13C NMR + DEPT (100 MHz, CHLOROFORM-d)  
 ppm 151.6 (C), 149.5 (C), 148.6 (C), 138.0 (2xC), 
134.3 (C), 132.6 (C), 130.7 (4xCH), 127.9 (CH), 
127.8 (4xCH), 126.2 (2xCH), 124.2 (CH), 121.7 
(CH), 117.3 (CH), 112.1 (CH), 107.3 (CH), 86.4 (CI), 
61.8 (CH2), 57.8 (CH2), 56.2 (OCH3), 56.0 (OCH3), 
49.9 (C), 44.3 (2xCH2) 
ESMS: m/z (%):     576 [M+H]
+ (100), 598 [M+Na]
+ (30). 
HRMS (ES +ve):     C31H30INO2 [M+H]
+ 576.1399, found 576.1394. 
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3,3-Dibenzyl-1-(2,6-diiodo-3,4,5-trimethoxy-benzyl)-2,3-dihydro-1H-indole 
(408) 
N
Ph
Ph
I
I
MeO
MeO OMe
N
H
Ph
Ph
Cl
I
I
OMe
OMe
OMe
+
K2CO3, KI, acetone
, 16 h, 83%
   406
C22H21N
(299.42)
      395
C10H11ClI2O3
  (468.46)
     408
C32H31I2NO3
  (731.42)
 
 
A solution of indoline (406) (0.84 mmol, 0.25 g), benzyl chloride (395) (1.25 mmol, 
0.59 g), K2CO3 (5.04 mmol, 0.70 g) and KI (1.25 mmol, 0.21 g) in acetone (60 mL) 
under nitrogen was heated at reflux for 16 h then cooled and concentrated in vacuo. 
The residue was partitioned between water (50 mL) and ether (50 mL). The aqueous 
phase was washed with ether (2 x 50 mL) then the combined organic phases were 
washed with brine (200 mL), dried (MgSO4), concentrated in vacuo and purified by 
column chromatography (silica, 5% diethyl ether in petroleum ether) to give the 
desired product (408) (0.70 mmol, 0.51 g, 83%) as a cream solid. 
 
Novel  
Mpt:  °C    96–99  °C (EtOAc in hexanes). 
IR (ATR / golden gate):  3027 (w), 3003 (w), 2925 (w), 2848 (w), 1602 (m), 
1487 (m), 1455 (s).    
1H NMR (400 MHz, CHLOROFORM-d):  
 ppm 7.20–7.10 (7H, m, 7 x aromatic CH), 6.95 (4H, 
app. dd, J=6.7, 2.9 Hz, 4 x aromatic CH), 6.85 (1H, 
dd, J=7.3, 0.6 Hz, aromatic CH), 6.69 (2H, app. dt, 
J=8.5, 7.3, 1.1 Hz, 2 x aromatic CH), 4.60 (2H, s, 
NCH2Ar), 3.97 (3H, s, OCH3), 3.91 (6H, s, 2 x 
OCH3), 3.05 (2H, s, NCH2), 2.98 (2H, d, J=13.5 Hz, 2 
x CHHPh), 2.87 (2H, d, J=13.5 Hz, 2 x CHHPh).
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13C NMR + DEPT (100 MHz, CHLOROFORM-d):  
 ppm 154.0 (C), 150.8 (2xC), 144.6 (C), 138.4 (2xC), 
136.8 (C), 134.9 (C), 131.1 (4xCH), 127.9 (4xCH), 
127.7 (CH), 126.3 (2xCH), 124.2 (CH), 117.4 (CH), 
107.6 (CH), 94.3 (2xCI), 61.6 (CH2), 61.2 (OCH3), 
61.0 (2xOCH3), 60.0 (CH2), 49.8 (C), 43.2 (2xCH2). 
ESMS: m/z (%):     732 [M+H]
+ (100). 
HRMS (ES +ve):     C32H31I2NO3 [M+H]
+ 732.0472, found 732.0466. 
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3-Benzyl-1-(3,4-dimethoxy-benzyl)-1H-indole (410). 
 
N
Ph
Ph
I
MeO
MeO
N
Ph
MeO
MeO
Bu3SnH (2.2 equiv.), VAZO (20 mol%) 
PhMe, 120 °C, 16 h, 95%
     407
C31H30INO2
  (575.49)
     410
C24H23NO2
  (357.46)
 
 
To a solution of 407 (0.61 mmol, 0.35 g) in toluene (25 mL) under nitrogen was 
added tributyltin hydride (1.34 mmol, 0.36 mL) and VAZO (0.12 mmol, 30 mg). The 
reaction mixture was heated at reflux for 16 h, cooled, concentrated in vacuo and 
purified by column chromatography (10% anhydrous K2CO3: 90% silica, 5% diethyl 
ether in petroleum ether) to give the desired product (410) (0.58 mmol, 0.21 g, 95%) 
as a brown oil. 
 
Novel  
IR (ATR / golden gate):   3052 (w), 3027 (w), 2999 (w), 2933 (w), 2901 (w), 
2823 (w), 1514 (s), 1463 (m), 1452 (m). 
1H NMR (400 MHz, CHLOROFORM-d):  
 ppm 7.60 (1H, dd, J=7.8, 0.9 Hz, aromatic CH), 
7.38–7.31 (4H, m, 4 x aromatic CH), 7.26–7.21 (3H, 
m, 3 x aromatic CH), 7.14 (1H, ddd, J=7.8, 6.9, 1.0 
Hz, aromatic CH), 6.93 (1H, s, aromatic CH), 6.86 
(1H, d, J=8.1 Hz, aromatic CH), 6.75 (1H, dd, J=8.1, 
1.9 Hz, aromatic CH), 6.71 (1H, d, J=1.9 Hz, aromatic 
CH), 5.27 (2H, s, CH2Ar), 4.20 (2H, s, NCH2Ar), 3.92 
(3H, s, OCH3), 3.83 (3H, s, OCH3). 
 
13C NMR + DEPT (100 MHz, CHLOROFORM-d):  
 ppm 149.3 (C), 148.5 (C), 141.4 (C), 136.9 (C), 
130.2 (2xC), 128.6 (2xCH), 128.3 (2xCH), 126.4 
(CH), 125.8 (CH), 121.7 (CH), 119.3 (CH), 119.2 
(CH), 119.0 (CH), 114.8 (C), 111.3 (CH), 110.1 (CH), 220 
 
109.6 (CH), 55.9 (OCH3), 55.8 (OCH3), 49.7 (CH2), 
31.5 (CH2). 
ESMS: m/z (%):     258 [M+H]
+ (100). 
HRMS (ES +ve):     C24H24NO2 [M+H]
+ 358.1807, found 358.1802. 
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11-Benzyl-8,9,10-trimethoxy-10b,11-dihydro-6H-isoindolo[2,1-a]indole (411). 
 
N
Ph
Ph
I
I
MeO
MeO OMe
N
Ph
H
OMe
OMe
OMe
Bu3SnH (4.4 equiv.), VAZO (20 mol%) 
PhMe, 120 °C, 16 h, 60%
      408
C32H31I2NO3
   (731.42)
     411
C25H25NO3
  (387.48)
 
To a solution of 408 (0.68 mmol, 0.50 g) in toluene (40 mL) under nitrogen was 
added tributyltin hydride (3.01 mmol, 0.81 mL) and VAZO (0.14 mmol, 33 mg). The 
reaction mixture was heated at reflux for 16 h, cooled, concentrated in vacuo and 
purified by column chromatography (10% anhydrous K2CO3: 90% silica, 5% diethyl 
ether in petroleum ether) to give the desired product (411) (0.40 mmol, 0.16 g, 60%) 
as a colourless oil. 
 
Novel  
IR (ATR / golden gate):   3032 (w), 2995 (w), 2938 (w), 2856 (w), 1597 (w). 
1H NMR (400 MHz, CHLOROFORM-d):      
 ppm 7.42–7.36 (4H, m, 4 x aromatic CH), 7.31 (1H, 
m, aromatic CH), 7.17 (1H, app. dt, J=7.5, 1.3 Hz, 
aromatic CH), 6.87–6.80 (2H, m, 2 x aromatic CH), 
6.78 (1H, ddd, J=7.9, 7.2, 0.8 Hz, aromatic CH), 6.51 
(1H, s, aromatic CH), 5.06 (1H, b s, NCH), 4.55 (1H, 
dd, J=14.6, 1.3 Hz, NCHH), 4.48 (1H, d, J=14.6 Hz, 
NCHH), 4.18 (1H, b dt, J=7.5, 1.9 Hz, CHCH2Ph), 
3.83 (3H, s, OCH3), 3.82 (3H, s, OCH3), 3.70 (3H, s, 
OCH3), 3.16 (1H, dd, J=13.3, 8.2 Hz, CHCHHPh), 
3.07 (1H, dd, J=13.3, 7.3 Hz, CHCHHPh). 
 
13C NMR + DEPT (100 MHz, CHLOROFORM-d):  
 ppm 154.1 (C), 154.1 (C), 149.5 (C), 140.9 (C), 
140.0 (C), 135.0 (C), 134.0 (C), 129.7 (2xCH), 128.2 
(2xCH), 127.8 (CH), 127.1 (C), 126.1 (CH), 124.8 222 
 
(CH), 120.3 (CH), 112.0 (CH), 101.3 (CH), 74.7 
(CH), 60.8 (OCH3), 60.3 (OCH3), 59.4 (NCH2), 56.1 
(OCH3), 48.1 (CH), 43.2 (CH2). 
1H-
1H and 
1H-
13C correlations and NOESY experiment obtained to confirm above 
NMR assignments. 
CIMS: m/z (%):     388 [M+H]
+· (80), 296 [M-CH2Ph]
+· (100), 280 (15), 
        195 (20), 167 (20), 91 (30). 
HRMS (ES +ve):     C25H26NO3 [M+H]
+ 388.1913, found 388.1907. 
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tert-Butyl 2-oxo-3,3-diphenethyl-2,3-dihydro-indole-1-carboxylate (419), tert-
butyl 3-phenethyl-2-phenethyloxy-indole-1-carboxylate (439)  and tert-butyl 2-
oxo-3-phenethyl-2,3-dihydro-indole-1-carboxylate  (440). 
 
N
O
O
O
N
O
O
O
Ph
Ph
N
O
O
O
Ph
Ph
N
O
O
O
Ph
+ +
       NaH, DMF
 2-phenylethylbromide
RT, 16 h
    382
C13H15NO3
 (233.27)
 419, 42%
C29H31NO3
 (441.58)
 439, 16%
C29H31NO3
 (441.58)
440, 11%
C21H23NO3
 (337.42)
 
To a solution of 382 (4.29 mmol, 1.00 g) in anhydrous DMF (100 mL) at 0 °C under 
argon, was added NaH (60% in mineral oil, 10.72 mmol, 0.43 g). After 1 h at 0 °C 
2-phenylethylbromide (10.72 mmol, 1.5 mL) was added followed after 16 h at room 
temperature by water (100 mL). The reaction mixture was extracted ethyl acetate (3 
x 100 mL) then the combined organic phases were washed with water (4 x 60 mL), 
brine (150 mL), dried (MgSO4), concentrated in vacuo and purified by column 
chromatography (silica, 10% diethyl ether in petroleum ether) to give firstly bis-
alkylated material 419 as a clear oil (1.79 mmol, 0.79 g, 42%), then O-alkylated 
material 439 as a clear oil (0.67 mmol, 0.29 g, 16%) and the mono-alkylated material 
440 (0.48 mmol, 0.16 g, 11%) as a yellow oil. 
 
Data for 419 
Novel  
IR (ATR / golden gate):   3088 (w), 3054 (w), 3032 (w), 2979 (w), 2930 (w), 
2858 (w), 1792 (m), 1763 (s), 1727 (s). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.89 (1H, d, J=8.1 Hz, aromatic CH), 7.37–7.09 
(9H, m, 9 x aromatic CH), 7.06–6.98 (4H, m, 4 x 
aromatic CH), 2.47–2.27 (4H, m, 2 x CH2CH2Ph), 
2.25–1.98 (4H, m, 2 x CH2CH2Ph), 1.67 (9H, s, 
OC(CH3)3). 
 
 224 
 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 178.3 (C=O), 149.3 (C=O), 141.2 (2xC), 140.3 
(C), 130.7 (C), 128.5 (8xCH), 126.2 (3xCH), 124.9 
(CH), 122.8 (CH), 115.3 (CH), 84.5 (C), 53.4 (C), 
40.9 (2xCH2), 30.8 (2xCH2), 28.3 (3xCH3).  
ESMS: m/z (%):    464 [M+Na]
+ (50), 906 [M2+Na]
+ (100). 
HRMS (ES +ve):     C29H31NNaO3 [M+Na]
+ 464.2202, found 464.2196. 
 
Data for 439 
Novel  
IR (ATR / golden gate):   3066  (w),  3028  (w), 2979 (w), 2930 (w), 1726 (s), 
1625 (m), 1591 (m), 1572 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.99 (1H, dd, J=6.8, 1.6 Hz, aromatic CH), 7.36 
(1H, dd, J=6.6, 2.1 Hz, aromatic CH), 7.32–6.99 (12H, 
m, 12 x aromatic CH), 4.04 (2H, t, J=7.1 Hz, 
OCH2CH2Ph), 3.05 (2H, t, J=7.1 Hz, OCH2CH2Ph), 
2.86–2.77 (2H, m, CH2CH2Ph), 2.76–2.67 (2H, m, 
CH2CH2Ph), 1.63 (9H, s, COOC(CH3)3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 149.5 (C=O), 147.6 (C), 142.1 (C), 138.1 (C), 
132.1 (C), 129.3 (2xCH), 128.6 (4xCH), 128.5 
(2xCH), 128.1 (C), 126.7 (CH), 126.1 (CH), 123.4 
(CH), 122.7 (CH), 118.4 (CH), 115.5 (CH), 105.2 (C), 
83.7 (C), 76.9 (CH2), 36.5 (CH2), 35.9 (CH2), 28.5 
(3xCH3), 25.1 (CH2). 
ESMS: m/z (%):    464 [M+Na]
+ (100), 906 [M2+Na]
+ (20). 
HRMS (ES +ve):     C29H31NNaO3 [M+Na]
+ 464.2202, found 464.2196. 
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Data for 440 
Novel  
IR (ATR / golden gate):   3085 (w), 3058 (w), 3028 (w), 2983 (w), 2933 (w), 
2858 (w), 1792 (m), 1762 (m), 1727 (s), 1607 (w).   
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.86 (1H, d, J=8.1 Hz, aromatic CH), 7.39–7.15 
(8H, m, 8 x aromatic CH), 3.61 (1H, t, J=5.9 Hz, 
CHCH2CH2Ph), 2.86–2.64 (2H, m, CH2CH2Ph), 2.45–
2.24 (2H, m, CH2CH2Ph), 1.68 (9H, s, COOC(CH3)3). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 176.1 (C=O), 149.4 (C=O), 141.0 (C), 140.4 
(C), 128.7 (2xCH), 128.6 (2xCH), 128.3 (CH), 127.9 
(C), 126.3 (CH), 124.5 (CH), 123.7 (CH), 115.1 (CH), 
84.4 (C), 45.4 (CH), 33.0 (CH2), 31.9 (CH2), 28.3 
(3xCH3). 
ESMS: m/z (%):    360 [M+Na]
+ (40), 697 [M2+Na]
+ (100). 
HRMS (ES +ve):     C21H23NNaO3 [M+Na]
+ 360.1576, found 360.1570. 
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3,3-Diphenethyl-1,3-dihydro-indol-2-one (420). 
 
N
O
O
O
Ph
Ph
N
H
O
Ph
Ph
     419
C29H31NO3
 (441.58)
    420
C24H23NO
 (341.46)
TFA, CH2Cl2
RT, 6 h, 99%
 
To a solution of oxindole 419 (1.77 mmol, 0.78 g) in dichloromethane (40 mL) 
under argon at 0 ºC was added TFA (2.0 mL). After 6 h at room temperature the 
reaction mixture was concentrated in vacuo to give the desired compound 420 as a 
brown oil (1.76 mmol, 0.60 g, 99%). 
 
Novel  
IR (ATR / golden gate):   3247 (w), 3081 (w), 3066 (w), 3032 (w), 2949 (w), 
2915 (w), 2858 (w), 1777 (m), 1699 (m), 1620 (m), 
1603 (m), 1471 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 9.80 (1H, b s, NH), 7.40–7.12 (9H, m, 9 x 
aromatic CH), 7.09–6.98 (5H, m, 5 x aromatic CH), 
2.48–2.05 (8H, m, 2 x CH2CH2Ph). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 185.1 (C=O), 140.9 (2xC), 140.5 (C), 132.1 
(C), 128.7 (CH), 128.5 (8xCH), 126.3 (2xCH), 124.2 
(CH), 123.4 (CH), 111.1 (CH), 54.6 (C), 39.7 
(2xCH2), 30.7 (2xCH2). 
ESMS: m/z (%):    364 [M+Na]
+ (100). 
HRMS (ES +ve):     C24H24NO [M+H]
+ 342.1858, found 342.1852. 
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3,3-Diphenethyl-2,3-dihydro-1H-indole (421). 
N
H
Ph
Ph
N
H
O
Ph
Ph
    420
C24H23NO
 (341.46)
   421
C24H25N
(327.47)
LiAlH4 (1.0 M in THF), THF
60 °C, 16 h, 68%
 
To a solution of 420 (2.34 mmol, 0.80 g) stirred in anhydrous THF (20 mL) at 0 °C 
under argon was added drop-wise LiAlH4 (1.0 M solution in THF, 4.69 mmol, 4.7 
mL). After 16 h at 60 ºC the reaction mixture was cooled to 0 ºC and water (50 mL) 
added cautiously. The reaction mixture was extracted with ether (3 x 50 mL), the 
organic phases combined, washed with brine (100 mL), dried (MgSO4) and 
concentrated in vacuo to give 421 as a brown oil (1.58 mmol, 0.52 g, 68%).  
 
Novel  
IR (ATR / golden gate):   3387 (w), 3081 (w), 3058 (w), 3028 (w), 2922 (w), 
2850 (w), 1599 (m), 1487 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm  7.32–7.23 (4H, m, 4 x aromatic CH), 7.22–7.06 
(8H, m, 8 x aromatic CH), 6.79 (1H, app. td, J=7.4, 0.6 
Hz, aromatic CH), 6.69 (1H, d, J=7.6 Hz, aromatic 
CH), 3.55 (2H, s, NHCH2), 2.70 (2H, app. td, J=12.8, 
5.2 Hz, 2 x CH2CHHPh), 2.51 (2H, app. td, J=12.8, 
5.0 Hz, 2 x CH2CHHPh), 2.10 (2H, ddd, J=13.5, 12.3, 
5.2 Hz, 2 x CHHCH2Ph), 1.98 (2H, ddd, J=13.5, 12.5, 
5.0 Hz, 2 x CHHCH2Ph). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 151.5 (C), 142.8 (2xC), 134.8 (C), 128.5 
(4xCH), 128.5 (4xCH), 127.9 (CH), 125.9 (2xCH), 
123.5 (CH), 118.7 (CH), 109.8 (CH), 57.4 (CH2), 49.2 
(C), 41.4 (2xCH2), 31.2 (2xCH2). 
ESMS: m/z (%):    328 [M+H]
+ (100). 
HRMS (ES +ve):     C24H26N [M+H]
+ 328.2065, found 328.2060. 
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1-(2-Iodo-4,5-dimethoxy-benzyl)-3,3-diphenethyl-2,3-dihydro-1H-indole (422). 
N
H
Ph
Ph
Cl
I
OMe
OMe
N
Ph
Ph
I
MeO
MeO
+
   421
C24H25N
(327.47)
KI, K2CO3, acetone
60 °C, 16 h, 57% 
     392
C9H10ClIO2
  (312.54)
     422
C33H34INO2
  (603.55)
 
 
A solution of indoline 421 (0.93 mmol, 0.31 g), benzyl chloride 392 (1.12 mmol, 
0.35 g), K2CO3 (5.58 mmol, 0.77 g) and KI (0.93 mmol, 0.15 g) in acetone (40 mL) 
under argon was heated at reflux for 16 h. The reaction mixture was cooled to room 
temperature and partitioned between water (50 mL) and ether (50 mL). The aqueous 
phase was extracted with ether (2 x 30 mL) then the combined organic phases were 
washed with brine (100 mL), dried (MgSO4), concentrated in vacuo and purified by 
column chromatography (silica, 5→25% diethyl ether in petroleum ether) to give the 
desired product 422 as a brown oil (0.53 mmol, 0.32 g 57%). 
 
Novel  
IR (ATR / golden gate):   3081 (w), 3062 (w), 3024 (w), 3002 (w), 2922 (w), 
2835 (w), 1602 (m), 1495 (s), 1454 (s), 1435 (m). 
1H NMR (400 MHz, CHLOROFORM-d)  
 ppm 7.31–7.23 (6H, m, 6 x aromatic CH), 7.21–7.08 
(7H, m, 7 x aromatic CH), 6.96 (1H, s, aromatic CH), 
6.77 (1H, app. t, J=7.4 Hz, aromatic CH), 6.51 (1H, d, 
J=7.8 Hz, aromatic CH), 4.25 (2H, s, NCH2Ar), 3.89 
(3H, s, OCH3), 3.69 (3H, s, OCH3), 3.37 (2H, s, 
NCH2), 2.70 (2H, app. td, J=12.9, 5.0 Hz, 2 x 
CH2CHHPh), 2.50 (2H, app. td, J=12.9, 4.7 Hz, 2 x 
CH2CHHPh), 2.09 (2H, app. td, J=12.9, 5.0 Hz, 2 x 
CHHCH2Ph), 1.98 (2H, ddd, J=13.2, 12.9, 4.7 Hz, 2 x 
CHHCH2Ph). 
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13C NMR + DEPT (100 MHz, CHLOROFORM-d)  
 ppm 151.9 (C), 149.7 (C), 148.8 (C), 142.7 (2xC), 
135.1 (C), 132.8 (C), 128.6 (4xCH), 128.4 (4xCH), 
128.1 (CH), 126.0 (2xCH), 123.2 (CH), 122.0 (CH), 
118.1 (CH), 112.0 (CH), 107.2 (CH), 86.5 (CI), 63.8 
(CH2), 58.1 (CH2), 56.4 (OCH3), 56.0 (OCH3), 47.7 
(C), 41.7 (2xCH2), 31.3 (2xCH2). 
ESMS: m/z (%):    604 [M+H]
+ (100), 626 [M+Na]
+ (90). 
HRMS (ES +ve):     C33H35INO2 [M+H]
+ 604.1707, found 604.1694. 
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1-(2,6-Diiodo-3,4,5-trimethoxy-benzyl)-3,3-diphenethyl-2,3-dihydro-1H-indole  
(423). 
N
H
Ph
Ph
Cl
I
I
OMe
OMe
OMe
N
Ph
Ph
I
I
MeO
MeO OMe
+
   421
C24H25N
(327.47)
      395
C10H11ClI2O3
   (468.46)
      423
C34H35I2NO3
   (759.47)
KI, K2CO3, acetone
60 °C, 16 h, 41% 
 
A solution of indoline 421 (0.61 mmol, 0.20 g), benzyl chloride 395 (0.51 mmol, 
0.24 g), K2CO3 (3.06 mmol, 0.42 g) and KI (0.51 mmol, 85 mg) in acetone (30 mL) 
under argon was heated at reflux for 16 h. The reaction mixture was cooled to room 
temperature and partitioned between water (50 mL) and ether (50 mL). The aqueous 
phase was extracted with ether (2 x 30 mL) then the combined organic phases were 
washed with brine (100 mL), dried (MgSO4), concentrated in vacuo and purified by 
column chromatography (silica, 5→25% diethyl ether in petroleum ether) to give 
firstly the desired product 423 as a brown oil (0.25 mmol, 0.19 g, 41%) and then the 
recovered starting material 421 (0.24 mmol, 80 mg, 40%). 
 
Novel  
IR (ATR / golden gate):   3081 (w), 3058 (w), 3020 (w), 2998 (w), 2926 (w), 
2850 (w), 2824 (w), 1599 (m), 1486 (m). 
1H NMR (400 MHz, CHLOROFORM-d)  
 ppm 7.30–7.09 (12H, m, 12 x aromatic CH), 6.83–
6.75 (2H, m, 2 x aromatic CH), 4.80 (2H, s, NCH2Ar), 
3.99 (3H, s, OCH3), 3.95 (6H, s, 2 x OCH3), 3.25 (2H, 
s, NCH2), 2.67 (2H, app. td, J=13.0, 5.1 Hz, 2 x 
CH2CHHPh), 2.48 (2H, app. td, J=13.0, 5.0 Hz, 2 x 
CH2CHHPh), 2.03 (2H, ddd, J=13.6, 12.2, 5.1 Hz, 2 x 
CHHCH2Ph), 1.95 (2H, ddd, J=13.6, 12.2, 5.0 Hz, 2 x 
CHHCH2Ph). 
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13C NMR + DEPT (100 MHz, CHLOROFORM-d)  
 ppm 154.1 (2xC), 151.3 (C), 144.6 (C), 142.9 (2xC), 
136.5 (C), 135.3 (C), 128.5 (8xCH), 127.8 (CH), 
125.8 (2xCH), 123.1 (CH), 117.8 (CH), 107.4 (CH), 
94.2 (2xCI), 61.9 (CH2), 61.6 (CH2), 61.2 (OCH3), 
61.0 (2xOCH3), 47.4 (C), 41.3 (2xCH2), 31.2 
(2xCH2). 
ESMS: m/z (%):    760 [M+H]
+ (100), 782 [M+Na]
+ (50). 
HRMS (ES +ve):     C34H36I2NO3 [M+H]
+ 760.0779, found 760.0771. 
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1-(3,4-Dimethoxy-benzyl)-3,3-diphenethyl-2,3-dihydro-1H-indole (424) and 1-
(3,4-Dimethoxy-benzyl)-3-phenethyl-1H-indole (425). 
 
 
 
 
 
 
 
 
To a solution of 422 (0.130 mmol, 80 mg) in toluene (10 mL) under argon was 
added tributyltin hydride (0.290 mmol, 0.08 mL) and VAZO (0.003 mmol, 6 mg). 
After 3 h at reflux the reaction mixture was cooled, concentrated in vacuo and 
purified by column chromatography (10% anhydrous K2CO3: 90% silica, 5% diethyl 
ether in petroleum ether) to give the firstly the fully reduced product (424) (0.059 
mmol, 28 mg, 45%) as a colourless oil and then the indole (425) (0.008 mmol, 3 mg, 
6%) as a colourless oil. 
 
Date for 424 
Novel  
IR (ATR / golden gate):   3054 (w), 3028 (w), 2930 (w), 2835 (w), 1603 (m), 
1513 (m), 1489 (m), 1455 (m). 
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.65–7.56 (5H, m, 5 x aromatic CH), 7.55–7.41 
(8H, m, 8 x aromatic CH), 7.26 (1H, d, J=7.0 Hz, 
aromatic CH), 7.21 (1H, app. t, J=8.9 Hz, aromatic 
CH), 7.10 (1H, app. t, J=7.3 Hz, aromatic CH), 6.92 
(1H, d, J=7.8 Hz, aromatic CH), 4.61 (2H, s, 
NCH2Ar), 4.24 (3H, s, OCH3), 4.16 (3H, s, OCH3), 
3.63 (2H, s,   NCH2), 3.00 (2H, app. td, J=12.8, 5.2 
Hz, 2 x CH2CHHPh), 2.82 (2H, app. td, J=12.8, 4.9 
Hz, 2 x CH2CHHPh), 2.40 (2H, ddd, J=13.4, 12.8, 5.2 
N
Ph
Ph
I
MeO
MeO
N
Ph
Ph
MeO
MeO
N
Ph
MeO
MeO
     422
C33H34INO2
  (603.55)
Bu3SnH (2.2 equiv.), VAZO (20 mol%) 
PhMe, 120 °C, 3 h
 424, 45%
C33H35NO2
 (477.65)
+
  425, 6%
C25H25NO2
 (371.48)233 
 
Hz, 2 x CHHCH2Ph), 2.29 (2H, ddd, J=13.4, 12.8, 4.9 
Hz, 2 x CHHCH2Ph). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 152.3 (C), 149.3 (C), 148.3 (C), 142.8 (2xC), 
135.3 (C), 131.2 (C), 128.5 (4xCH), 128.5 (4xCH), 
128.0 (CH), 125.9 (2xCH), 123.3 (CH), 120.0 (CH), 
117.8 (CH), 111.3 (CH), 110.9 (CH), 107.0 (CH), 
63.4 (CH2), 56.1 (OCH3), 56.0 (OCH3), 53.0 (CH2), 
47.5 (C), 41.6 (2xCH2), 31.2 (2xCH2) 
ESMS: m/z (%):    478 [M+H]
+ (100), 500 [M+Na]
+ (30). 
HRMS (ES +ve):     C33H35NNaO2 [M+Na]
+ 500.2560, found 500.2561. 
 
Data for 425  
Novel  
IR (ATR / golden gate):   3058 (w), 3024 (w), 2998 (w), 2933 (w), 2854 (w), 
1607 (w), 1514 (m), 1463 (m), 1453 (m). 
1H NMR (300 MHz, CHLOROFORM-d) 
  ppm 7.63 (1H, d, J=7.5 Hz, aromatic CH), 7.32–7.08 
        (9H, m, 9 x aromatic CH), 6.83 (1H, s, aromatic CH), 
    6.79  (1H,  d,  J=8.0 Hz, aromatic CH), 6.67 (1H, app. t, 
    J=2.3 Hz, aromatic CH), 5.19 (2H, s, NCH2Ar), 3.86 
    ( 3 H ,   s ,   O C H3), 3.79 (3H, s, OCH3), 3.12–2.98 (4H, m, 
    C H2CH2Ph). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
 ppm 142.6 (C), 136.9 (C), 132.8 (C), 131.2 (C), 
130.4   (C), 128.7 (2xCH), 128.5 (2xCH), 128.0 (C), 
126.0 (CH), 125.6 (CH), 121.8 (CH), 119.5 (CH), 
119.2 (CH), 119.1 (CH), 111.5 (CH), 110.5 (CH) 
109.8 (CH), 56.1 (OCH3), 56.1 (OCH3), 49.9 (CH2), 
36.9 (CH2), 27.5 (CH2). 
N.B. 1 x aromatic (C) not observed. 
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3,3-Diphenethyl-1-(3,4,5-trimethoxy-benzyl)-2,3-dihydro-1H-indole (426). 
 
 
 
 
 
 
 
 
 
To a solution of 423 (0.25 mmol, 0.19 g) in toluene (100 mL) under argon was added 
tributyltin hydride (1.10 mmol, 0.29 mL) and VAZO (0.05 mmol, 12 mg). After 16 h 
at reflux the reaction mixture was cooled, concentrated in vacuo and purified by 
column chromatography (10% anhydrous K2CO3: 90% silica, 5% diethyl ether in 
petroleum ether) to give the fully reduced product (426) (0.065 mmol, 33 mg, 26%) 
as a colourless oil. 
 
Novel
  
1H NMR (300 MHz, CHLOROFORM-d)  
 ppm 7.30–7.05 (12H, m, 12 x aromatic CH), 6.75 
(1H, app. t, J=7.3 Hz, aromatic CH), 6.60 (2H, s, 2 x 
aromatic CH), 6.54 (1H, d, J=7.8 Hz, aromatic CH), 
4.25 (2H, s, NCH2Ar), 3.85 (3H, s, OCH3), 3.79 (6H, 
s, 2 x OCH3), 3.32 (2H, s, NCH2), 2.67 (2H, app. td, 
J=12.9, 5.2 Hz, 2 x CH2CHHPh), 2.47 (2H, app. td, 
J=12.9, 4.8 Hz, 2 x CH2CHHPh), 2.15–1.88 (4H, m, 2 
x CH2CH2Ph). 
13C NMR + DEPT (75 MHz, CHLOROFORM-d)  
  ppm 153.6 (2xC), 152.2 (C), 142.7 (2xC), 137.1 (C), 
    135.2  (C), 134.5 (C), 128.6 (4xCH), 128.4 (4xCH), 
    128.1  (CH), 125.9 (2xCH), 123.3 (CH), 117.9 (CH), 
    107.0  (CH), 104.4 (2xCH), 63.5 (CH2), 61.1 (OCH3), 
N
Ph
Ph
I
I
MeO
MeO OMe
N
Ph
Ph
MeO
MeO OMe
Bu3SnH (4.4 equiv.), VAZO (20 mol%) 
PhMe, 120 °C, 6 h, 26%
      423
C34H35I2NO3
   (759.47)
    426
C34H37NO3
 (507.68)235 
 
    56.2  (2xOCH3), 53.4 (CH2), 47.6 (C), 41.7 (2xCH2), 
    31.3  (2xCH2). 
ESMS: m/z (%):    508 [M+H]
+ (100), 530 [M+Na]
+ (90). 
HRMS (ES +ve):     C34H37NNaO3 [M+Na]
+ 530.2666, found 530.2663. 
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